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ABSTRACT 
Gene therapy has the potential to revolutionize healthcare for millions of people. However, it has 
yet to become a common treatment for the variety of diseases that could benefit from the delivery of 
therapeutic genes.  Limited progress is primarily due to the lack of a safe and efficient means of delivering 
genetic material. Viral vectors, for instance, are extremely efficient but potentially pathogenic and 
immunogenic. They also typically possess a tropism towards specific cellular receptors which is difficult to 
modify without signiﬁcant loss in efficiency. Non-viral vectors are typically non-pathogenic and non-
immunogenic, yet lack the efficiency necessary for gene therapy and are also typically toxic at clinically 
useful concentrations. It is clear that the current implementation of gene therapy must be preceded by the 
development of vectors with improved characteristics. The research proposed here focuses on producing 
improved gene therapy vectors through development of synthetic polymer-based – chitosan (χ) and lipid-
based (φ) envelopes for Moloney Murine Leukemia Virus (MLV) -like particles (M-VLPs). M-VLPs are 
essentially intact viruses lacking the envelope protein most necessary for transfection, thus making them 
inactive. Both chitosan and liposomes composed of DOTAP, DOPE and cholesterol electrostatically 
associated with M-VLPs forming hybrid vectors that could deliver M-VLPs without the need for the 
biological envelope protein. The transfection efficiency of these hybrid vectors (χ/M-VLPs and φ/M-VLPs) 
was not only better than our earlier hybrid vectors (PEI/M-VLPs and PLL/M-VLPs) but also of the same 
order of magnitude as amphotropic MLVs (MLV-A).  
The size and transfection efficiency of χ/M-VLPs was dependent on certain design parameters such 
as the chitosan pH, pKa of acidic solvent, chitosan stock concentration and M-VLP particle density. High 
transfections and low sizes could be achieved via using chitosan dissolved at 0.5 mg/ml at 0.6% glutamic 
acid, pH 3 for conjugating with M-VLPs (>10 x 109 M-VLPs/ml). The toxicity of chitosan was negligible 
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compared to using polymers such as PEI and PLL. Chitosan in low pKa acids such as HCl were unable to 
mediate any transfections with M-VLPs. χ/M-VLPs were serum resistant and also provided stable transgene 
expression over three weeks. χ/M-VLP suffered from high precipitation issues when stored at 4 °C for > 4 
days but exhibited better transfection efficiency than MLV-A in the same testing period. Both serum 
resistance and storage stability were dependent on χ/M-VLPs stoichiometry. Uptake of χ/M-VLPs was 
primarily via endocytic pathways but intracellular trafficking was dependent on the pH of the chitosan used 
for forming the hybrid vectors. χpH3/M-VLPs were dependent on clathrin-mediated endocytosis whereas 
χpH4/M-VLPs were caveolae mediated with macropinocytosis playing a minor role. 
Transfection efficiency of φ/M-VLPs was dependent on the lipid composition used for the 
synthetic lipid envelope. Liposomes with low DOTAP, low DOPE and high cholesterol content were able 
to mediate better transfections with M-VLPs. Cellular uptake of φ/M-VLPs was dependent on DOTAP 
content with high DOTAP mediating higher cell entry although successful transfections were not dependent 
on total uptake levels. Overall, φ325/M-VLPs was one of the most optimal synthetic lipid compositions in 
terms of transfection efficiency. The lipid toxicity was also dependent on the composition of the lipid 
envelope with higher cholesterol content leading to low toxicity. Significant size reduction of the φ/M-
VLPs was achieved via liposomal extrusion prior to association with M-VLPs. φ/M-VLPs were able to 
provide stable transgene expression over a period of three weeks but exhibited poor serum stability. The 
storage stability of φ/M-VLPs was significantly better than χ/M-VLPs and MLV-A in terms of transfection 
efficiency and vector size. Uptake of φ/M-VLPs was via both endocytosis as well as passive fusogenicity 
with the plasma membrane. However, successful gene delivery required an endocytic pathway. Intracellular 
trafficking of φ/M-VLPs was dependent on the lipid composition with a high presence of DOPE being 
clathrin-dependent and high cholesterol content being caveolae mediated. φ/M-VLPs also had significantly 
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faster trafficking kinetics as compared to χ/M-VLPs but slower than MLV-A which was confirmed by 
inhibition of reverse transcription and visualization via confocal microscopy. It can be concluded that the 
synthetic component of the hybrid vectors not only allows for a modified trafficking mechanism of the 
retroviral particle but also modulates the kinetics of delivery of the retrovirus to the nucleus for efficient 
expression of the target gene. 
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CHAPTER 1 
GENE THERAPY: RETROVIRAL AND HYBRID VECTORS 
 
Introduction 
Recent technical advancements in biotechnology and biomolecular engineering such as quicker and 
cheaper sequencing of genomes, particularly the Human Genome Project1, have enabled medicinal sciences 
to question, interpret and analyze the form and functions of the approximately 25,000 genes in the human 
body. It has been known for more than three decades that many of the diseases aﬄicting the human race are 
a result of a genetic mutation that results in malformed proteins or inappropriate production of proteins. 
These mutations are of many kinds which can theoretically be corrected by inserting the correct genetic 
code in place of the erroneous sequence.  This concept of gene therapy was initially proposed in a landmark 
paper in 19722 that has paved the way for further research since then in a variety of ways.  
Gene therapy can be potentially used to treat inherited diseases such as cystic fibrosis 3,4 muscular 
dystrophy 4–6 and severe combined immunodeficiency disease (SCID) 4. In acquired diseases, gene 
therapeutics can be delivered to introduce new functions or augment the production of enzymes and 
proteins from the expression of existing genes that can cure or contain diseases such as cancers 7, 
cardiovascular diseases 4, intraocular diseases4 and viral infections 8,9.  
However, Gene therapy has yet to deliver on its promise due in large part to the lack of safe and 
efficient means of delivering therapeutic genes 10. In addition, given the wide array of diseases that can be 
potentially treated through gene therapy, it is unlikely that any single vector will be suitable for all 
applications. The characteristics that should be common amongst all the vectors is the ability to be 
reproducibly and stably propagated and purified to high titers, to mediate targeted delivery and to induce 
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no harmful side effects11 . It should also be noted that the possible uses of human gene therapy involve both 
enhancement (e.g. cancer gene therapy) as well as provoking the immune system (e.g. generic gene 
replacement or suppression), making vector design important12. 
Gene therapy is a significant advancement in the field of medicine given that it is one step closer to 
the realization of personalized medicine. One of the first trials for a federally approved gene therapy 
protocol employed a retroviral vector for treatment of SCID in two patients13. This disease is caused due to 
a defect in the protein adenosine deaminase (ADA) and can be fatal within 1-2 years of diagnosis. The 
results of the trial were mixed with 1 patient maintaining consistent ADA levels long after the infusions 
whereas ADA levels were silenced over time in the other patient to pre-infusion levels. Significantly, the 
standard enzyme replacement treatment using PEG-ADA was maintained, although at much reduced levels 
for both patients long after the infusions14. This initial success spurred a multitude of trials that included the 
now infamous case of Jesse Gelsingher in 1999. Gelsinger suffered from ornithine transcarbamylase 
deficiency and was enrolled in an adenoviral gene therapy trial but suffered a massive and fatal immune 
response to the adenoviral vector. Also, in 2002, three of 16 patients in a French trial for SCID developed 
leukemia out of which one patient died15. Following these mistrials, gene therapy went through a lean patch 
with greater scrutiny on establishing clinical tests up until the late 2000s. However, there have been a string 
of successes in the last 3 years of clinical trials. Fourteen of the 16 patients treated for SCID via retroviral 
gene therapy in 2001 as stated above are leading healthy normal lives as of 201116,17. In 2009, three patients 
received adeno-associated viral capsids containing copies of a functional gene that allowed them to produce 
useful amounts of alpha-1 antitrypsin to help fight lung inflammation and liver cirrhosis for at least up to a 
year18.  Three patients with congenital blindness (Leber Congenital Amaurosis) were administered two 
doses of recombinant AAVs with the RPE65 gene that was determined to be safe and efficacious as well19. As 
of April 2010, 189 companies were developing gene therapies with 354 U.S. clinical studies currently 
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underway with participation from the major pharmaceutical companies such as Pfizer, Novartis and 
Genzyme20. Gene therapy always had a sound theoretical basis for successful implementation but with the 
identification of the appropriate genetic targets, diseases and the best commercial markets, it will need the 
right push for becoming viable as a potent therapeutic method on a global scale. 
Delivery of genes to mammalian cells can be achieved via means of gene delivery vehicles such as 
recombinant viruses or synthetic molecules including lipids and polymers 21. Viruses have evolved for the 
sole purpose of transferring genetic material into cells and have developed highly efficient mechanisms for 
navigating the barriers to cellular transfection. There are many classes of viruses that have been used for 
human gene therapy such as adenoviruses (AdV)22,23, adeno-associated viruses (AAV)24, herpes-simplex 
viruses (HSV)25, retroviruses (RV)26,27, lentiviruses (LV)28, baculoviruses (BV)29 and plant viruses such as 
cowpea mosaic viruses (CMV)30. This thesis exclusively discusses the design of retroviral vectors and the 
reader is directed to the references as stated above for further study on other viral vectors. Table 1 
summarizes some of the viral vectors that have been developed for human gene therapy. 
 
Retroviral Vectors 
The RV is a spherical particle of 80-100 nm diameter surrounded by a lipid envelope largely 
derived from the packaging cell plasma membrane31. There are three prominent genes in the retroviral 
genome – gag, pol and env which are responsible for the production of the structural proteins such as matrix 
(MA), capsid (CA) and nucleocapsid (NC), functional proteins such as protease (PRO), integrase (IN) and 
reverse transcriptase (RT) and the envelope protein (ENV) respectively. The ψ+ directs the packaging of the 
retroviral RNA genome into the viral particle. The genome also includes the active regions of 5’-LTR that 
acts as a transcriptional promoter and 3’-LTR that acts as a polyadenylation signal in the DNA form. Both  
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Table 1: Comparison of different viral vectors with advantages and limitations32 
Vector Insert Size 
(kb) 
Ability to 
integrate 
Titers 
(tu/ml) 
Advantages Limitations 
MLV 
(RV) 
≤ 8 Yes 106 Stable transfection of 
dividing cells 
Inability to transfect non-
dividing cells 
HIV-1 
(LV) 
≤ 10 Yes 106-107 Transfect both dividing 
and non-dividing cells 
Conversion to wild-type 
HIV-1 and possible 
recombination events 
AdV ≤ 7.5 No 1012 High titers Transient expression; high 
immunogenicity 
‘Gutted’ 
AdV 
30 No 107 Low Toxicity and 
Immunogenicity 
Hard to produce 
AAV ≤ 4.5 Yes 109 Stable Transfection; low 
toxicity and 
immunogenicity 
Small insert size 
HSV ≤ 30 No 1011 Large transgene 
capacity; high titers 
Transient expression; high 
immunogenicity 
HSV 
Amplicon 
≥ 50 No 107 Large transgene 
capacity; low toxicity 
and immunogenicity 
Low titer 
Vaccinia ≥ 25 No NA Large transgene 
capacity; cytoplasmic 
expression 
Limited to non-small pox 
vaccinated or 
immunocompetent 
individuals 
tu = transducing units 
 
LTR sequences contain important instructions for reverse transcription in the RNA form12,26,27. Figure 1 
shows the simple retroviral genomic architecture and a representative drawing of a simple retrovirus. 
Retroviruses were the earliest class of viruses used for clinical trials since the concept was first 
envisioned. They are capable of integrating their genetic cargo within the target cell genome with 
remarkable efficiency. The earliest retroviral vectors were produced by using helper virus for effective 
replication. However, many of the applications such as those in genetic studies or human gene therapy 
would not tolerate viral spread post infection. The development of packaging cell lines that could provide 
all the necessary viral proteins was a major development in vector design33. Retroviral vectors can either be  
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Figure 1: (Top) Cis sequences (shown in black) are those that are directly active as nucleic acids, they include the 5' 
long terminal repeat (LTR) which, in the DNA form found in the provirus acts as a transcriptional promoter, and in 
the RNA (genomic) form contains sequences important for reverse transcription of the genome; the primer binding 
site (PBS) for first strand DNA synthesis during reverse transcription; the psi (ψ) sequence which directs packaging of 
the genomic RNA into the virion; the polypurine tract (ppt) which is the primer binding site for second strand DNA 
synthesis during reverse transcription and the 3' LTR which, in the DNA form (in the provirus) acts as a 
polyadenylation signal, and in the RNA (genomic) form contains sequences important for the reverse transcription 
process. The trans functions (shown in green) are the protein coding sequences, these are the gag-pol gene, which 
encodes the Gag and Pol polyproteins, and the env gene that encodes the viral envelope protein27. (Bottom) Cartoon 
representation of a simple retrovirus - (1 – envelope protein, 2 – lipid bilayer, 3 – protease, 4 – integrase, 5 – 
reverse transcriptase, 6 – icosahedral capsid shell, 7 – RNA). 
 
replication competent (RCR) or replication defective (RDR) – a property that can be programmed based 
on the presence or absence of certain cis-acting genetic elements in the packaging cell line. While RCRs can 
be an attractive choice for therapy of certain disease models such as cancer wherein the infected cells can 
serve as reservoirs of viral persistence34, the uncertain nature of recombination events makes RDR a more 
viable option for most other applications.  Certain retroviruses such as RSV also possess the unique 
property to be replication competent in avian cells but replication defective in mammalian cells which 
makes them attractive designs for human gene therapy but their transduction efficiency is relatively low12.  
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Another variation of the RCR are self-inactivating retroviruses (SIN) wherein inactive proviruses are 
produced after one round of vector replication due to changes in the LTR promoter and enhancer 
sequences or in the packaging signal12,35. However, SINs suffer from low titer and low transfection 
efficiency27. 
The overall concept of using retroviral and lentiviral replication-incompentent vectors revolves 
around three main principles. If only mRNA needs to be transduced, LTR regions should lack elements that 
interact with the RT or co-treatment with RT inhibitors such as azidothymidine (AZT) should be followed. 
If episomal (non-integrating) delivery of transgene DNA is required, then LTR regions should be disallowed 
from interacting with IN or IN should be inhibited. The third method of using the provirus for direct 
genomic integration has been the most popular vector design26. These viral vectors are still by far the best 
choice for gene therapy applications that require stable insertion of the target gene although AAVs have 
recently gained prominence due to their known insertion sites in the human chromosome24. AAVs, 
however, are incapable of packagine large target genes (> 5 kb) (Table 1).  
The ability to transfect a variety of cells is dependent on the envelope protein of the retrovirus 
which can be of multiple types – amphotropic (almost universal to all cell types), ecotropic (mouse and 
rat), xenotropic (reproducibility in all cells except host) and polytropic (multiple cell types) along with 
many other pseudotypes12. Since the 1980s, there have been numerous studies on changing the retroviral 
tropism through pseudotyping which allows a foreign envelope protein such as Vesicular Stomatitis Virus – 
Glycoprotein (VSV-G) to be expressed on the retrovirus, thus allowing transfection in different cells 12,26,27.  
Retroviral vectors have enjoyed a variety of experimental applications such as regulated gene 
expression through external stimuli (e.g. insulin production in response to blood sugar level), cell lineage 
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analysis, cDNA library screening, development of transgenic animals, gene expression marking and 
chromosome tagging12. The potential therapeutic application of retroviral vectors in curing genetic diseases 
lies in the fact that the retroviral genome has a simpler genetic cassette that can be reprogrammed as per the 
desired application. 
 However, immune responses to the envelope protein, insertional mutagenesis due to semi-random 
genomic integration followed by oncogene activation as well as possible reversion to a replication-
competent pathogenic virus, are significant disadvantages for their use in the clinical setting 26,27. These risks 
can be mitigated either through targeting integration to inactive regions of the host genome or include the 
site specific integration machinery of bacteriophage C31 used in non-viral delivery approaches into 
retroviruses16. Additional concerns include restrictions on inclusion of certain AT-rich cDNA as target 
genes, poor stability during storage and expensive and low-titer production of retroviruses12,36–39. Certain 
retroviruses such as Murine Leukemia Virus (MLV) can infect only dividing cells while others such as 
Human Foamy Virus (HFV) and Human Immunodeficiency Virus (HIV) can transfect non-dividing cells due 
to their ability to penetrate the nuclear envelope. Also, retroviral vector expression can be suppressed 
especially in embryonic cells which can be overcome through vector alterations12. 
Retroviral vectors can transfect a variety of different cell lines based on the envelope protein 
expressed on the lipid bilayer enveloping the viral capsid. It is known that this envelope protein also plays 
an important role in intracellular trafficking as to whether the virions are deposited close to the plasma 
membrane or deeper inside the cell via transport in endosomes. In short, the initial uptake pathway for the 
retrovirus is influenced by the type of the envelope protein. For e.g., the HIV-1 envelope protein fuses with 
the plasma membrane leaving the viral core to traffic through the cortical actin with the aid of an accessory 
protein, Nef. The VSV-G envelope protein is pH-dependent and uses endosomes to allow the retrovirus to 
bypass the cortical actin and reach closer to the nucleus. Alternatively, actin can also play a crucial role in 
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the development of the reverse transcription complexes (RTC) improving the transfection process which is 
completely bypassed if the initial uptake mechanism was via the endosomes. Once the initial uptake is 
complete, the virion cores are released leading to maturation of the Gag precursor proteins (MA, CA and 
NC) and reverse transcription of the RNA genome. This complex is known as the RTC during reverse 
transcription of the RNA to cDNA and when the reverse transcription completes, it is known as the pre-
integration complex (PIC) or the provirus which also contains IN. However, very little is known on the 
mechanism of this evolution of the viral particles. In the case of MLV, MA and CA are shed from the PIC 
when closer to the nucleus leaving only the NC and IN alongwith the cDNA. The MLV PIC is unable to use 
the nuclear pore complexes (NPC) or nuclear localization signals (NLS) to move into the nucleus unlike the 
HIV PIC. It must rely on the breakdown of the nuclear envelope during mitosis to move into the nucleus40. 
 
Non-Viral Vectors 
In the last two decades, researchers have also synthesized alternative materials for delivering genetic 
material to cells. Two prominent classes of these synthetic materials are polymers such as polyethylenimine 
(PEI)41,42, poly-L-lysine (PLL)43,44, polyamidoamine (PAMAM)45,46 and chitosan47 and various lipids48 such as 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)49 and 3ß-[N-(N',N'-dimethylaminoethane)-
carbamoyl]cholesterol (DC-Chol)50. These are materials that electrostatically bind DNA or RNA and 
condense the genetic material into nano-particles21,51. Such synthetic vectors typically offer improved safety, 
greater flexibility, ability to target specific cells and facile manufacturing but are comparatively inefficient 
and typically provide short duration of gene expression52.  
The choice of synthetic vectors for conjugation with plasmid DNA, siRNA or other 
oligonucleotides depends on the suitable function offered by the synthetic component or overcoming the 
various delivery barriers. Steric stabilization of the vectors in the presence of human complement and blood 
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is critical for the eventual success of the vector which can be done via PEGylation of the vector53–57 (PEG – 
polyethylene glycol). The ability to target specific cells can be achieved through covalent association of 
synthetic vectors with ligands, proteins and antibodies of interest52,56,58–63. The nuclear entry of the non-viral 
vectors can also be enhanced through addition of a component that can be an effective nuclear localization 
signal such as viral proteins (Tat)63. However, viral vectors remain much more efficient in terms of clinical 
efficiency. 
 
Hybrid Vectors 
As discussed above, both viral vectors and non-viral vectors have significant advantages as well as 
severe limitations in different aspects of human gene therapy. Therefore, the design of a hybrid viral/non-
viral vector to obtain a superior vector with all the desired properties of both kinds of vectors is definitely a 
noteworthy option. The development of hybrid vectors that include both viral and non-viral components 
has taken prominence in recent years mainly for two reasons – reduction of immunogenicity of the host 
virus or introduction of a non-native function to the virus64.  
For example, a previous study reported the formation of artificially enveloped AdV using cationic 
and zwitterionic liposomes. The aim of the study was to design a template over which further lipid envelope 
designs could be layered via self-assembly with a potential for modifying AdV tropism65,66. However, gene 
delivery of the encapsulated AdVs was reduced and delayed as compared to the native adenoviruses possibly 
due to sub-optimal trafficking within the cell65. The addition of folate-targeted PEGylated lipids (DSPE-
PEG2000-folate) to these enveloped AdVs also led to a significant change in the biodistribution of 
adenoviruses towards tumors in vivo67. Thus, artificial lipid envelopes for non-enveloped AdVs allowed for a 
change in transduction dynamics along with change in systemic delivery properties. Similarly, encapsulation 
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of AdVs within PLG microspheres reduced their native immunogenicity apart from providing a novel 
controlled release mechanism68. Encapsulation of AdVs within anionic liposomes also led to improved 
transduction in cells that were non-native for adenoviral receptors69. Multiple alternate layering of AdVs 
with hyaluronic acid and protamine70 and covalent conjugation of AdV capsids to PEG linkers via amines of 
lysine residues64,71 has also been reported. PEGylated AdVs exhibited reduced immunogenicity, T-cell 
responses and macrophage vector uptake while maintaining significant transfection efficiency over the 
unPEGylated virions. 
In a recent study, AAVs were encapsulated within polyketal shells containing siRNA thereby 
allowing simultaneous expression of a foreign gene and silencing of a native gene72. AAVs have also been 
covalently conjugated with PEG to reduce antibody neutralization64. Picornaviruses such as polioviruses 
have been previously encapsulated within large unilamellar lipid vesicles in order to allow for transfections 
of cells that lack the required receptors73,74. Plant viruses such as the CMV have been used as biological 
templates for nanoscale synthesis as well as human gene therapy via surface modification through click 
chemistry30,75–78. Additionally, various viral hybrids combining retroviruses, adenoviruses and other viruses 
have also been studied for improved transduction efficiency, alteration of viral tropism and regulation of 
transgene expression32. All of these hybrid vectors had one singularly important feature – the viruses were 
active in the absence of the synthetic component. The synthetic component brought in additional features as 
part of the vector design without modifying the native infectivity of the virus. 
In the past, there have been multiple studies to develop RV based hybrid gene delivery vectors. 
Initial efforts yielded chimeric viruses with extensive use of viral pseudotyping where the envelope protein 
from one virus was used to impart novel tropism to a RV31,79–81 but with reduced delivery efficiency80,81. 
RVs have been associated with cationic lipids such as DOTAP, DC-Chol and polymers such as PEI, 
protamine and polybrene in order to improve their transduction82,83. There have also been recent reports on 
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non-covalently attaching proteins and lipids to the retroviral lipid bilayer84–86. Lipid conjugates of DSPE-
PEG2000-biotin were non-covalently inserted into the lipid bilayer of RVs for potential use in targeted 
vaccines or for reduced immunogenicity in clinical gene therapy84. GPI-anchored proteins were incubated 
with RVs and LVs in order to impart novel functions without the need for genetic reprogramming85,86. 
These studies, however, required the presence of the envelope protein for cellular uptake.  
RVs without the envelope protein are incapable of transfections and are known as retrovirus-like 
partcles (RVLPs). RVLPs have been conjugated with cationic liposomes such as DOTAP, DC-Chol87 and 
cationic transfection agents such as Lipofectin and Transfectamine88 that restored the capability of the RVs 
to transfect human cells. Our lab has also previously reported on the formation of retroviral hybrid vectors 
through non-covalent association of PEI and PLL with RVLPs89–92. In this report, we extend the design of 
these retroviral hybrid vectors through association of chitosan and lipid conjugates with Moloney Murine 
Leukemia Virus-Like Particles (M-VLPs). The use of RVLPs for the design of hybrid vectors is an important 
distinguishing feature between the hybrid vectors discussed so far. The synthetic component is essential for 
the infectivity of the virus particle and acts to restore this function without the need for expensive genetic 
reprogramming.  
 
Design of Retroviral Hybrid Vectors 
We and others have shown previously that the envelope protein which is responsible for the 
transfection capabilities of retroviruses is also a prime reason for their disadvantages such as freeze-thaw 
stability, short half-life and difficult retargeting for target-specific gene therapy38,89,93. We, therefore, 
emphasize the advantage of replacing the biological envelope protein with a synthetic variant using lipids 
and polymers through a non-covalent method. This has been done in our lab primarily using non-infectious 
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RVLPs based of the Moloney Murine Leukemia Virus (M-VLPs) and synthetic agents (SA) to create a new 
class of hybrid gene delivery vectors. M-VLPs are similar in composition, size and morphology to MLV, but 
lack the envelope protein making them non-infectious88. In brief, capsid particles form inside producer cells 
(GP293Luc) expressing gag-pol genes and spontaneously encapsidate viral RNA via the presence of the 
extended retroviral packaging signal Ψ+ (331 bp). The other viral proteins – PRO, IN and RT - are also 
incorporated during capsid assembly. The assembled particle buds oﬀ from the producer cell to form a viral 
particle surrounded by a lipid bilayer membrane (Figure 2). GP293Luc also has a reporter gene (luciferase) 
that is integrated within the viral genome and is used as a marker of gene delivery efficiency of M-VLPs. In 
order to obtain GP293Luc cells, GP2-293 cells which are a part of the Pantropic Retroviral Expression kit 
(Clontech, Mountain View, CA) are stably transfected with pLLRN - a control vector which expresses the 
luciferase reporter gene (Luc) by using the Rous Sarcoma Virus Promoter (PRSV) and neomycin resistance 
(Neor). MLVs can be generated through co-transfection of GP293Luc cells with the corresponding plasmid 
such as pVSV-G for the VSV-G envelope protein (Vesicular Stomatitus Virus – Glycoprotein) and pMDM-
4070A for the Amphotropic Envelope Protein. In place of pLLRN, one can use pLXRN or pLNCX for 
generation of retroviruses with any gene of interest (X) (Figure 2). The absence of the viral structural and 
functional genes (gag-pol) in the M-VLP genome makes these particles replication incompetent. In the case 
of M-VLPs, gene delivery is possible only if the SA successfully mitigates the primary barrier of entry into 
the cell. It is expected that once the M-VLPs are in, efficient intracellular trafficking mechanisms would 
kick in leading to successful gene delivery. In Chapter 5, we discuss in depth as to whether these 
mechanisms would be related to the virus or the SA associated with the hybrid vector. It is expected that 
the final stages of trafficking including un-coating and reverse transcription would be driven by the viral 
cargo. However, since the cell uptake is initiated by the SA, it is expected to affect the initial trafficking 
mechanisms of endocytosis. 
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Figure 2: (top) cartoon schematic of protocol to obtain MLVs with target gene X, plasmids – pLNHX, pLXRN and 
pVSV-G, (bottom) gene cassette based on pLXRN that gets stably integrated into the target cell 
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We propose that an ideal gene delivery vector would combine certain advantages stemming from 
both recombinant retroviruses and non-viral vectors.  Table 2 compares the various advantages and 
disadvantages of retroviruses, hybrid vectors and synthetic vectors. For example, large-scale production and 
puriﬁcation of retroviruses is a major challenge for clinical trials and for development of commercially 
viable therapies, due largely to instabilities in the viral envelope protein39. A stable synthetic component or 
the mere absence of the envelope protein is expected to facilitate the concentration and puriﬁcation steps 
needed for production of high titer formulations. Further, hybrid vectors may be targetable by conjugation 
of synthetic or biomolecular targeting ligands. Finally, the potential for efficient intracellular processing, 
especially genome integration and stable expression, stemming from the retrovirus component represents a 
major advantage over conventional non-viral vectors. 
In this thesis, we will explore the parameters of the hybrid vectors as mentioned in Table 2 and 
further elucidate their advantages. While the hybrid vectors as described here provide immediate, valuable 
advantages, future efforts will expand on this work by continuing to strip away virus functionality and 
replacing it with synthetic components. Further, it will be possible to extend these methods to other types 
of viral particles such as “self-inactivating” retroviruses, lentiviruses89 and adenoviruses. Thus, the most 
innovative aspect of the project may be in laying the groundwork for a novel “top-down” approach to design 
of gene delivery systems. 
 
Preliminary Results 
Our recently published results indicate that polymers such as PEI and PLL can be used to form 
hybrid vectors with M-VLPs and successfully transfect HEK293 cells89–91. For optimal development of the 
hybrid vectors, it was essential to be able to measure the concentration of M-VLPs in a given supernatant 
sample for which we have developed an in-house real-time PCR assay (q-RT-PCR) based on Clontech’s  
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Table 2: Advantages and limitations of retroviruses as compared to synthetic vectors 
 Retroviruses Polymer/M-VLPs Lipid/M-VLPs Synthetic Vectors 
In vitro efficiency Excellent Poor Good Good-excellent 
In vivo efficiency Excellent Poorb Poorb Poor-medium 
Size Small Medium-Large Medium-Large Depends 
Gene expression Stable Stablea Stablea Transient 
Toxicity No Yes/No Yes/No Yes/No 
Flexible Targeting No Yes Yes Yes 
Pathogenicity Yes Unknown/No Unknown/No Unknown/No 
Immunogenicity Yes Littleb Littleb Little 
Production Expensive Inexpensive Inexpensive Inexpensive 
Stability Poor Good Good Robust 
 
retroviral packaging cell line GP293Luc to measure the M-VLP titer of our samples accurately91,92. We have 
optimized our M-VLP production for maximum density of M-VLPs by varying the initial seeding density of 
GP293Luc.  For this optimization, we varied the initial seeding density of GP293Luc from 0.5-3 x 106 
cells/plate and measured M-VLP titer using q-RT-PCR after 4 days of incubation. As we can see in Figure 
4, the titer increases over the range of seeding density. While it is possible that a higher incubation period at 
lower seeding densities would also have led to high M-VLP titers, we decided to use a four day incubation 
period for uniformity and simplicity. The typical titer after four days was 5-12 x 109 M-VLPs/ml.  
 
Scope 
In Chapter 2, we explore the idea of using chitosan as the basis for the design of a truly 
biocompatible hybrid vector with high transfection efficiency along with suitable size reduction strategies. 
Chapter 3 extends the design of lipid-based hybrid vectors as reported in past studies through optimization 
of composition and size reduction protocols using DOTAP, DOPE and cholesterol as the basis for the 
synthetic lipid envelope. In Chapter 4, we investigate the potential of retargeting the retrovirus for the 
folate-receptor pathway for effective cancer gene therapy via the lipid-based hybrid retroviral vectors.  
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Figure 3: Cartoon Schematic for methodology of producing hybrid retroviral vectors.  
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Figure 4: M-VLP titer (#/ml) measured via q-PCR after 4 days of incubation of the producer cell line – GP293Luc 
seeded at a seeding density of 0.5-2.5 x 106 cells/100 mm tissue culture plate. M-VLP titer was higher at a seeding 
density of 2 and 2.5 x 106 cells/plate. 
 
Chapter 5 elucidates the differences in cellular uptake and trafficking mechanisms of the hybrid vectors with 
regard to the use of chitosan or lipids as the SA along with testing of the stability of these vectors in storage 
and in the presence of serum. In this report, experiments with MLVs as a positive control expressed the 
amphotropic envelope protein (MLV-A) thereby allowing a direct comparison to the hybrid retroviral 
vectors. Also, transfection data is mentioned in two formats – TE and TEs. TEs is the transfection efficiency 
of the vector in Relative Light Units per mg total protein in the cell lysate. In some experiments there are 
appropriate controls established whose transfection efficiency is defined as TEc (c = control). TE is defined 
as the normalized transfection efficiency of the sample with respect to the control. Therefore TE = 
TEs/TEc.  
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Experimental Methods 
Cell Lines and Assays The MLV producer cell line, GP293Luc, expressing the MLV viral gag-pro-pol genes 
and a viral packaging sequence encoding neomycin resistance and luciferase reporter genes was purchased 
from Clontech (Mountain View, CA) and grown in DMEM supplemented with 10% FBS and cultured at 37 
oC in 5% CO2. Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-buffered saline (PBS) was 
produced in-house at the Cell Culture Media Facility, School of Chemical Sciences, University of Illinois. 
Fetal Bovine Serum (FBS) was bought from Gemini Bio-Products and used as purchased.  
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) seeded in a 
10 cm dish. The cells were cultured for four days before the M-VLP containing supernatant was collected 
and filtered through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs 
in the supernatant was measured using a q-RT-PCR protocol91. RNA Standards were obtained from the 
Clontech qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was 
extracted using the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further 
use. Standards and viral RNA samples were prepared for reverse transcription using Taqman reverse 
transcription reagents (Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR 
tubes using the reagent concentrations suggested by the kit plus 250 nM sequence-specific primers. 
Thermal cycling was carried out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of 
the cDNA standards and samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a 
Taqman 7900 Real-Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied 
Biosystems). The final reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time 
PCR reagent:forward primer:reverse primer:cDNA volume). The final concentration of the sample RNA 
was calculated using the calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA 
copies which enabled us to calculate the total number of M-VLPs in a given volume of supernatant. Two 
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RNA extracts were collected for each M-VLP sample and quantified using 3 dilutions of each cDNA 
sample. M-VLP supernatant was either used immediately or stored at 4 oC for short term storage (< 4 
weeks) or stored at -80 oC for long term storage. 
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CHAPTER 2 
DESIGN OF HYBRID CHITOSAN/RETROVIRAL GENE DELIVERY VECTORS 
 
Introduction 
As mentioned in Chapter 1, we previously reported the design of hybrid polymer-based retroviral 
gene delivery vectors associating M-VLPs with cationic polymers – polyethylenimine (PEI) and poly-L-
lysine (PLL)1–3. Both PEI/M-VLPs and PLL/M-VLPs were able to successfully transfect HEK293 cells in 
vitro. However, PEI is significantly toxic and cannot provide for stable transgene expression. PLL is 
comparatively less toxic but is expensive in terms of a synthetic replacement (PEI – $0.30/g; PLL – 
$0.30/mg). These hybrid vectors were also much larger in size (≈ 1000 nm). Most of all, the transfection 
efficiency was much lower (≈100-fold) compared to MLVs pseudotyped with the VSV-G envelope 
protein3,4. 
   In this chapter, we have expanded upon the polymer parameter space using a natural biopolymer 
- chitosan as a synthetic envelope replacement. Chitosan has been studied extensively as an important 
controlled release system in biomaterials research with particular emphasis as a non-viral gene therapy 
vector 5–10. The two main advantages of chitosan lie in its biodegradability and good transfection efficiency 
in the presence of serum5,7. This chapter provides proof-of-principle of associating chitosan with non-
infectious retrovirus-like particles (M-VLPs) to form efficient hybrid gene therapy vectors known as 
chitosan/M-VLPs (hereby referenced as χ/M-VLPs). This chapter also explores improvements in the 
design of the vectors via change of solution parameters such as acid type, strength and concentration in 
order to optimize vector morphology and size along with transfection efficiency. Figure 5 shows the 
29 
 
chemical structure for chitosan which is a linear polysaccharide composed of randomly distributed β-(1-4)-
linked D-linked Glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). There are 
two important parameters for the use of chitosan as a gene delivery vector - molecular weight (Mw) and the 
degree of deacetylation (DDA). Previous studies using chitosan as a non-viral gene delivery vector for 
plasmid DNA delivery had mixed results with regards to optimization of Mw with efficient transfections 
measured using both low Mw
5 and high Mw
11. Others have also optimized the coupling of Mw and DDA 
wherein both combinations of high Mw with low DDA and high DDA with low Mw could be used to obtain 
good transfection efficiency12,13. Our previous studies using polymers to deliver M-VLPs concluded that a 
high Mw of PEI and PLL was needed to obtain good transfection efficiency with M-VLPs. Therefore, it was 
decided to use chitosan with a high Mw of 190-310 kDa along with a medium-high DDA of 85% for our 
studies with M-VLPs. Chitosan is inexpensive ($0.60/g) and naturally obtained via chitin from shrimp and 
crab shells (Figure 5). 
 
Figure 5: Chemical structure of chitosan 
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Results and Discussion 
Transfection Efficiency (TE) and Cellular Uptake of χ/M-VLPs, PEI/M-VLPs and PLL/M-VLPs 
In order to demonstrate the potential of chitosan as a potent synthetic polymer-based envelope for 
the development of hybrid retroviral vectors, experiments to compare the transfection efficiency and 
cellular uptake of χ/M-VLPs with PEI/M-VLPs and PLL/M-VLPs in HEK293 cells were performed. 
Chitosan was dissolved in 0.6% (w/v) acetic acid with a pH of 5.5 to a stock concentration of 1 mg/ml. 
Hybrid vectors were synthesized in different ratios of polymer (μg)/109 M-VLPs and used to transfect 
HEK293 cells. Luciferase activity was measured 48 h post transfection and normalized by the total protein 
content of the cells. As can be seen in Figure 6, chitosan provided higher reporter gene expression 
compared to PEI and PLL across the entire range of stoichiometry tested. At the optimal transfection 
stoichiometry, χ/M-VLPs provided a three-fold improvement over PEI/M-VLPs (p < 0.002) and a 13-fold 
improvement over PLL/M-VLPs (p < 0.0005). Optimal polymer:M-VLP ratios for transfections were 
between 6-9 µg chitosan/109 M-VLPs, 3-5 µg PEI/109 M-VLPs and 8 µg PLL/109 M-VLPs.  
We also characterized the cellular uptake of fluorescently labeled hybrid vectors via flow cytometry 
(Figure 7). The highest uptake for all hybrid vectors occurred at the lowest polymer:M-VLP ratio tested (2 
µg/109 M-VLPs) and increasing polymer:M-VLP ratios resulted in reduced uptake. The most notable 
difference between χ/M-VLPs compared to PEI/M-VLPs and PLL/M-VLPs was the correlation between 
uptake and transfection efficiency. Transfection efficiency of χ/M-VLPs decreased with χ/M-VLP ratios 
greater than 8 µg/109 M-VLPs but vector internalization remained fairly constant. In contrast, transfection 
efficiency of PEI/M-VLPs and PLL/M-VLPs remained constant at polymer:M-VLP ratios greater than 4 
µg/109 M-VLPs but the uptake decreased two- to four-fold. Additionally, PEI/M-VLPs exhibited greater 
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Figure 6: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs, PEI/M-VLPs and PLL/M-VLPs with 1 x 10
9 
M-VLPs/well of a 12-well tissue culture plate using M-VLP density of 10 x 109 M-VLPs/ml. Y-axis - RLU/mg total 
protein = Relative Light Units normalized to total mg protein in cell lysate. X-axis – Polymer stoichiometries in 
μg/109 M-VLPs. Chitosan (in 0.6% acetic acid, 1 mg/ml, pH 5.5) provides a three-fold improvement over PEI (*, p 
< 0.002, n = 3) and a 13-fold improvement over PLL (#, p < 0.0005, n = 3). Error bars indicate standard 
deviation. 
 
uptake at low stoichiometry as compared to either χ/M-VLPs or PLL/M-VLPs which is not surprising 
given the higher cationic charge density of PEI14.  
 
Physicochemical Characterization of χ/M-VLPs, PEI/M-VLPs and PLL/M-VLPs 
The size of χ/M-VLPs increased with increasing chitosan stoichiometry as reported in Table 3 and 
was much higher than M-VLPs alone (93±4 nm). The range of sizes measured were similar to the sizes of  
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Figure 7: Mean Fluorescence in HEK293 cells measured 2 h after transfecting with χ/M-VLPs, PEI/M-VLPs and 
PLL/M-VLPs using M-VLP density of 10 x 109 M-VLPs and 1 x 109 M-VLPs/well in a 12-well tissue culture plate. 
M-VLPs were tagged with lipophilic tracer dye, DiD, prior to formation of hybrid vectors. Y-axis - Normalized 
Uptake = [(Mean Fluorescence of treated sample - Mean Fluorescence of untreated samples)/Mean Fluorescence of 
untreated samples]. PEI/M-VLPs exhibit higher uptake as compared to χ/M-VLPs and PLL/M-VLPs at low 
stoichiometry. X-axis – Polymer stoichiometries in μg/109 M-VLPs. Error bars indicate standard deviation (n=3). 
 
PEI/M-VLPs and PLL/M-VLPs as mentioned in our previous studies1,3. The sizes of the vectors also 
suggested the formation of aggregated hybrid vectors associating multiple M-VLPs with chitosan. The 
hybrid vectors were also visualized via TEM as shown in Figure 8. The structure of M-VLPs is similar to 
that of the enveloped retrovirus15 (Figure 8a). χ/M-VLP complexes appeared as aggregates of multiple M-
VLPs held together by an electron dense material, presumably chitosan surrounded by stain (Figure 8b). 
The size of the aggregates ranged from 1200-1400 nm when measured end to end. The sizes measured in 
TEM correlate well with the sizes obtained from DLS at this stoichiometry (Table 3). No smaller structures 
were visualized in the sample suggesting that these structures were stable and did not dissociate into smaller 
hybrid entities.  
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Figure 8: (a) Negative Stain Transmission Electron Microscopy of M-VLPs alone, scale bar = 100 nm. The lipid 
envelope surrounding the capsid is clearly visible. The M-VLPs look similar in morphology and size as the enveloped 
retroviruses. Envelope proteins are indistinguishable at this magnification. (b) Negative Stain Transmission Electron 
Microscopy of χ/M-VLPs. These hybrid vectors were formed at a stoichiometry of 12 µg chitosan in 0.6% acetic acid 
at pH 5.5/109 M-VLPs. An electron-dense layer of chitosan (in white block arrow) forms a layer amongst multiple 
M-VLPs (black block arrow) forming an aggregated condensed hybrid vector.  
Table 3: Sizes (in nm) measured via Dynamic Light Scattering of χ/M-VLPs formed at different chitosan 
stoichiometries. Errors are standard deviations (n=2; 10 readings for every sample). The size of M-VLPs without 
addition of chitosan was 93 ± 4 nm.  
Vector stoichiometry (μg/109 M-VLPs) χ/M-VLPs 
2 167 ± 5 
4 436 ± 14 
6 1163 ± 376 
8 1270 ± 41 
12 1223 ± 127 
 
The greater transfection activity of χ/M-VLPs over PEI/M-VLPs and PLL/M-VLPs is a significant 
result (Figure 6) considering that most chitosan-based non-viral gene delivery vectors perform poorly as 
compared to PEI-based non-viral gene delivery vectors16,17. This improvement in transfection efficiency 
represents a marked difference between non-viral polymer-based vectors and hybrid polymer-based 
vectors. The difference in transfection efficiency and uptake levels with the choice of synthetic agent (PEI, 
PLL or chitosan) suggests that the choice of synthetic envelope is crucial for optimal delivery of the M-VLP 
via hybrid vectors. It has been demonstrated previously that the choice of the pseudo-typed or wild-type 
envelope protein affects the pathway of the retrovirus towards the nucleus18. It is possible that the choice of 
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synthetic envelope might also decide the optimal trafficking pathway for the M-VLP. Given that the PEI/M-
VLPs exhibit higher uptake levels as compared to χ/M-VLPs, but show decreased transfection efficiency 
(Figures 6 and 7), it can be suggested that the pathway of choice for χ/M-VLPs was better suited for 
polymer hybrid vectors compared to PEI/M-VLPs. At higher polymer stoichiometry, it is possible that the 
large vector sizes led to further reduction in cellular uptake19. Further elucidation of cellular uptake and 
trafficking mechanisms of χ/M-VLPs will be done in Chapter 5.  
 
Cyotoxicity of chitosan, PEI and PLL 
Chitosan is biodegradable and hence more desirable as a component of gene delivery vectors compared to 
PEI and PLL11,20. We investigated the cytotoxicity of chitosan, PEI and PLL using an assay of cellular 
metabolic activity (Cell-Titer BlueTM) upon exposure of HEK293 cells to various concentrations of the 
polymers (Figure 9). No significant difference in metabolic activity of HEK293 cells was observed upon 
exposure to various concentrations of polymers up to 10 µg/ml. Chitosan exhibited nearly negligible 
toxicity even at very high concentrations (up to 300 µg/ml). In contrast, PEI and PLL exhibited notably 
deleterious effects above 20 µg/ml. IC50 (polymer concentration at which metabolic activity was reduced to 
50% of the control) was between 40-50 µg/ml for PEI and 80-90 µg/ml for PLL. These results suggest that 
transfections with χ/M-VLP vectors may be further improved by increasing hybrid vector doses which is 
difficult with PEI/M-VLP and PLL/M-VLP vectors due to their higher toxicity. We tested this hypothesis 
by transfecting HEK293 cells with χ/M-VLP vectors at four vector doses of 1X, 2X, 3X and 4X, where 
X=109 M-VLPs/well at 4 different chitosan stoichiometry of 4, 7, 10 and 13 μg/109 M-VLPs. As 
predicted, the transfections improved at 4 (>8-fold) and 7 (> 3-fold) μg/109 M-VLPs but decreased at 
higher stoichiometry. This decrease cannot be attributed to the toxicity as confirmed via Figure 9 and also  
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Figure 9: Cell-Titer Blue Cytotoxicity Assay conducted on HEK293 cells in the presence of chitosan, PEI and PLL. 
Y-axis - Normalized Absorbance values compared to untreated cells which are a direct indicator of metabolic activity 
based on the ability to reduce resazurin to resorufin by living cells. X-axis is the concentration of the polymers. Error 
bars indicate standard deviation (n=3). 
 
via visual inspection of cells upon transfection. It is possible that the vectors aggregated with the free 
chitosan that remained uncomplexed with the M-VLPs when additional vector doses were added to the 
transfection media leading to a change in the vector composition and morphology. 
 
Variation of M-VLP density for design of optimal χ/M-VLPs 
Previously, we demonstrated that M-VLP density (particles/ml) in the suspension upon 
complexation with PEI played a significant role in  determining the optimal stoichiometry for PEI/M-VLP 
vectors 2. A similar trend was observed with χ/M-VLPs wherein higher densities of M-VLPs reduced the  
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Figure 10: Transfection Efficiency (TE) in HEK293 cells of χ/M-VLPs transfected with 4 polymer stoichiometries of 
4, 7, 10 and 13 μg/109 M-VLPs using M-VLP density of 12.5 M-VLPs/ml and with 4 vector doses of 1, 2, 3 and 4 x 
109 M-VLPs/well of a 12-well tissue culture plate. Y-axis – Normalized RLU/mg total protein = Relative Light 
Units normalized to total mg protein in cell lysate compared to the same value for vector doses of 1 x 109 M-
VLPs/well for each chitosan stoichiometry.  X-axis – Vector Load/well. Error bars indicate standard deviation 
(n=3). The transfection efficiency increased with increased vector doses for polymer stoichiometries of 4 and 7 
μg/109 M-VLPs but decreased for polymer stoichiometries of 10 and 13 μg/109 M-VLPs. 
 
required polymer:M-VLP ratio for improved transfection efficiency (Figure 11). Various amounts of 
chitosan were complexed with appropriate volumes of M-VLP supernatant at three different concentrations 
and transfected as before. The optimal χ/M-VLP ratios were 8, 17 and 40 µg chitosan/109 M-VLPs at M-
VLP density of 10 x 109 M-VLPs/ml, 5 x 109 M-VLPs/ml and 2.5 x 109 M-VLPs/ml, respectively. 
Furthermore, it was evident that at these densities, any increase in M-VLP density led to a proportionate 
decrease in chitosan requirement for optimal transfection. For example, optimal transfection for χ/M-VLPs 
at an M-VLP density of 10 x 109 M-VLPs/ml required 8 µg chitosan/109 M-VLPs whereas the 
corresponding requirement for an M-VLP density of 2.5 x 109 M-VLPs/ml was 40 µg/109 M-VLPs. This  
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Figure 11: Transfection Efficiency (TE) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 2.5, 5, 10 x 109 
M-VLPs/ml and with 1 x 109 M-VLPs/well of a 12-well tissue culture plate. Y-axis – Normalized RLU/mg total 
protein = Relative Light Units normalized to total mg protein in cell lysate compared to the same value for chitosan 
vector stoichiometry of 12.5 μg/109 M-VLPs at 10 x 109 M-VLPs/ml. X-axis – Polymer (μg): 109 M-VLPs. Higher 
density is optimal for transfection as well as reduces chitosan load for optimal gene delivery. Error bars indicate 
standard deviation (n=3).  
 
change in optimal χ/M-VLP ratios can be explained by the fact that χ/M-VLPs are ternary complexes 
between M-VLPs, chitosan and serum proteins. The dilution of the M-VLP supernatant solution by DMEM 
containing serum led to greater interaction between the cationic polymer and serum proteins following 
which additional polymer was required for synthesizing optimal complexes with M-VLPs. In all further 
experiments, the vector stoichiometry for optimal transfections was identified using this result as a 
guideline. We also measured the sizes of the vectors formed at different M-VLP densities as shown in Table 
4. The sizes of the hybrid vectors were much larger than M-VLPs alone (98±11 nm) with the change in M-
VLP density offering no significant reduction in vector sizes. Notably, the most optimal vector  
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Table 4: Sizes (in nm) measured via Dynamic Light Scattering of χ/M-VLPs formed at different chitosan 
stoichiometry and M-VLP density of 2.5, 5 and 10 x 109 M-VLPs/ml. Errors are standard deviations (n=2; 10 
readings for every sample). The size of M-VLPs without addition of chitosan was 98 ± 11 nm. 
 M-VLP density (M-VLPs/ml) 
 Chitosan stoichiometry (μg/109 M-
VLPs) 
10 x 109 5 x 109 2.5 x 109 
5 464 ± 110   
7 1836 ± 788   
10 185 ± 50 557 ± 250  
12  776 ± 150  
15  908 ± 349  
20  1270 ± 273  
25  2271 ± 960 410 ± 83 
30  1919 ± 393 706 ± 176 
40   1883 ± 479 
 
 
stoichiometry in terms of transfection efficiency (Figure 11) had much higher vector sizes (>1000 nm) than 
M-VLPs alone (italicized in Table 4). This indicates that the most significant factor in the design of χ/M-
VLPs is the binding capacity of the polymer to condense multiple M-VLPs into a larger hybrid vector 
aggregate that can settle upon cells to initiate transfection via charge interactions of the unbound polymer. 
This is true regardless of the choice of the polymer – PEI, PLL and chitosan. 
 
Variation of pH for design of optimal χ/M-VLPs  
In order to improve vector morphology and reduce sizes, we explored the idea of changing the 
chitosan solution parameters during complexation such as the pH, acidic solvent and stock concentration. 
The alteration of M-VLP density also had an effect on the chitosan acidic solvent concentration in the final 
vector solution as well as the resultant solution pH. The dilution of M-VLPs in DMEM resulted in greater 
buffering capacity for the M-VLP suspension prior to the addition of chitosan. However, this difference was 
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expected to be minimal considering that the pH of the chitosan stock was 5.5 and DMEM + FBS had a pH 
of 7.2-7.4. In order to study if lower pH could provide better transfections via a possible change in the 
cationic charge density of chitosan, the pH of the chitosan stock was varied from 3-6 and complexed with 
M-VLPs as before. The effect of lowering the pH of the chitosan stock solution was clearly seen in Figure 12 
wherein the transfection efficiency improved 124-fold between the most optimal vector stoichiometries at 
pH 3 and pH 5 (p<0.001). Similarly, the transfection efficiency improved 62-fold between the most 
optimal vector stoichiometries at pH 4 and pH 5 (p<0.003). This improvement in the transfection 
efficiency via a simple change in the stock pH is significant considering that the transfection efficiency of 
χ/M-VLPs is of the same order as the native MLVs themselves. The use of low pH chitosan stock solutions 
also led to decrease in the polymer requirements for optimal transfections (4 μg/109 M-VLPs at pH 3, 6 
μg/109 M-VLPs at pH 4 and 7-8 μg/109 M-VLPs at pH 5) .χ/M-VLPs synthesized using chitosan stock at 
pH 6 failed to transfect HEK293 cells. There was no significant change in the pH of the vector solution 
between using chitosan stock solution at different pH values with the resulting pH between 7 and 7.5 at all 
vector stoichiometries (Table 5). The only significant difference between the different vectors was that pH 
decreased with increase in χ/M-VLP ratio which was expected as higher stoichiometry required higher 
amounts of chitosan to be added to the M-VLPs that led to higher amounts of acidic solvent being added. 
The size and zeta potential of the hybrid vectors was also measured with variation in chitosan stock 
pH (Tables 6 and 7). The sizes of the hybrid vectors increased with increase in χ/M-VLP ratio but lowered 
at higher stoichiometry especially at pH 3 and pH 4. The sizes were maximal at 6 μg/109 M-VLPs (pH 3) 
and at 10 μg/109 M-VLPs (pH 4). A similar effect was also seen with non-viral vectors using plasmid DNA 
wherein chitosan dissolved in different acids showed increase in vector sizes at lower stoichiometry which 
decreased rapidly at higher ratios21. The average size of the hybrid vectors was also lower with the use of 
low pH chitosan stock solutions. The zeta potential of the hybrid vectors formed via pH 3 and pH 4 chitosan  
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Figure 12: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 18.1 x 10
9 M-
VLPs/ml and using chitosan in 0.6% acetic acid with a density of 1 mg/ml and transfected with 1 x 109 M-VLPs/well 
of a 12-well tissue culture plate. Y-axis – RLU/mg total protein = Relative Light Units normalized to total mg 
protein in cell lysate. X-axis – chitosan (μg): (109) M-VLPs stoichiometry. Lower pH of the chitosan stock solution 
used to synthesize the hybrid vectors improved transfections (#, p<0.001 and *, p<0.003). Error bars indicate 
standard deviation (n=3). 
 
stock solutions was between 6-11 mV in the range of tested polymer stoichiometries whereas the vectors 
formed using chitosan at pH 6 had a higher surface charge (>16 mV). 
In contrast, the polymer particles in the chitosan stock solution prior to association with M-VLPs 
increased in size with lower pH (Table 6). The pKa of chitosan amines is 6.50 whereas pKa of acetic acid is 
4.00. Lowering of pH of the chitosan stock solution to pH 3 shifted the equilibrium dissociation from 
acetate ions to undissociated acetic acid compared to pH 5. The chitosan amines were protonated at both 
pH 3 as well as pH 5. However, the degree of protonation was higher at pH 3 compared to pH 5. This 
higher degree of protonation led to repulsive forces amongst the chitosan polymer chains resulting in higher  
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Table 5: pH of χ/M-VLPs formed at different chitosan stoichiometries using chitosan stock at pH 3, 4 and 5 at 1 
mg/ml. DMEM + FBS = pH 7.80; M-VLPs in DMEM + FBS = pH 7.75; M-VLPs in 5% Glucose = pH 7.10.  
 Chitosan pH at 1 mg/ml 
μg/109 M-VLPs pH 3 pH 4 pH 5 
1 7.51 7.56 7.49 
2 7.57 7.40 7.45 
3 7.38 7.27 7.37 
4 7.30 7.26 7.37 
5 7.28 7.21 7.37 
6 7.23 7.17 7.32 
7 7.01 7.12 7.30 
8 7.16 7.04 7.31 
 
Table 6: Sizes (in nm) measured via Dynamic Light Scattering of χ/M-VLPs using chitosan stock at pH 3, 4 and 5 at 
1 mg/ml. Errors are standard deviations (n=2; 10 readings for every sample). The size of M-VLPs without addition 
of any chitosan was 113 ± 6 nm. The size of chitosan in solution before complexing was 615 ± 46 nm at pH3, 359 ± 
41 nm at pH 4, 166 ± 13 nm at pH 5 and 157 ± 12 nm at pH 6. 
 Chitosan pH at 1 mg/ml 
μg/109 M-VLPs pH 3 pH 4 pH 5 
1 491 ± 22 352 ± 25 - 
2 766 ± 31 815 ± 95 - 
3 878 ± 81 1707 ± 236 - 
4 1031 ± 308 1523 ± 345 - 
5   878 ± 105 1544 ± 376 1033 ± 84 
6 568 ± 54 1751 ± 575 - 
7 549 ± 52 1717 ± 114 - 
8 771 ± 72 1676 ± 282 - 
10        330 ± 7 304 ± 16 1010 ± 171 
15 520 ± 33 362 ± 14 2810 ± 402 
20 589 ± 39 648 ± 36 630 ± 49 
 
Table 7: Zeta Potential (in mV) measured via ZetaPALS of χ/M-VLPs formed at different chitosan stoichiometries 
using chitosan stock at pH 3, 4 and 5 at 1 mg/ml. Errors are standard deviations (n=2; 10 readings for every sample). 
The zeta potential of M-VLPs without addition of any chitosan was -6.8 ± 1.2 mV. The zeta potential of chitosan 
stock solution prior to addition to M-VLPs was 6.8 ± 1.7 at pH 3, 7.8 ± 1.8 at pH 4 and 10.9 ± 2.0 at pH 5. 
 Chitosan pH at 1 mg/ml 
μg/109 M-VLPs pH 3 pH 4 pH 5 
5 11.0 ± 2.2 8.6 ± 1.3 16.2 ± 2.9 
10 7.1 ± 1.6 11.4 ± 2.0 23.2 ± 1.4 
15 9.1 ± 1.0 11.2 ± 2.1 13.5 ± 2.3 
20 6.5 ± 0.9 10.6 ± 1.9 20.7 ± 2.0 
 
42 
 
hydrodynamic sizes as measured via DLS. Low protonation at pH 5 led to lower repulsion leading to a high 
degree of folding of polymer chains amongst themselves leading to lower sizes.  
As per Figure 12 and Table 6, the hybrid vectors with the greatest size were the best in terms of 
transfection efficiency (italicized in Table 6). However, with the use of lower pH, the average size of the 
vectors across all polymer stoichiometries was decreased to sub-micron ranges with good transfection 
efficiency. It is highly likely that the vector morphology formed using chitosan at pH 3 was better compared 
to the vectors formed using chitosan at pH 5 thereby leading to much better transfections at all the tested 
polymer stoichiometries. The introduction of chitosan at pH 3 into the supernatant containing M-VLPs 
probably led to interactions of chitosan as individual chains considering the high protonation of the polymer. 
In contrast, the chitosan at pH 5 probably had multiple chains interacting with multiple M-VLPs leading to 
higher vector sizes. This mechanism is also suggestive of the low vector sizes at higher polymer 
stoichiometry at pH 3. The high stoichiometry led to higher repulsion of the polymer chains amongst 
themselves leading to low steric hindrances during complex formation. The morphology of the vectors is 
likely better condensed when using pH 3 stock solution than at pH 5 leading to optimal detachment from 
the M-VLPs during intracellular trafficking within the HEK293 cells. This is also explained by the fact that 
the polymer requirements for optimal TE were lower upon using the pH 3 stock solution. The use of higher 
polymer stoichiometries at the same pH of the stock solution would probably lead to sub-optimal and 
delayed release of the M-VLPs into the cytosol.  
 
Variation of pKa for design of optimal χ/M-VLPs 
Since, chitosan (pKa = 6.5) requires an acidic buffer for dissolution, there have been studies in the 
past that compared the performance and vector properties by using chitosan in different acidic solutions to 
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conjugate plasmid DNA21. We showed above that a decrease in pH of the acetic acid buffer containing 
chitosan led to major improvements in transfections (Figure 12) with minor improvements in size and 
vector morphology (Table 6) and reduction in surface charge (Table 7) of the vectors. Our goal in this study 
was to evaluate if the type of acid used to prepare chitosan stock would enable better transfections and 
improved physicochemical properties. We prepared chitosan at pH 3 in five different acids at 0.6% (w/v), 
– acetic acid (Ac, pKa = 4.54), hydrochloric acid (HCl, pKa = [-3] – [-7]), lactic acid (La, pKa = 3.86), 
aspartic acid (D, pKa = 4.00) and glutamic acid (E, pKa = 4.00) and followed the same protocol for χ/M-
VLP synthesis and transfections as before. As evident from Figure 13, transfections with chitosan prepared 
in HCl led to no transfections at all. It is possible that the use of low pKa acids such as HCl can result in 
competitive interaction of H+ ions with negatively-charged surfaces of M-VLPs leading to either higher 
amounts of chitosan needed for optimal transfections or lack of transfections due to sub-optimal vector 
formation21. The most optimal transfections were seen with χ/M-VLPs synthesized using chitosan prepared 
in Ac, D and E which were the weakest acids in the study. The sizes of χ/M-VLPs (Ac) were the smallest, 
although the transfections via χ/M-VLPs (D) and χ/M-VLPs (E) were marginally better. Owing to their 
greater biodegradability, it was decided to use chitosan at pH 3 dissolved in 0.6% glutamic acid for future 
experiments. Precipitation was observed with chitosan stocks dissolved in aspartic acid after two weeks in 
storage at 4 °C that led to the elimination of aspartic acid as a viable candidate for further studies. 
 
Variation of chitosan stock concentration for design of optimal χ/M-VLPs 
 Density of the M-VLPs supernatant was a significant factor in the formation of optimal 
χ/M-VLPs resulting in different optimal stoichiometries required for efficient transfections. We decided to  
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Figure 13: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 18.1 x 10
9 M-
VLPs/ml and chitosan concentration of 1 mg/ml, pH 3 and transfected with 1 x 109 M-VLPs/well of a 12-well tissue 
culture plate. Chitosan stock was prepared using different acids – acetic acid, hydrochloric acid, lactic acid, aspartic 
acid and glutamic acid at pH 3. Y-axis – RLU/mg total protein = Relative Light Units normalized to total mg protein 
in cell lysate. X-axis – chitosan (μg):M-VLP (109) stoichiometry. Error bars indicate standard deviation (n=3). 
 
explore if the chitosan stock concentration would also affect transfections and vector sizes. As per Figure 
14, decrease in the chitosan stock concentration resulted in reduced TE. However, the sizes of the optimal 
vectors decreased on using lower chitosan stock concentrations (italicized in Table 9). It is possible that the 
reduction in chitosan concentration led to a greater amount of dissociated H+ ions to interact with the M-
VLP surface leading to sub-optimal vector formation that could affect either the uptake of the hybrid 
vectors or eventual release of the M-VLPs in the cytosol during intracellular trafficking but also enabled 
lower vector sizes. The most optimal vectors were those that were formed using chitosan at pH 3, 0.5 
mg/ml in 0.6% glutamic acid in terms of good TE and low vector sizes.  
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Table 8: Sizes (in nm) measured via Dynamic Light Scattering of χ/M-VLPs formed at different chitosan 
stoichiometries and M-VLP density of 10 x 109 M-VLPs/ml using chitosan dissolved in different acidic buffers at pH 3 
– acetic, hydrochloric, lactic, glutamic and aspartic acid. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of chitosan was 98 ± 11 nm. 
 Acid 
 μg/109 M-VLPs Acetic Hydrochloric Lactic Glutamic Aspartic 
2 942 ± 61 705 ± 123 1945 ± 233 659 ± 49 909 ± 229 
4 311 ± 9 1198 ± 300 1335 ± 225 1161 ± 209 1197 ± 127 
5 342 ± 24 1247 ± 138 1040 ± 168 1164 ± 130 1065 ± 121 
7 593 ± 32 1593 ± 454 345 ± 19 2454 ± 155 620 ± 64 
 
Use of M-VLPs in 5% glucose solution for design of χ/M-VLPs 
In order to completely eliminate the effects that DMEM and serum proteins might have on vector 
formation, the M-VLPs were ultracentrifuged and resuspended in 5% glucose solution (M-VLPs-5G). As 
per Figure 15, the χ/M-VLPs-5G were much lower in size and showed a steady growth of size with 
increase in polymer amount leading to the possibility that the enveloping of M-VLPs with polymer was 
optimal in the absence of serum proteins and DMEM salts. χ/M-VLPs-5G were also tested for their 
transfection efficiency as compared to χ/M-VLPs formed using M-VLPs in DMEM (χ/M-VLPs-DMEM) 
(conventional protocol) as shown in Figure 16. χ/M-VLPs-5G showed a 1773-fold reduction (p<0.0003) 
in transfection efficiency between the most optimal χ/M-VLP ratios as compared to χ/M-VLPs-DMEM. 
Both samples used chitosan stock at pH 3 in 0.6% glutamic acid. In order to further increase the cationic 
charge density of chitosan, the stock solution was lowered in pH and χ/M-VLPs were formed with chitosan 
at pH ranging from 1 to 5. However, as seen in Figure 17, there was no discernible difference in the 
transfection efficiency of χ/M-VLPs-5G by using chitosan stock at any of the tested pH. There have been 
attempts to reduce the serum content during vector formation by re-concentrating the M-VLPs in different 
buffers and purifying via chromatography. However, the transfections were lower than using M-VLPs in the 
presence of serum proteins. In fact, transfections were restored to their original capabilities by adding  
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Figure 14: Transfection Efficiency (TE) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 12.5 x 109 M-
VLPs/ml and chitosan concentration of 0.25, 0.5 and 1 mg/ml and transfected with 1 x 109 M-VLPs/well of a 12-
well tissue culture plate. Y-axis – Normalized RLU/mg total protein = Relative Light Units normalized to total mg 
protein in cell lysate compared to the same value for chitosan stoichiometry of 1 μg/109 M-VLPs and at 10 mg/ml.  
X-axis – Polymer (μg):M-VLP (109) stoichiometry. Higher chitosan stock concentration is optimal for transfections. 
Error bars indicate standard deviation (n=3) 
 
Table 9: Sizes (in nm) measured via Dynamic Light Scattering of χ/M-VLPs formed at different chitosan 
stoichiometries using chitosan stock at three densities – 0.25, 0.5 and 1 mg/ml. Errors are standard deviations (n=2; 
10 readings for every sample). The size of M-VLPs without addition of any chitosan was 113 ± 6 nm. 
 Chitosan stock concentration (mg/ml) at pH 3 
μg/109 M-VLPs 1 0.5 0.25 
5 878 ± 105 259 ± 13 415 ± 27 
10 330 ± 7 479 ± 43 342 ± 14 
15 520 ± 33 492 ± 58 1137 ± 144 
20 589 ± 39 1192 ± 177 696 ± 35 
 
serum proteins to the purified M-VLPs and complexing with polymers (unpublished work, Dr. Joshua 
Ramsey, Oklahoma State University).  
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Figure 15: Sizes measured via DLS and zeta potential via electrophoretic mobility of χ/M-VLPs formed using M-
VLPs in 5% glucose solution. Y-axis – Size in nm and Zeta Potential in mV. X-axis – Chitosan (μg):M-VLPs (109) 
stoichiometry. Error bars indicate standard deviation (n=2). 
 
We also tested the possibility of glutamic acid forming hybrid vector complexes with M-VLPs 
(E/M-VLPs). They were formed with the same volume as per the chitosan stock solution volume used and 
transfected into HEK293 cells (Figure 17). The E/M-VLPs did have transfection potential but there was a 
4800-fold difference (p<0.0005) between using chitosan and glutamic acid only at their most optimal 
vector stoichiometries which proved that the presence of glutamic acid is insignificant in terms of vector 
formation between chitosan in 0.6% glutamic acid and M-VLPs. 
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Figure 16: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 6.1 x 10
9 M-
VLPs/ml in DMEM + FBS and 5 % Glucose solution and chitosan concentration of 1 mg/ml, pH3 in glutamic acid 
and transfected with 1 x 109 M-VLPs/well of a 12-well tissue culture plate. Y-axis – RLU/mg total protein = 
Relative Light Units normalized to total mg protein in cell lysate. X-axis – chitosan (μg):M-VLP (109) stoichiometry. 
Error bars indicate standard deviation (n=3). χ/M-VLPs formed in DMEM + FBS were much more efficient as 
compared to χ/M-VLPs formed in 5% Glucose solution at all tested vector stoichiometries.(#,  p<0.0003 for 1773-
fold difference between optimal transfections). 
 
Use of Caffeine to improve M-VLP titer and TE of χ/M-VLPs 
Caffeine has been known to inhibit various kinases such as ATM (ataxia telangiectasia mutated), 
ATR (ataxia telangiectasia and Rad3-related protein) and DNA-PKcs (DNA-dependent protein kinase 
catalytic subunit) which are important cell signaling proteins leading to increase in lentiviral titer22. We 
decided to explore if similar effects can be measured in GP293Luc M-VLP producer cells and M-VLP titer. 
Firstly, we optimized the concentration of caffeine that might affect the M-VLP titer without affecting cell  
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Figure 17: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 6.1 x 10
9 M-
VLPs/ml in DMEM + FBS and 5 % Glucose solution and chitosan concentration of 1 mg/ml, pH 1-5 in glutamic acid 
and transfected with 1 x 109 M-VLPs/well of a 12-well tissue culture plate. Y-axis – RLU/mg total protein = 
Relative Light Units normalized to total mg protein in cell lysate. X-axis – (μg):M-VLP (109) stoichiometry. Error 
bars indicate standard deviation (n=3). χ/M-VLPs formed in DMEM + FBS were much more efficient as compared 
to χ/M-VLPs formed in 5% Glucose solution at all tested vector stoichiometries and pH of chitosan stocks. As a 
negative control, transfections with 0.6% glutamic acid without chitosan were also attempted to compare the role of 
the amino acid, if any, in mediating transfections. There was a > 4800-fold difference between using chitosan in 
glutamic acid and glutamic acid alone at their most-optimal stoichiometries for transfections (#, p<0.0005). 
 
viability. Figure 18 shows the cytotoxicity profile of caffeine on GP293Luc cells measured via the Cell-Titer 
BlueTM assay. High concentrations of caffeine (> 4 mM) were toxic to cells with lower than 60% cell 
viability. We then tested the effect of caffeine on M-VLP titer by seeding GP293Luc cells in DMEM + FBS 
in the presence of < 4 mM caffeine. As per Figure 19, M-VLP titer peaked at a caffeine concentration of 
0.25 mM (≈ 40% higher, p < 0.02) and steadily decreased beyond 0.25 mM due to possible toxic effects. 
Next, we decided to perform a time-course experiment in order to determine the most optimal time of  
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Figure 18: Cell-Titer Blue Cytotoxicity Assay conducted on GP293Luc cells in the presence of caffeine. Y-axis - 
Normalized Absorbance values compared to untreated cells which are a direct indicator of metabolic activity based on 
the ability to reduce resazurin to resorufin by living cells. X-axis is the concentration of caffeine (mM). Error bars 
indicate standard deviation (n=3). 
 
exposure of the required caffeine concentration to maximize viral titer as shown in Figure 20. The effect of 
adding caffeine at the various time points was insignificant as compared to 0 h wherein the cells were seeded 
in DMEM-containing caffeine. Additionally, the M-VLP titer improved at all time-points with respect to 
the control cells containing no caffeine, especially at 24 h (≈ 40% higher, p < 0.05). The improvement in 
M-VLP titer, however, did not offer any significant improvement in transfection efficiency over M-VLPs-
DMEM as shown in Figure 21. 
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Figure 19: Normalized M-VLP titer from GP293Luc cells seeded at 2 x 106 cells/100 mm cell culture plate exposed 
to various concentrations of caffeine (0-4 mM). Y-axis – Normalized M-VLP titer – M-VLP titer from each sample 
normalized to M-VLP titer from cells containing no caffeine. X-axis – Caffeine concentration in mM. Error bars 
indicate standard deviation (n=3, ## - p < 0.02). 
 
Use of reduced serum growth media for design of χ/M-VLPs 
In our earlier studies, we had shown that M-VLPs grown in serum-free media when complexed 
with PEI led to >10-100 -fold improvement in transfections2,23. In that study, GP293Luc cells were seeded 
at 2 x 106 cells/100 mm tissue culture plate with media containing serum which was replaced after 48 h 
with media containing no serum. The supernatant containing M-VLPs (OptiMEM = M-VLPs-OM and 
serum-free DMEM = M-VLPs-SF) were collected 18 h post-media change and quantified using q-PCR. We 
decided to investigate the possibility of growing GP293Luc cells in the minimum possible serum  
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Figure 20: Normalized M-VLP titer from GP293Luc cells seeded at 2 x 106 cells/100 mm cell culture plate exposed 
to caffeine (0.25 mM) at various times during cell growth (0-72 h). Y-axis – Normalized M-VLP titer – M-VLP titer 
from each sample normalized to M-VLP titer from cells containing no caffeine. X-axis – Caffeine concentration in 
mM. Error bars indicate standard deviation (n=3, # - p < 0.05). 
 
concentration through sequential adaption to lower serum content over multiple splits following which 
their ability to transfect through χ/M-VLPs vector synthesis would be tested on HEK293 cells. However, 
GP293Luc cells were unable to grow in DMEM containing <10% serum. In order to improve their viability 
at lower serum concentration, we decided to use SFM (Serum-free Media, Life Technologies, Carlsbad, 
CA) instead of DMEM which is specially formulated to help grow cells in the absence of serum proteins. 
Through sequential adaption, we were able to lower the required serum concentration to 3% instead of 
10%. Lowering serum content to < 3% led to cell death within 48 h. The typical M-VLP titer of the SFM 
+ 3% serum supernatant (M-VLPs-SFM) as measured via q-PCR was comparable to M-VLPs-DMEM (data 
not shown). The transfection efficiency of χ/M-VLPs-SFM was 140-fold lower at the most optimal vector  
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Figure 21: Transfection Efficiency (TEs) in HEK293 cells of χ/M-VLPs formed at M-VLP density of 13.4 x 10
9 M-
VLPs/ml (DMEM + 10% FBS), 17.5 x 109 M-VLPs/ml (SFM + 3% FBS) and 19.3 x 109 M-VLPs/ml (DMEM + 
10% FBS + 0.25 mM Caffeine, 24 h) and using chitosan in 0.6% glutamic acid, pH 3 with a concentration of 0.5 
mg/ml and transfected with 1 x 109 M-VLPs/well of a 12-well tissue culture plate. FBS = Fetal Bovine Serum. Y-
axis – RLU/mg total protein = Relative Light Units normalized to total mg protein in cell lysate. X-axis – chitosan 
(μg): (109) M-VLPs stoichiometry. SFM with reduced serum-based vectors performed poorly with a 140-fold 
reduction in TE at the most optimal vector stoichiometry compared to DMEM with full serum-based vectors (#, 
p<0.01). Error bars indicate standard deviation (n=3). 
 
stoichiometry compared to χ/M-VLPs-DMEM (p < 0.01). This result was definitely surprising considering 
that the use of M-VLPs-OM and M-VLPs-SF led to significant improvements in transfection efficiency2. 
Additionally, the polymer requirement for optimal transfection efficiency was reduced by using M-VLPs in 
serum-free media. It was concluded in our earlier studies (Figure 11) that the formation of complexes 
containing M-VLPs-DMEM are tertiary complexes of M-VLPS, polymer and serum proteins2. However, 
the absence of serum proteins led to the formation of binary complexes of M-VLPs and polymer that 
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lowered the polymer requirement for optimal transfections2. Similarly, the presence of lower amounts of 
serum in M-VLPs-SFM should have also led to better transfections with lower polymer requirements for 
optimal performance. However, as seen in Figure 21, transfections decreased along with increase in 
polymer requirement for optimal transfections. It is likely that the change in media from DMEM to SFM 
and the lowering of serum concentration led to the budding of sub-optimal M-VLPs with lower transfection 
potential. 
 
Conclusions 
 In this chapter, we investigated the possibility of using chitosan as a potent synthetic envelope for 
the design of polymer-based hybrid vectors (χ/M-VLPs). These hybrid vectors were more efficient at 
transfecting HEK293 cells in vitro compared to PEI/M-VLPs and PLL/M-VLPs despite the lower uptake of 
the vectors. Chitosan was also highly biocompatible as compared to PEI and PLL exhibiting much lower 
toxicity on HEK293 cells. The sizes of these vectors were on the same order of magnitude as PEI/M-VLPs 
and PLL/M-VLPs. Transfections were also improved by using high density M-VLP supernatant with 
reduction in chitosan requirement for optimal transfections.   
 In order to improve the transfections further and reduce vector sizes, we explored the idea of 
modulating various solution parameters of the chitosan stock such as pH, acid type and concentration. The 
reduction in pH of the chitosan stock solution to pH 3 led to > 100-fold improvements in transfections. 
This result is especially significant considering that transfections by MLV-A viruses under similar conditions 
were of the same order of magnitude as χ/M-VLPs. The transfections were marginally improved by 
changing the acid solvent from acetic acid to glutamic acid and aspartic acid. The sizes of the vectors were 
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further improved by reducing the stock concentration of the chitosan from 1 mg/ml to 0.5 mg/ml with 
marginally reduced transfection efficiency.  
 In order to reduce the complexity of vector formation using M-VLPs in DMEM containing serum, 
we re-concentrated the M-VLPs in 5% glucose and achieved much better control over the size of the hybrid 
vectors but TE was decreased significantly. We also attempted to produce M-VLPs from GP293Luc 
producer cells in low serum media (SFM + 3% FBS). However, despite insignificant change in M-VLP 
titer, the transfection abilities of χ/M-VLPs-SFM were severely reduced. We improved M-VLP titer by the 
inhibition of certain cell-signaling proteins in GP293Luc cells with caffeine. However, the transfection 
capabilities of the vectors formed using these M-VLPs was as good as using M-VLPs in media containing no 
caffeine. 
 Overall, transfection efficiency of χ/M-VLPs was improved by using chitosan at lower pH and high 
pKa acids (weak acids). The sizes of the vectors could be modulated by using a reduced stock concentration 
of chitosan and even further by using M-VLPs resuspended in 5% glucose solutions although with reduced 
transfection efficiencies. The vector formation of χ/M-VLPs is strongly driven by pH that affects size, 
surface charge and transfection capabilities of the vectors. Further studies are needed to optimize the 
vectors in solutions with less complexity such as M-VLPs in PBS or HEPES-based buffers in order to impart 
clinical relevance to these vectors.  
It is also important to understand the difference between using PEI and chitosan as synthetic 
envelope replacements for hybrid vector designs. Non-viral vectors typically use plasmid DNA that have a 
much higher negative surface charge than M-VLPs that lends to the fact the higher-cationically charged 
surfaces are needed to condense them into effective gene therapy vectors. In contrast, it is possible that 
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hybrid vectors would be better condensed by chitosan at pH 3 compared to PEI which might lead to 
optimal release of M-VLPs within the cells thereby improving transfection efficiency.  
 
Experimental Procedures: 
Cell Lines and Assays Human embryonic kidney cells, HEK293, were purchased from the American Type 
Culture Collection (Manassas, VA). The MLV producer cell line, GP293Luc, expressing the MLV viral gag-
pro-pol genes and a viral packaging sequence encoding neomycin resistance and luciferase reporter genes was 
purchased from Clontech (Mountain View, CA). Both cell lines were grown in DMEM supplemented with 
10% FBS and cultured at 37 oC in 5% CO2. Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-
buffered saline (PBS) was produced in-house at the Cell Culture Media Facility, School of Chemical 
Sciences, University of Illinois. Fetal Bovine Serum (FBS) was bought from Gemini Bio-Products and used 
as purchased. Luciferase assay and Cell-Titer BlueTM assay kits were bought from Promega and used as per 
manufacturer's instructions. BCA assay was bought from Thermo Scientific and used as per manufacturer's 
instructions. 
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) (in DMEM 
+ 10% FBS or DMEM + 10% FBS + 0.25 mM caffeine or SFM + 3% FBS) seeded in a 10 cm dish. The 
cells were cultured for four days before the M-VLP containing supernatant was collected and filtered 
through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs in the 
supernatant was measured using a q-RT-PCR protocol2. RNA Standards were obtained from the Clontech 
qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was extracted using 
the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further use. Standards 
and viral RNA samples were prepared for reverse transcription using Taqman reverse transcription reagents 
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(Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR tubes using the reagent 
concentrations suggested by the kit plus 250 nM sequence-specific primers. Thermal cycling was carried 
out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of the cDNA standards and 
samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a Taqman 7900 Real-
Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied Biosystems). The final 
reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time PCR reagent:forward 
primer:reverse primer:cDNA volume). The final concentration of the sample RNA was calculated using the 
calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA copies which enabled us 
to calculate the total number of M-VLPs in a given volume of supernatant. Two RNA extracts were 
collected for each M-VLP sample and quantified using 3 dilutions of each cDNA sample. M-VLP 
supernatant was either used immediately or stored at 4 oC for short term storage (<2 weeks) or stored at -
80 oC for long term storage. 
Synthesis of PEI/PLL/χ/M-VLPs PEI (Molecular Weight = 750 kDa, Sigma Aldrich, 1 mg/ml in 
ultrapure water), PLL (Molecular Weight = 150-300 kDa, Sigma Aldrich, 1 mg/ml in ultrapure water) or 
Chitosan (Molecular Weight = 190-310 kDa, Sigma Aldrich, 1 mg/ml dissolved overnight at 55 oC in 0.6 
% acid and filtered through a 0.22 µm surfactant-free cellulose acetate syringe filter, pH 1-6) was added 
drop-wise to required volume of M-VLP supernatant while vortexing to achieve the desired polymer:M-
VLP ratio. The hybrid vectors were then incubated at 4 oC for 4 h.  
Transfection by χ/M-VLPs HEK293 cells were seeded 18-24 h prior to transfection at 4 x 105 cells/well 
in 12 well plates. Growth media containing serum was replaced with serum-free DMEM prior to drop-wise 
addition of vectors and replaced again with normal growth media 4 h post-transfection. 
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Luciferase expression assay Luciferase expression was quantified 24 h or 48 h post-transfection using the 
Promega luciferase assay system following the manufacturer's protocol. Luciferase activity was measured in 
relative light units (RLU) using a Lumat LB 9507 luminometer (Berthold, GmbH, Germany). Lysate 
protein concentration was then determined by BCA assay to standardize expression values.  
Cellular Uptake 20 ml of M-VLP supernatant was centrifuged at 60,000g for 2 h at 4 oC and the pellet was 
resuspended in 50 mM HEPES with 145 mM NaCl so as to obtain a M-VLP density of 1010 M-VLPs/ml. 
1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) (Invitrogen, 
1 mM in DMSO, Ex = 644 nm, Em = 665 nm) was added to the resuspended M-VLPs to give a final 
concentration of 2 µM DiD. The mixture was incubated for 1 h at room temperature. Labeled M-VLPs 
were separated from the free dye through a PD-10 gel filtration desalting column (GE Healthcare). 
HEK293 cells were seeded in 12-well plates at 4 x 105 cells per well 18-24 h prior to transfection. Hybrid 
vectors composed of polymer and DiD-labeled M-VLPs were synthesized as described above and 
transfected onto HEK293. The target cells were washed with PBS containing 0.001% SDS 2 h post 
transfection to remove surface-bound, uninternalized vectors followed by a regular PBS wash. Cells were 
then trypsinized followed by neutralization with 50 µl of FBS, collected, and analyzed by flow cytometry 
using a Becton Dickinson (Franklin Lakes, NJ) LSR II Flow Cytometer with a 633 nm laser. 
Negative Stain Transmission Electron Microscopy (TEM) M-VLPs and χ/M-VLP vectors were fixed by 
adding 1 ml of Karnovsky’s fixative to 3 ml of sample. The sample was then centrifuged at 60,000g for 2 h 
at 4 oC. The pellet was resuspended in a small volume of 5% glucose and diluted with the fixative. A 40 µl 
drop of the sample was placed on a parafilm sheet, a copper grid was placed face down on the sample drop 
and incubated for 30 minutes. Excess sample was wicked off the grid using filter paper. The grid was then 
placed grid-face down on a drop of 7% uranyl acetate stain for 1 min. Excess stain was again wicked off 
using filter paper and the grid was dried for 15 min before viewing in a Hitachi H600 Electron Microscope. 
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Size and Surface Charge Measurements Vectors were prepared as described above and diluted 10-fold in 
5% glucose. The sizes of the resulting complexes and the constituents were measured using dynamic light 
scattering with a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments). Light scattering was 
measured over 10 10-second intervals for each sample. Electrophoretic mobility was measured over 30 runs 
per measurement and 10 measurements per sample via the ZetaPALS module attached to the 90Plus 
Particle Size Analyzer. Zeta potential was estimated via Smoluchowski's theoretical model.  
Cytotoxicity studies The toxicity of chitosan, PEI, PLL and caffeine was determined using the Cell Titer-
BlueTM Cell Viability Assay. Target cells were seeded in a 96-well plate at 5 x 104 cells/well 18-24 h prior 
to addition of polymer. The polymers (0 – 300 µg/ml) or caffeine (0-100 mM) were added to the cells in 
serum-free medium and left for 4 h before the medium was replaced. Fifteen µl of CellTiter-BlueTM reagent 
was added to each well 24 h post-addition of polymers or caffeine. The cells were incubated for further 4 h 
at 37 oC before adding 100 µl per well of stop reagent following which fluorescence (λ = 570 nm, 650 nm) 
was measured in a SpectraMax 340PC 96-well plate reader. 
Statistical Analysis All statistical analyses mentioned in this study was done using the Student’s t-test. 
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CHAPTER 3 
DESIGN OF HYBRID LIPID/RETROVIRAL GENE DELIVERY VECTORS 
 
Introduction  
In Chapter 2, we expanded upon the design of hybrid polymer-based vectors using chitosan in place 
of PEI and PLL1,2. We showed that chitosan is a less expensive, non-toxic, highly efficient synthetic 
envelope as compared to PEI and PLL. However, the large vector sizes of χ/M-VLPs are a major barrier 
towards their successful in vivo implementation as well as in clinical studies. In this chapter, we explore the 
possibility of using lipids in place of polymers as synthetic envelopes in order to design smaller hybrid 
vectors. DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) has been used as a gene delivery vector for 
non-viral gene therapy3–6, viral gene therapy7–11 and RNAi12,13 since its first formulation in 198814. It has a 
polar, cationic head-group with a hydrophobic (oleoyl) unsaturated aliphatic tail as seen in Figure 22. Most 
formulations of DOTAP used in gene therapy applications include a neutral “helper” lipid such as DOPE 
(1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) or cholesterol to reduce the high cationic charge density 
that could disallow efficient release of the genetic cargo at the right location within the cellular 
microenvironment15,16. DOTAP is extremely stable at 4 °C (12 months, aqueous solution) and is relatively 
cheap ($4/mg in powder form). 
DOPE has also been extensively used in gene therapy studies5,7–10,17. As shown in Figure 22, it has a 
neutral head-group with the same hydrophobic chain (oleoyl) as DOTAP. Due to the overall neutral charge, 
the use of DOPE on its own as a drug or gene delivery agent is extremely difficult due to its inability to 
initiate active cellular uptake via charge based interactions or receptor-mediated uptake. Hence, it is 
commonly used along with a cationic moiety such as DOTAP or targeted lipids that are conjugated with  
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Figure 22: Chemical Structures of DOTAP, DOPE and cholesterol 
 
ligands, antibodies or peptides. However, the role of DOPE becomes significant once the cargo is inside the 
intracellular domains of the target cell. It promotes fusion with the endosomal membrane through adoption 
of a hexagonal inverted phase (HII) structure thereby allowing efficient escape of the cargo into the 
cytosol5,6,15. However, in vivo studies have shown that DOPE has much higher fusogenicity with 
erythrocytes as compared to cholesterol (Figure 22), leading to a larger use of the latter in clinical trials as 
the helper lipid compared to DOPE6. 
Cholesterol has a ubiquitous presence in all mammalian systems providing a host of useful functions 
such as cell membrane permeability and fluidity and production of hormones. It has also been used as a 
significant component of lipid-based gene delivery vectors both as DC-Chol, a cationic lipid formulation 
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based on cholesterol8,18,19 as well as on its own as a neutral, helper lipid16,20,21. Hence, considering that there 
has been massive research supporting the use of DOPE and cholesterol as optimal helper lipids in the design 
of lipid-based non-viral gene delivery vectors, they were used in this study with DOTAP to formulate lipid-
based hybrid retroviral gene delivery vectors (hereby referenced as φ/M-VLPs or φxyz/M-VLPs for specific 
φ/M-VLPs with composition DOTAP:DOPE:cholesterol = x:y:z on a weight basis). In addition, DOPE 
and cholesterol are cheap lipids ($2/mg and $0.23/mg respectively, cheaper still if bought in bulk).  
Similar studies have reported attempts to develop a lipid-based synthetic envelope for retroviruses. 
One of the first studies on the rescue of infectivity of M-VLP particles was done using proprietary lipid 
formulations such as Lipofectin, Cellfectin, Lipofectamine and Transfectamine11. In that study, M-VLP 
particles were either incubated with these transfection reagents post-production from producer cell lines or 
were added to target HEK293 cells that were pre-incubated with the transfection reagents. Similar work 
was also done using DOTAP and DC-Chol:DOPE (3:2) liposomes7,8. In this study, we specifically expand 
upon this previous research in two ways. We aim to optimize the best lipid composition using a ternary 
lipid mixture of DOTAP, DOPE and cholesterol followed by further optimization using a variety of size-
reduction protocols in order to obtain individual hybrid vectors rather than aggregates – an issue that 
hampered both the studies mentioned above as well as our polymer-based hybrid vectors. We also elucidate 
design parameters based on a critical packing parameter (P) of lipids for incorporating other lipids in the 
development of these hybrid vectors. 
 
Results and Discussion 
Optimization of Lipid Composition for Efficient Transfection in HEK293 cells 
In order to investigate hybrid vectors using liposomes of varied compositions, multi-lamellar 
liposomes were produced by the dry-film method (Protocol 1) wherein a dry film of the lipid mixture was 
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resuspended in 5% glucose solution via vortexing with minimal sonication to form liposomes22. The 
liposomes were combined with M-VLPs through simple mixing that led to electrostatic interactions 
between the negatively-charged viral lipid bilayer and the positively-charged DOTAP head-group. This 
simple protocol allowed the opportunity to efficiently explore a wide array of compositions for testing an 
optimal lipid composition for high transfection efficiency. Once the optimal composition was established, 
various liposomal fabrication protocols were used in order to optimize the vector design further for size and 
morphology as characterized via DLS, TEM and surface charge measurements.  
HEK293 cells were transfected with φ/M-VLPs carrying the luciferase reporter gene at four 
lipid/M-VLP stoichiometries of 4, 8, 12 and 16 μg lipid/109 M-VLPs synthesized via Protocol 1. The cells 
were lysed 48 h later and the cell lysate was measured for luminescence. The results are shown in Figure 23 
in a ternary diagram wherein the transfection efficiency of φ/M-VLPs normalized to LF2000/M-VLPs at 5 
μg lipid/109 M-VLPs is plotted as a function of the lipid composition. The grey contour line in each plot 
indicates lipid compositions that exhibited TE > 100 (TE = normalized transfection efficiency). DOTAP-
rich compositions performed poorly at all lipid/M-VLP stoichiometries (lower right corner of triangle). 
DOPE-heavy formulations also exhibited poor TE overall (upper region of triangle). The best lipid 
compositions were those that contained ≤ 50% DOTAP and cholesterol-rich formulations with 10-40% 
DOPE content.  
The best binary DOTAP:DOPE composition was φ550/M-VLPs which provided for TE = 70-260 
across all the four lipid/M-VLP stoichiometries. The TE of the best binary DOTAP:cholesterol liposomes 
was by φ103/M-VLPs (DOTAP:cholesterol = 25:75) ranging from 25-90. Cholesterol was needed in higher 
proportions in binary formulations with DOTAP which is surprising given that DOTAP is the cationic lipid 
and is definitely needed as part of the lipid composition to introduce minimal transfections 
(DOPE:cholesterol φ/M-VLPs with no DOTAP were unable to transfect HEK293 cells). 
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Figure 23: Ternary plots of TE of different lipid formulations of DOTAP, DOPE and cholesterol on weight basis in 
HEK293 cells. Each axis on the ternary plot represents one of the lipid components starting from 0% to 100% weight 
basis. To identify any formulation, draw 3 lines from the dot towards each axis parallel to 1) the line that is 60o from 
the horizontal for DOTAP, 2) the line that is 0o from the horizontal for DOPE and 3) the line that is 1200 from the 
horizontal for cholesterol. The color of the dots represents the improvement of TE (from red to green). There are 
four plots that represent four different φ/M-VLP stoichiometries - a) 4 μg lipid/109 M-VLPs, b) 8 μg lipid/109 M-
VLPs, c) 12 μg lipid/109 M-VLPs and d) 16 μg lipid/109 M-VLPs. The grey contour line is drawn around those dots 
that represent lipid formulations that achieved > 100-fold improvement in transfection efficiency over LF2000/M-
VLPs. Transfection data obtained with delivery of 1 x 109 M-VLPs/well of a 12-well tissue culture plate with vector 
formation using M-VLP density of 17.6 x 109 particles/ml. 
 
The transfections by the most optimal ternary φ/M-VLPs, as shown by the grey contour line, were 
repeated again in HEK293 cells over three trials and triplicate each in order to generate a more robust set of 
data (Figure 24). We used binary φ505/M-VLPs, φ550/M-VLPs and φ103/M-VLPs to compare the decrease in 
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TEs of φ/M-VLPs when one neutral helper lipid was completely eliminated. φ325/M-VLPs were the best 
performing hybrid vectors in the range of 4-16 μg/109 M-VLPs with the most optimal stoichiometry being 
16 μg/109 M-VLPs. There was a > 2.5-fold improvement in TEs (#, p < 0.0005) as compared to using 
only DOTAP:DOPE as well as DOTAP:cholesterol at their most optimal stoichiometry of 12 μg/109 M-
VLPs. Additionally, even the minor substitution of cholesterol into a DOTAP:DOPE (1:1:0) lipid 
composition in place of DOTAP (4:5:1) led to a > two-fold improvement in TEs (*, p < 0.0005) but 
further reduction in DOTAP content decreased TEs drastically as seen in φ121/M-VLPs. Similarly, a three-
fold improvement in TEs was achieved by substituting DOPE into DOTAP:cholesterol (1:0:1) in place of 
DOTAP (3:2:5) (p < 0.0005), but again any further reduction in DOTAP content reduced TEs (φ235/M-
VLPs) as well. Hence, it is clear that the most optimal lipid composition for lipid-based hybrid retroviral 
gene delivery is DOTAP:DOPE:cholesterol = 3:2:5 or φ325/M-VLPs. 
In our earliest pilot experiments, we had established that φ587/M-VLPs was an optimal composition 
for efficient TE (data not shown). We repeated experiments comparing φ325/M-VLPs and φ587/M-VLPs in 
HEK293 cells as shown in Figure 25. The plot shows TE that is normalized to 2 μg lipid/109 M-VLPs of 
φ587/M-VLPs instead of LF2000/M-VLPs as in Figure 23. Both lipid compositions provided similar TE 
across the entire range of lipid stoichiometries tested. φ587/M-VLPs represented both neutral helper lipids 
in similar proportions (≈1:1) which was in contrast to φ325/M-VLPs where the DOPE:cholesterol ratio was 
2:5. An equal proportion of both helper neutral lipids would allow for better characterization of φ/M-VLPs 
in terms of size optimization protocols and trafficking studies compared to the negative controls – φ505/M-
VLPs and φ550/M-VLPs. These control compositions were chosen since they were one of the most efficient 
binary lipid formulations and the presence of equal proportions of DOTAP in either that was double the 
proportion in φ587-M/VLPs would enable better comparisons between results especially in internalization 
and trafficking studies as summarized in Chapter 5. 
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Figure 24: Transfection Efficiency (TEs) of the most optimal tertiary φ/M-VLPs (n = 3) as compared to φ550/M-
VLPs, φ505/M-VLPs and φ103/M-VLPs in HEK293 cells at 4 different lipid stoichiometries of 4, 8, 12 and 16 μg 
lipid/109 M-VLPs. Y-axis - RLU/mg total protein = TEs =  Relative Light Units per mg total protein in cellular 
lysate. X-axis – Different lipid formulations and transfections performed using 1 x 109 M-VLPs/well of a 12-well 
tissue culture plate with vector formation using M-VLP density of 4.66 x 109, 6.20 x 109 and 10.9 x 109 particles/ml. 
Error bars indicate standard deviation (n=9). # - p<0.0005.  
 
Cellular Uptake of φ/M-VLPs in HEK293 cells 
Apart from transfections, it was also necessary to establish the effects of the different lipid 
compositions on the cellular uptake of the vectors. While the presence of DOTAP is necessary to mediate 
cellular uptake via electrostatic interactions, it was important to understand whether the presence of DOPE 
and cholesterol leading to improved TE was due to improved cellular uptake or not. This was significant 
considering that cationic DOTAP-rich lipids were amongst the least efficient in transfections and 
electrostatic interactions between the positively charged hybrid vectors and the negatively charged cell  
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Figure 25: Transfection Efficiency (TE) of φ325/M-VLPs and φ587/M-VLPs in HEK293 cells at lipid stoichiometries 
of 2-30 μg/109 M-VLPs. Both lipid compositions provide similar TE in HEK293 cells. Y-axis – Normalized RLU/mg 
total protein = Relative Light Units per mg of total protein in cellular lysate normalized to φ587/M-VLPs at 2 μg/10
9 
M-VLPs. X-axis – Lipid stoichiometries/109 M-VLPs and transfections were performed with 1 x 109 M-VLPs/well of 
a 12-well tissue culture plate with vector formation using M-VLP density of 11.6 x 109 particles/ml. Error bars 
indicate standard deviation (n=3). 
 
surface bilayer was assumed to be the main driving force for cellular uptake. M-VLPs tagged with the 
lipophilic fluorescent dye DiD were complexed with the lipids of desired composition at three 
stoichiometries of 5,10 and 20 μg/109 M-VLPs. In order to compare the effect of all three lipids, we used 
the following lipid compositions – φ100/M-VLPs , φ550/M-VLPs  and φ587/M-VLPs which represented 
DOTAP in decreasing concentration. Figure 26 shows the uptake profiles of φ/M-VLPs at various lipids 
stoichiometries. φ100/M-VLPs exhibited the highest mean fluorescence at all lipid/M-VLP stoichiometries 
followed by φ550/M-VLPs and φ587/M-VLPs. A rightward shift of the mean fluorescence on the x-axis 
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implies higher uptake of the vectors into the cells. Hence, uptake for φ/M-VLPs decreased with decreasing 
DOTAP content. This was expected since increasing the cationic charge density of the vectors should 
correlate with their association with the cell membrane leading to higher uptake. However, higher DOTAP 
content led to low transfection efficiency (Figures 23 and 24). Transfections with pure DOTAP liposomes 
(φ100/M-VLPs) were amongst the lowest efficiency lipid compositions (data not shown). In fact, the 
transfection efficiency was inversely correlated to the uptake of φ/M-VLPs amongst φ100/M-VLPs, φ550/M-
VLPs and φ587/M-VLPs. Therefore, it appears that cellular uptake represents a minor barrier in the overall 
trafficking mechanism and subsequent transfection of φ/M-VLPs. 
 
Toxicity of DOTAP, DOPE and cholesterol liposomes on HEK293 cells 
The toxicity of these lipid compositions on HEK293 cells was also measured to determine if it affected the 
transfection efficiency at higher lipid stoichiometries. Figure 27 shows the relative metabolic activity of cells 
in the presence of lipid compositions 5:8:7, 5:5:0 and 5:0:5 (DOTAP:DOPE:cholesterol) measured using 
the Cell-Titer BlueTM assay. Both 5:5:0 and 5:8:7 had almost no toxic effect up to concentrations of 150 
μg/ml whereas the cell viability was reduced to <80% for 5:0:5 at concentrations of >25 μg/ml with an 
IC50 > 100 μg/ml (IC50 = concentration at which cell viability is 50% of untreated cells). It was surprising 
that 5:8:7 showed no deleterious effects on the cells despite the presence of cholesterol since 5:0:5 
exhibited mild toxicity as mentioned above. This can be explained by the presence of DOPE in 5:8:7 that 
could have led to an efficient trafficking mechanism and/or exocytosis of the lipids leading to lower 
toxicity. The maximum concentration of these lipid compositions used for our transfections and uptake 
studies was <25 μg/ml. Hence, it is clear that the toxicity of these lipids had no influence on the overall 
transfection efficiency, trafficking and uptake of the vectors in HEK293 cells. 
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Figure 26: Uptake of φ/M-VLPs in HEK293 cells at 3 different stoichiometries - a) 5 μg/109 M-VLPs, b) 10 μg/109 
M-VLPs and c) 20 μg/109 M-VLPs. M-VLPs were labeled with fluorescent lipophilic dye DiD prior to complexing 
with lipids of different compositions. Any increase in mean fluorescence is measured via a rightward shift on the x-
axis when compared to the blank sample and denotes increased presence of M-VLPs within the cells.  Y-axis is the 
cell count (10000 cells were measured). X-axis shows the fluorescence signal of the sample. The mean fluorescence 
signal was higher for φ100/M-VLPs as compared to φ550/M-VLPs and φ587/M-VLPs indicating a higher uptake within 
cells. Transfections were performed with 1 x 109 M-VLPs/well of a 12-well tissue culture plate with vector 
formation using M-VLP density of 29.1 x 109 particles/ml. 
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Figure 27: Cell-Titer Blue Cytotoxicity Assay conducted on HEK293 cells exposed to 3 lipid compositions; 
DOTAP:DOPE:cholesterol = 5:8:7, 5:0:5 and 5:5:0. Y-axis is the normalized absorbance values compared to 
untreated cells which are a direct indicator of their metabolic activity based on the ability to reduce resazurin to 
resorufin. X-axis is the concentration of the lipids. Error bars indicate standard deviation (n=3). 
 
Size Reduction and Visualization of φ/M-VLPs 
The dry-film method for preparation of liposomes (Protocol 1) allowed for the simultaneous 
testing of different lipid compositions for optimal transfection efficiency. However, as seen in Table 10, the 
sizes of the hybrid vectors as measured via dynamic light scattering (DLS) were much larger than the M-
VLPs, especially at higher stoichiometry (≥ 10 μg/109 M-VLPs). The formation of a lipid film around the 
M-VLPs was clearly visualized via transmission electron microscopy (TEM) as seen in Figure 28. However, 
the sizes as seen in the images (a-c) were smaller than the sizes measured via DLS. The difference can be 
explained by the fact that DLS measures hydrodynamic diameter which is a true indicator of the vector size 
in suspension. The aggregation of these hybrid vectors was also visualized in Figure 28d which likely more  
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Table 10: Sizes (in nm) measured via Dynamic Light Scattering of φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs 
formed via Protocol 1 at 3 different lipid stoichiometries. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of any lipid was 93 ± 4 nm. The size of these hybrid vectors increased 
with lipid/M-VLP ratios and exceeded 1 μm at stoichiometries > 10 μg/109 M-VLPs. 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs 269 ± 8 278 ± 10 697 ± 60 1916 ± 99 
φ505/M-VLPs 353 ± 5 443 ± 6 601 ± 7 758 ± 12 
φ550/M-VLPs 294 ± 48 493 ± 114 1190 ± 184 1754 ± 60 
 
closely represents the true morphology of the hybrid vector as it correlated well with the sizes measured via 
DLS. It is possible that the vectors seen in Figure 28(a-c) were remnants of a larger aggregated hybrid 
vector that separated during the sample preparation. It was evident from their large size and poor 
morphology (Table 10 and Figure 28d) that Protocol 1 was not the best method to synthesize φ/M-VLPs 
and an alternative protocol with the best size-reduction strategy was needed. Hence, we tested different 
protocols (Table 11) that have been used in liposomal gene and drug delivery protocols to reduce vector 
sizes.  
Sonication of hybrid vectors formed with multi-lamellar liposomes (Protocol 2) was one of the first 
protocols attempted to address the issues which limited Protocol 1 as noted above. It was expected that a 
prolonged period of sonication would not only allow a uniform vesicle size for the lipids but would also 
enable a constant rearrangement of lipid molecules enveloping the M-VLPs leading to smaller-sized φ/M-
VLPs. However, the sizes of these vectors were highly variable with lipid/M-VLP stoichiometries and lipid 
composition (Table 12). φ550/M-VLPs achieved better size reduction with Protocol 2 compared to φ587/M-
VLPs and φ505/M-VLPs. φ550/M-VLPs were <500 nm at all the three stoichiometries. φ587/M-VLPs and 
φ505/M-VLPs were very large at lower lipid/M-VLP stoichiometries but decreased to <500 nm at higher  
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Figure 28: Negative-stained Transmission Electron Microscopy images of φ587/M-VLPs at 10 μg/10
9 M-VLPs. The 
inner structures of M-VLPs (solid black arrows) are clearly seen in all the images (a-d) that are very similar in 
morphology to intact viruses. The enveloping of M-VLPs with lipids (solid white arrows) is also observed in (a-c). In 
(a-b) the formation of a bridge-like structure between two M-VLPs is also visualized forming a dual structure in 
contrast the unitary structure seen in (c). The formation of aggregates as seen in (d) is a common phenomenon when 
using Protocol 1 to synthesize φ/M-VLPs. 
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Table 11: Summary of size-reduction protocols for φ/M-VLPs tested in this project 
Protocol Name Description Limitations Advantages 
1 Dry-Film Method Lipid drying + hydration 
+ addition of M-VLPs 
Multilamellar 
liposomes; large sizes 
greater storage 
stability 
2 Sonication Lipid drying + hydration 
+ sonication with M-VLPs 
Irreproducibility; M-
VLP instability due to 
sonication and high 
temperature; 
High drug 
encapsulation 
3 Magnetic Stirrer 
Vortexing 
Lipid drying + hydration 
+ vortexing with M-VLPs 
Irreproducibility; M-
VLP instability due to 
intense vortexing 
Smaller liposomal 
sizes 
4 Single-Pass 
Extrusion 
Lipid drying + hydration 
+ addition of M-VLPs + 
extrusion 
M-VLP degradation Unilamellar 
liposomes; small 
sizes 
5 Multiple-Pass 
Extrusion 
Lipid drying + hydration 
+ addition of M-VLPs + 
extrusion 
M-VLP degradation Unilamellar 
liposomes; small 
sizes 
6 Multiple-Pass 
Syringe Filtration 
Lipid drying + hydration 
+ addition of M-VLPs + 
filtration 
M-VLP degradation Small sizes 
7 Multiple-Pass 
Extrusion 
without M-VLPs 
Lipid drying + hydration 
+ extrusion + addition of 
M-VLPs 
Larger sizes than 
liposomes; sub-
optimal encapsulation 
Unilamellar 
liposomes; small 
sizes; 
8 Sonication + 
Magnetic Stirrer 
Vortexing 
Lipid drying + hydration 
+ sonication + vortexing 
+ addition of M-VLPs 
Sub-optimal 
encapsulation 
Small sizes 
9 Lipid Pre-
incubation 
Lipid drying + hydration 
+ incubation with 
GP293Luc cells 
Precise vector 
stoichiometry not 
possible 
High Encapsulation; 
small sizes 
10 Ether 
Vaporization 
Lipid dissolution in diethyl 
ether + rapid addition of 
M-VLPs + vaporization 
under vacuum 
M-VLP degradation High Encapsulation; 
small sizes 
11 Alcohol Injection Lipid dissolution in ethanol 
+ rapid addition of lipids 
to M-VLPs + vaporization 
under vacuum 
M-VLP degradation High Encapsulation; 
small sizes 
 
ratios. The higher sizes at low lipid/M-VLP stoichimetries could be attributed to concentration effects 
where large vesicle sizes are stable compared to smaller vesicles. However, the major disadvantage with this 
protocol was that this size reduction could be achieved only by a prolonged period of sonication (2 h)  
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Table 12: Sizes (in nm) measured via Dynamic Light Scattering of φ550/M-VLPs, φ505/M-VLPs and φ587/M-VLPs 
formed via Protocol 2 at 3 different lipid stoichiometries. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of any lipid was 225 ± 6 nm. The sizes decreased with increasing lipid 
stoichiometries. 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs 794 ± 40 1395 ± 148 1809 ± 121 590 ± 42 
φ505/M-VLPs 692 ± 137 3955 ± 944 422 ± 19 473 ± 32 
φ550/M-VLPs 462 ± 25 423 ± 11 350 ± 8 311 ± 10 
 
resulting in increase of the solution temperature to >40 °C. It is known that these viruses have very low 
half-lives (≈5 h) of infectivity at 37 °C23. Sonication can also be damaging to viral particle integrity and 
genomic RNA molecule itself. However, the effects are not known to affect retroviral transfection 
capabilities24. It should also be noted that the sizes of the M-VLPs themselves were larger than expected 
prior to sonication (225 ± 6 nm). This increase in size has always been measured in our lab whenever an 
ultracentrifugation and re-suspension protocol has been used to concentrate viruses or substitute buffers. In 
order to achieve better sizes of these M-VLPs alone in a different buffer or solution such as a 5% glucose 
solution, various chemical and physical methods such as PEG precipitation25,26, Retro-XTM precipitation 
(Clontech, Mountain View, CA), ammonium sulfate precipitation27 and ultrafiltration (Amicon Ultra-15 
centrifugal filter units, MilliporeTM, Billerica, MA) were attempted. The typical recovery of M-VLPs was 
46% ± 3%, 49% ± 14%, 58% ± 11% and 53% ± 8%, respectively, using the methods listed above, which 
was lower than using ultracentrifugation (76% ± 13%) (n=2).  
Protocol 3 involved the use of magnetic stirrers for providing the external energy for rapid 
micellization. This protocol was used for making very small micelles of a PEGylated lipids DSPE-PEG2000-
carboxyfluorescein and DSPE-PEG2000-folate28. The protocol failed at reducing sizes of φ/M-VLPs. On 
the contrary, the sizes were >10 μm at all lipid/M-VLP ratios for all three lipid compositions (data not 
shown). 
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Protocols 4 and 5 used lipid extrusion as the basis for reducing liposomal sizes. Extrusion is a 
common procedure used for producing uniformly sized and unilamellar liposomes29 along with efficient 
encapsulation of cargo. However, the encapsulation efficiency can vary with lipid composition and type of 
cargo. In Protocol 4, we used 100 nm polycarbonate (PC) membranes to extrude the φ/M-VLPs formed 
via Protocol 1. The large size of these vectors led to very inefficient extrusion as the yield of M-VLPs in the 
post-extruded solution was extremely low (~1%), as determined by q-RT-PCR. Since the membrane pore 
diameter was very small, we modified this in Protocol 5 by using 400 nm and 200 nm pore diameter 
membranes along with progressive extrusion whereby φ/M-VLPs are extruded initially through a 400 nm 
and then through a 200 nm membrane. The final sizes of these φ/M-VLPs were <200 nm but the yield of 
M-VLPs was still very low (<10%, n=2). This showed that extrusion is a very inefficient protocol for 
encapsulating M-VLPs within smaller lipid vesicles once the vectors are already associated in a hybrid vector 
complex. It was possible that the membrane extrusion was destroying the viral structure leading to further 
RNA degradation upon multiple passes through the extruder.  
Protocol 6 was essentially the same as Protocol 4 and 5 but used syringe filters of appropriate pore 
diameters. However, the lipids were collected as residue within the filter membrane instead of escaping as 
smaller vesicles into the filtrate. An alternate method for improving encapsulation of cargo was to use 
repeated freeze thawing of lipid mixed with the cargo that results in rearrangement and subsequent size-
reduction and better encapsulation30,31. However, the M-VLPs cannot sustain repeated freeze-thaw cycles 
and would result in reduced infectivity1. 
 Since the extrusion of φ/M-VLPs was infeasible, the protocol was modified as in Protocol 7 to 
obtain smaller, extruded liposomes (≈100 nm) prior to conjugation with M-VLPs. Table 13 summarizes the 
sizes of φ/M-VLPs formed via this protocol. The sizes of these vectors were much smaller (200-400 nm) as 
compared to the ≈1000 nm sizes of φ/M-VLPs formed via Protocol 1. A possible explanation for the  
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Table 13: Sizes (in nm) measured via Dynamic Light Scattering of φ550/M-VLPs, φ505/M-VLPs and φ587/M-VLPs 
formed via Protocol 7 at 3 different lipid stoichiometries. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of any lipid is 133 ± 3 nm. 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs 176 ± 3 334 ± 5 374 ± 10 329 ± 7 
φ505/M-VLPs 172 ± 3 235 ± 5 244 ± 5 483 ± 12 
φ550/M-VLPs 134 ± 2 202 ± 2 397 ± 8 1759 ± 99 
 
differences between sizes achieved via Protocols 1 and 7 is that the sizes of the liposomes alone without M-
VLPs underwent drastic reduction from 300-400 nm to ≈150 nm. This might have led to the formation of 
smaller aggregates when the M-VLPs are introduced into the lipid solution. In order to understand the 
morphology of the φ/M-VLPs formed via Protocol 7, we visualized them via TEM as shown in Figure 29. 
The liposomal structure after extrusion is normally unilamellar wherein the lipid bilayers arrange 
themselves neatly in a unitary spherical structure. The liposomes formed via this protocol prior to 
complexing with M-VLPs were small (≈150 nm) as visualized in Figure 29a and measured via DLS (Table 
13). Also, as seen in Figure 29 (b-d), the lipid bilayer (solid white arrows) appeared to form an envelope 
around the M-VLPs (solid black arrows), thereby resulting in very small sizes as measured via DLS in Table 
13. The exception to the small sizes achieved through this protocol was the formulations containing 
DOTAP:DOPE which resulted in very large vector sizes and will be explained in more detail at the end of 
this chapter.  
The transfection efficiency of φ-M-VLPs formed via Protocol 7 was also tested (Figures 30,31 and 
32). TE increased for φ505/M-VLPs by 50% (15 μg/10
9 M-VLPs) and decreased by 33% for φ550/M-VLPs 
(5 μg/109 M-VLPs) and φ587/M-VLPs (12.5 μg/10
9 M-VLPs) at their most optimal lipid stoichiometries. 
The transfection efficiency decreased rapidly for high lipid/M-VLP stoichiometries for φ550/M-VLPs where  
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Figure 29: Negative-stained Transmission Electron Microscopy images of (a) 5:8:7 liposome after extrusion prior to 
conjugation with M-VLPs, (b-d) φ/M-VLPs (φ587/M-VLPs, 10 μg/10
9 M-VLPs) via Protocol 7. The inner structures 
of M-VLPs (solid black arrows) are clearly seen in all the images (b-d) that are very similar in morphology to intact 
viruses. The enveloping of M-VLPs with lipids (solid white arrows) is also observed in (b-d). 
 
80 
 
 
Figure 30: Transfection Efficiency (TE) in HEK293 cells transfected with varied lipid/M-VLP ratios of φ587/M-VLPs 
at 1 x 109 M-VLPs/well of a 12-well tissue culture plate formed via Protocol 1 and 7 using M-VLP density of 11.3 x 
109 particles/ml. Y-axis – Normalized RLU/mg total protein = Relative Luciferase Units per mg of total protein in 
cellular lysate normalized to the same measurement at a lipid stoichiometry of 2.5 μg/109 M-VLPs of φ587/M-VLPs 
formed via Protocol 1. X-axis – Lipid stoichiometries/109 M-VLPs. Error bars indicate standard deviation (n=3). 
 
Figure 31: Transfection Efficiency (TE) in HEK293 cells transfected with varied lipid stoichiometries of φ550/M-
VLPs at 1 x 109 M-VLPs/well of a 12-well tissue culture plate formed via Protocol 1 and 7 using M-VLP density of 
11.3 x 109 particles/ml. Y-axis – Normalized RLU/mg total protein = Relative Luciferase Units per mg of total 
protein in cellular lysate normalized to the same measurement at a lipid stoichiometry of 2.5 μg/109 M-VLPs of 
φ550/M-VLPs formed via Protocol 1. X-axis – Lipid stoichiometries/10
9 M-VLPs. Error bars indicate standard 
deviation (n=3). 
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Figure 32: Transfection Efficiency (TE) in HEK293 cells transfected with varied lipid stoichiometries of φ505/M-
VLPs at 1 x 109 M-VLPs/well of a 12-well tissue culture plate formed via Protocol 1 and 7 using M-VLP density of 
11.3 x 109 particles/ml. Y-axis – Normalized RLU/mg total protein = Relative Luciferase Units per mg of total 
protein in cellular lysate normalized to the same measurement at a lipid stoichiometry of 2.5 μg/109 M-VLPs of 
φ505/M-VLPs formed via Protocol 1. X-axis – Lipid stoichiometries/10
9 M-VLPs. Error bars indicate standard 
deviation (n=3). 
 
we also measured very high vector sizes (Table 13). Comparing Figures 30,31 and 32 along with Table 13, 
the presence of cholesterol in lipid formulation seems to allow for better condensing of hybrid vectors 
resulting in improved sizes and better transfections.  
Protocol 8 was derived from Protocols 2 and 3 incorporating both sonication and magnetic stirrer 
vortexing. However, as can be seen in Table 14, the sizes of both liposomes as well as φ/M-VLPs were 
larger than samples formed via Protocol 1. In prior studies, micelles of DSPE-PEG2000 were formed in our 
lab using magnetic vortexing alone and were typically small (<100 nm)28. It has been known that in lipid 
systems containing >75% PEGylated lipids, the liposomal structures are small and spherical, which was  
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Table 14: Sizes (in nm) measured via Dynamic Light Scattering of φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs 
formed via Protocol 8 at 3 different lipid stoichiometries. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of any lipid is 101 ± 2 nm. 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs 748 ± 45 923 ± 93 1222 ± 62 1361 ± 177 
φ505/M-VLPs 821 ± 54 915 ± 109 998 ± 125 1391 ± 97 
φ550/M-VLPs 269 ± 7 494 ± 24 1621 ± 141 1816 ± 86 
 
observed in our earlier studies wherein we used 100% PEGylated lipids32. Our current lipid system had no 
PEGylated lipids, which might explain the formation of larger aggregates. 
Protocol 9 was an innovative method based on the premise that the lipid bilayer surrounding the 
retroviral capsid has a very strong correlation to the cellular membrane lipid composition33,34. Incorporation 
of lipids onto cellular membranes has been studied in order to transfer phospholipid characteristics from 
synthetic vesicles onto cells for a variety of applications such as lipid membrane characterization, lipid 
metabolism and fluorescent label tagging35–37. Such protocols are possible mainly because of the 
characteristics of lipids to be incorporated freely into existing lipid bilayers such as in the mechanism of 
post-insertion wherein micelles of PEGylated lipids can be incorporated onto preformed liposomes38–40. 
DOPE and cholesterol being naturally derived lipids should be incorporated into the cell membrane. 
However, it is unknown whether they would be metabolized internally or recycled within the lipid 
membrane itself. DOTAP has been used in the past to engineer cell surfaces with unique lipid-based 
molecular markers although at very low weight proportions (2%)41. For the implementation of Protocol 9, 
it was hypothesized that if the three lipids, DOTAP, DOPE and cholesterol were pre-incubated with the 
GP293Luc cells, their incorporation onto the cell membrane might lead to the budding of M-VLPs with a 
lipid membrane envelope that contains these three lipids as well. These M-VLPs would now be capable of 
transfections as well as be of similar sizes as the native M-VLPs themselves. The main disadvantage of this  
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Table 15: Sizes (in nm) measured via Dynamic Light Scattering of φ587/M-VLPs formed via Protocol 9 at 2 different 
lipid stoichiometries of 250 and 500 μg per cell culture plate. Errors are standard deviations (n=2; 10 readings for 
every sample). The size of M-VLPs without addition of any lipid was 101 ± 2 nm.  
 φ587/M-VLPs w/ serum w/o serum 
Filtered (a) 250 µg/50 mm plate 364 ± 40 142 ± 4 
 500 µg/50 mm plate 441 ± 65 173 ± 7 
    
Not Filtered (b) 250 µg/50 mm plate 164 ± 4 130 ± 3 
 500 µg/50 mm plate 145 ± 3 141 ± 3 
 
method was that the lipid/M-VLP stoichiometry could not be controlled since the lipids would be added 
while the M-VLPs were still budding. In order to characterize this system, we used the stoichiometry of 
lipid weight per tissue culture plate. GP293Luc cells were seeded at 106 cells per 50 mm diameter tissue 
culture plate and allowed to grow for 2 days prior to the addition of lipids. The cell supernatant was 
collected 2 days after addition of lipids either with filtration through a 0.45 μm pore diameter syringe filter 
(a) or without (b). It is also known that the incorporation of gangliosides onto the cell membrane was 
inhibited in the presence of serum37. Hence, we compared our protocol in the presence of serum (+) and 
absence of serum (-). For the protocol without serum, we replaced the serum-free media with complete 
media 6 hours post-addition of lipids. Table 15 summarizes the sizes of φ/M-VLPs formed via Protocol 9. 
Filtration of the cell supernatant containing the hybrid vectors led to a greater than two-fold decrease in 
size. The absence of serum resulted in low sizes and the size reduction after filtration was minimal. Figure 
33 shows the normalized transfection efficiency of φ/M-VLPs formed via Protocol 9b as compared to using 
φ587/M-VLPs formed via Protocol 1. Protocol 9b vectors performed poorly with the most optimal being 
less than 2% efficient as Protocol 1 vectors. The hybrid vectors formed via Protocol 9a failed to transfect 
HEK293 cells. 
In order to characterize this method further, we analyzed the morphology of the M-VLPs via TEM 
as shown in Figure 34. The association of the lipids with the M-VLPs is clearly visible but it was unclear 
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whether the hybrid vectors were formed due to the M-VLPs budding from the cell surface containing lipids 
or if the lipids electrostatically conjugated to the M-VLPs post-budding in the cell supernatant. The 
formation of hybrid vectors via this protocol would allow for the synthetic envelope to be a part of the 
natural lipid bilayer of the M-VLPs. The TEM image shows synthetic envelopes as a separate entity from the 
M-VLPs indicating that the hybrid vectors were most likely formed post-budding. The low transfection 
efficiency coupled with significant size reduction upon filtration of the hybrid vectors also suggests the 
formation of hybrid vectors post-budding. The majority of the lipids was suspended in the cell supernatant 
and was visible in the TEM images (not shown) as aggregates not conjugated with the M-VLPs. Both 
filtration (9a vs 9b) and replacing media for (-) samples led to the lower presence of the freely suspended 
lipids which suggests that the lipids in our study were not favored to associate with the cell membrane. The 
previous study using DOTAP to engineer cell surfaces claimed that the lipids had higher propensity to be 
internally recycled in the cell but that enough lipids molecules were present on the cell surface for their 
intended application41. Also, it is unclear from their procedure as to how long the cells remained tagged 
with the lipids. In our experiments, a minimum of 48 h would be necessary for incubation of lipids with the 
cells to allow for sufficient budding of M-VLPs for a titer high enough for efficient transfections. 
Protocol 10 was formulated for the preparation of large lipid vesicles within which cargo could be 
efficiently packed42. An aqueous solution containing the cargo of interest (in our case, M-VLPs in DMEM or 
5% glucose) was added rapidly to lipids dissolved in diethyl ether. The ether was then evaporated under 
vacuum leading to a slow transfer of the lipids into the aqueous phase followed by their enveloping around 
the M-VLPs. However, the lipids in our study formed thick precipitates once ether evaporated. This 
protocol was aborted in favor of Protocol 11 as outlined below. 
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Figure 33: Transfection Efficiency (TE) in HEK293 cells transfected with φ587/M-VLPs of varied lipid 
stoichiometries formed via Protocol 9. Y-axis – Normalized RLU/mg total protein = Relative Luciferase Units per 
mg of total protein in cellular lysate normalized to the same measurement at a lipid stoichiometry of 10 μg/109 M-
VLPs of φ587/M-VLPs formed via Protocol 1 with 1 x 10
9 M-VLPs/well of a 12-well tissue culture plate. X-axis – 
Lipid (μg) incubated with one 50 mm tissue culture plate along with the volume (μl) of GP293Luc cell-supernatant 
containing the hybrid vectors used to transfect HEK293 cells. Error bars indicate standard deviation (n=3). 
 
 
Figure 34: Negative-stained Transmission Electron Microscopy images of φ587/M-VLPs (250 μg/50 mm plate) via 
Protocol 9 without filtration (left) and with filtration (right). The inner structures of M-VLPs (solid black arrows) are 
clearly seen that are very similar in morphology to intact viruses. The enveloping of M-VLPs with lipids (solid white 
arrows) is also observed. Freely suspended lipid particles are also visualized in the samples without filtration (left). 
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 Protocol 11 was a modification of the ether protocol (Protocol 10) and can be used to prepare large 
liposomes for encapsulating proteins, mRNA, siRNA and DNA with 10-fold improvement in encapsulation 
over Protocol 1013,43–45. There have also been studies suggesting that DOPE-rich cationic liposomes 
prepared by this method are optimal non-viral gene delivery vectors with better transfection efficiency and 
size stability as compared to the dry-film method in Protocol 145. The basis of this protocol was that an 
alcoholic solution of lipids when injected rapidly into an aqueous solution containing M-VLPs and upon 
evaporation under vacuum led to a slow transfer of lipids into the aqueous phase thereby leading to the 
formation of smaller hybrid vectors. This protocol also suffered from similar issues of precipitation of the 
lipids upon alcohol evaporation except when synthesizing φ550/M-VLPs. No precipitates were formed and 
the sizes of the vectors formed were smaller and better than those formed via Protocol 7 (Table 16). Figure 
35 shows the morphology of the hybrid vectors formed via this protocol. The lipid (white arrow) 
enveloping the M-VLP (black arrow) is clearly visible thereby proving that the smaller sizes of these vectors 
is not just the presence of smaller sized liposomal structures formed during the transfer of the lipid from the 
alcohol to the aqueous phase, but also the association of the lipid with M-VLPs. However, as seen in Figure 
36, the transfection efficiency of these hybrid vectors was poor as compared to those formed using Protocol 
1. Broadly speaking, the transfection abilities of these hybrid vectors improved as the percentage of ethanol 
in the M-VLP solution decreased. However, any further reduction below 8% led to no more improvements 
in transfections. The transfection efficiency of hybrid vectors formed via Protocol 1 was at least 20-fold 
higher than those formed via Protocol 11 at their most optimal stoichiometry (p < 0.005). According to a 
study done on plasmid DNA based non-viral vectors, the lipoplexes prepared by this method were more 
efficient in in vitro transfections as compared to Protocol 145. However, in this study liposomes were formed 
by this method prior to conjugation with DNA via simple mixing whereas in our study, we aimed to achieve 
better vector morphology by forming the vectors with this method rather than just the liposomes. It is  
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Table 16: Sizes (in nm) measured via Dynamic Light Scattering of φ550/M-VLPs formed via Protocol 11 at 3 different 
lipid stoichiometries. Errors are standard deviations (n=2; 10 readings for every sample). The size of M-VLPs 
without addition of any lipid is 101 ± 2 nm. 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs - - - - 
φ505/M-VLPs - - - - 
φ550/M-VLPs 183 ± 1 320 ± 7 271 ± 4 305 ± 3 
 
  
Figure 35: Negative-stained Transmission Electron Microscopy images of φ550/M-VLPs (10 μg/10
9 M-VLPs) via 
Protocol 11. The inner structures of M-VLPs (solid black arrows) are clearly seen that are very similar in morphology 
to intact viruses. The enveloping of M-VLPs with lipids (solid white arrows) is also observed.   
 
evident that this protocol leads to minimal aggregation thereby forming smaller vectors but ethanol 
probably deactivates the virus by fixing - the study of which is beyond the scope of this document. 
 Through stringent testing of all protocols as summarized in this chapter, it was clear that 
Protocol 7 wherein extruded liposomes were used to conjugate with M-VLPs was the most optimal in 
terms of size, morphology and efficient transfection in HEK293 cells. In Chapter 2, we concluded that 
polymer concentration also had a major influence on subsequent vector formation and transfection  
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Figure 36: Transfection Efficiency (TEs) of φ550/M-VLPs in HEK293 cells with varied lipid stoichiometries formed 
via Protocol 1 and Protocol 11 using M-VLP density of 16.4 x 109 particles/ml with transfections by 1 x 109 M-
VLPs/well of a 12-well tissue culture plate. The hybrid vectors were formed with different concentrations of ethanol 
as a percentage of the M-VLP containing DMEM supernatant from 5.25% to 26.27% in order to gauge the effect of 
alcohol on the activity of M-VLPs (#, p < 0.005).  
 
efficiency. We tested this parameter with φ/M-VLPs as well (Table 17 and Figure 37). As can be seen, the 
transfection efficiency decreased with decreasing lipid concentration similar to using chitosan as the 
synthetic envelope.  Additionally, the optimal lipid/M-VLP ratio required for efficient transfection changed 
with the lipid concentration from 10 μg/109 M-VLPs at 1 mg/ml to 17.5 μg/109 M-VLPs at 0.5 mg/ml 
and 12.5-20 μg/109 M-VLPs at 0.25 mg/ml. The significant difference in the transfection efficiency at 5 
and 10 μg/109 M-VLPs at the three different lipid concentrations was surprising considering that the 
difference in size and charge was minimal at these lipid/M-VLP stoichiometries (Table 17). It is likely, 
however, that at low lipid concentrations, the amount of lipids condensing one or more M-VLPs into a  
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Figure 37: Normalized Transfection Efficiency of φ587/M-VLPs formed by associating M-VLPs with liposomes at 
concentrations of 1, 0.5 and 0.25 mg/ml via Protocol 7 using M-VLP density of 16.4 x 109 particles/ml with 1 x 109 
M-VLPs/well of a 12-well tissue culture plate. Y-axis = Relative Luciferase Units/mg total protein in cell lysate 
normalized to the same data at a lipid stoichiometry of 2.5 μg/109 M-VLPs for φ587/M-VLPs formed using a lipid 
concentration of 1 mg/ml. X-axis = lipid stoichiometries from 2.5-20 μg/109 M-VLPs. 
 
hybrid structure was less than that at higher concentrations. This could potentially lead to inefficient release 
of M-VLPs within the cytosol. The higher lipid amounts would allow for the hybrid vector structure to be 
preserved for longer within the cell trafficking pathway thereby leading to greater success in transfection. 
This is also evident from Figure 37 wherein the transfection efficiency improved or remained stable even at 
lipid/M-VLP ratios > 10 μg/109 M-VLPs for lipid concentrations of 0.5 and 0.25 mg/ml thus suggesting 
that a higher lipid coating was required to obtain better transfection efficiency which was attained at lower 
lipid/M-VLP ratios using high lipid concentrations. Another possible reason could be the time required for 
complexing between M-VLPs and lipids which was 2 h for all lipid experiments. Low lipid concentrations  
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Table 17: Sizes (in nm) measured via Dynamic Light Scattering and Zeta Potential (in mV) via ZetaPALS of φ587/M-
VLPs, φ505/M-VLPs and φ550/M-VLPs formed via Protocol 7 at 3 different lipid stoichiometries using liposomes at 3 
different concentrations of 1, 0.5 and 0.25 mg/ml. Errors are standard deviations (n=2; 10 readings for every 
sample). The size of M-VLPs without addition of any lipid was 101 ± 2 nm and the zeta potential was -6.8 ± 1.2 mV. 
Size 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs (1 mg/ml) 144 ± 6 336 ± 12 443 ± 21 921 ± 204 
φ505/M-VLPs (1 mg/ml) 139 ± 2 327 ± 21 286 ± 7 456 ± 25 
φ550/M-VLPs (1 mg/ml) 119 ± 4 364 ± 14 372 ± 12 2604 ± 292 
     
φ587/M-VLPs (0.5 mg/ml)  315 ± 12 364 ± 14 1196 ± 354 
φ505/M-VLPs (0.5 mg/ml)  246 ± 7 197 ± 29 350 ± 10 
φ550/M-VLPs (0.5 mg/ml)  240 ± 6 350 ± 18 2275 ± 176 
     
φ587/M-VLPs (0.25 mg/ml)  242 ± 7 323 ± 12 634 ± 94 
φ505/M-VLPs (0.25 mg/ml)  224 ± 7 218 ± 6 317 ± 25 
φ550/M-VLPs (0.25 mg/ml)  226 ± 6 285 ± 14 1986 ± 354 
 
Zeta Potential 
  Lipid/M-VLP ratios (μg/109 M-VLPs) 
Type Only Lipid 5 10 20 
φ587/M-VLPs (1 mg/ml) 5.08 ± 1.9 -2.1 ± 2.7 5.7 ± 1.7 20.3 ± 1.2 
φ505/M-VLPs (1 mg/ml) 10.6 ± 2.3 -1.2 ± 2.0 4.3 ± 2.3 11.0 ± 1.4 
φ550/M-VLPs (1 mg/ml) 2.7 ± 2.1 -1.7 ± 1.7 15.9 ± 1.4 9.1 ± 2.1 
     
φ587/M-VLPs (0.5 mg/ml)  -7.4 ± 2.2 7.2 ± 1.7 21.9 ± 0.7 
φ587/M-VLPs (0.25 mg/ml)  -4.7 ± 1.5 6.4 ± 2.3 21.1 ± 1.7 
 
may require more time for forming effective hybrid structures than the high concentration solutions. 
Additionally, the change in lipid composition also affected the size and charge of φ/M-VLPs. The presence 
of DOPE in φ550/M-VLPs and φ587/M-VLPs led to much higher sizes for vectors especially at higher 
lipid/M-VLP stoichiometries. It is known that both DOPE and cholesterol (in presence of cationic lipids 
such as DOTAP) prefer to form inverted hexagonal HII phase structures compared to flexible binary layers 
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(Lα) preferred by cationic-charged DOTAP but only at >50% lipid compositions or due to other external 
factors such as salt composition and pH46,47. This is because the critical packing parameter (P) is > 1 for both 
these lipids and < 1 for DOTAP. P is mathematically defined as the ratio of the effective volume to the 
head-group area and chain length of the lipid molecule. During the formation of these lipid vectors, it is 
likely that the presence of DOPE led to the formation of the HII phase much better than cholesterol. This 
explains the fact that both φ550/M-VLPs and φ587/M-VLPs were larger in size at very high lipid 
stoichiometries due to a certain degree of inverted phase structures. It also explains why φ550/M-VLPs had a 
lower surface charge at 20 μg/109 M-VLPs as compared to 10 μg/109 M-VLPs (Table 7). The rate of 
change in surface charge with respect to lipid stoichiometries was steeper in φ587/M-VLPs as compared to 
φ505/M-VLPs suggesting that the outer surface was cholesterol-rich in lipid formulations containing only 
cholesterol. This is also confirmed from other studies that claim the presence of cholesterol nano-domains 
in cholesterol-rich lipid-based formulations48. 
 The potential for formation of HII appears to be an important parameter for optimal transfection 
efficiency. The very low transfection efficiency of φ100/M-VLPs could be explained with the fact that almost 
the entire hybrid vector was in Lα phase with very minimal potential for enabling the HII phase during 
transfections. Additional transition from Lα to HII would only happen within the cellular microenvironment 
in acidified vesicles. As seen in Figures 30,31 and 32, the optimal lipid stoichiometry for efficient 
transfection decreased with increased DOPE content in the lipid formulation. It is known that both 
cholesterol49,50 and DOPE46,50 enable the transition from lamellar to inverted phase within the endosomes. 
But it is possible that DOPE favored the inverted phase structure to a greater degree and at lower lipid 
stoichiometries compared to cholesterol thereby enabling quicker release of M-VLPs into the cytosol. It is 
also possible that the DOPE-based vectors were already oriented to a certain degree in HII phase which can 
be inferred from the larger vector sizes in DOPE-containing vectors at high lipid/M-VLP ratios as well as 
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the surface charge of the lipids alone (Table 17, 5:0:5 has higher zeta potential as compared to 5:5:0 despite 
the presence of the same amount of DOTAP). Hence, any higher lipid stoichiometries in DOPE-based 
vectors led to loosely-condensed M-VLPs that did not perform as efficiently as compared to lower lipid 
stoichiometries due to poor vector morphology. At the same time, a greater amount of cholesterol was 
required to achieve the desired inverted phase structure for optimal vector morphology as well as optimal 
release of the M-VLPs within the cytosol, which explains the larger lipid stoichiometry required for 
efficient transfections.  
For φ587/M-VLPs the optimal transfection efficiency is in between that of φ550/M-VLPs and 
φ505/M-VLPs which seemed surprising given that the presence of both the neutral helper lipids promoting 
the inverted phase structure would enable efficient transfections at lower lipid stoichiometries. However, it 
is probable that the mechanism of phase inversion might differ for the two neutral species. The first neutral 
helper lipid to allow for this transition would be DOPE but due to its lower ratio as compared to φ550/M-
VLPs, the optimal transfection efficiency was achieved at higher lipid stoichiometries. It should be 
mentioned that upon comparing Figures 30,31 and 32 and Table 13, it can be concluded that φ/M-VLPs 
formed via Protocol 7 with the smallest sizes had very high transfection efficiencies. Conversely, higher 
vector sizes led to poor transfections. 
 
Conclusions 
 In this chapter, we expanded upon previous studies of associating lipids with M-VLPs in order to 
restore infectivity to envelope protein-deficient viruses. The lipids of choice for this study were DOTAP, 
DOPE and cholesterol. The first step in this direction was to optimize the best lipid composition using these 
lipids for efficient transfection in HEK293 cells. Amongst all the lipid compositions tested, it was inferred 
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that φ3:2:15/M-VLPs, φ235/M-VLPs, φ325/M-VLPs, φ121/M-VLPs and φ451/M-VLPs were amongst the best 
in terms of transfection efficiency. Upon further testing, we confirmed that φ325/M-VLPs was the most 
efficient lipid composition. However, for advanced characterization of liposome fabrication protocols as 
well as intracellular trafficking and design of targeted vectors, φ587/M-VLPs was chosen as the composition 
of choice that also performed favorably in comparison to φ325/M-VLPs. Additionally, we chose φ505/M-
VLPs and φ550/M-VLPs as partial negative controls as they were the most optimal binary lipid composition-
based hybrid vectors in terms of transfection efficiency and also included DOTAP in equal proportions that 
would make for accurate analysis of the effect of lipid composition on hybrid vector performance and 
morphology. 
Amongst all the protocols we chose to perform for obtaining the best vector morphology, 
sonication led to smaller vector sizes but heated the solution to >40 °C which could inactivate the M-VLPs 
in a short period of time. Extrusion of the hybrid vectors themselves led to a very high degree of 
destruction of the M-VLPs. On the other hand, extrusion of lipids prior to associating with M-VLPs led to 
improved sizes and better transfections. Use of the ether vaporization technique led to the formation of 
lipid precipitates during transfer to the aqueous phase. The alcohol injection method also precipitated the 
lipid mixtures except for φ550/M-VLPs. Additionally, the sizes of these vectors improved in comparison to 
Protocol 1. However, the presence of ethanol in the solution led to possible fixation of M-VLPs that 
lowered the transfection efficiency. It was decided to use Protocol 7, i.e. extrusion of lipids prior to 
conjugating with M-VLPs, for further tests discussed in Chapter 5. The three lipids in this study also 
differed in the arrangement of their individual molecules in terms of packing into self-assembled structures. 
DOTAP prefers the Lα phase as compared to DOPE and cholesterol that prefer the HII inverted phase since 
P < 1 for DOTAP and > 1 for DOPE and cholesterol. On comparison of the sizes, surface charge and 
transfection efficiencies of these hybrid vectors, it can be summarized that lipids which promoted the 
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formation of this HII phase at the appropriate lipid/M-VLP ratios as well as the right time during 
transfection provided for most optimal transfections. We suggest that the most optimal lipid formulation as 
well as lipid stoichiometry were such that the hybrid vector structure was on the verge of arranging in the 
HII phase which occurred during transfection in the appropriate vesicles within the cellular 
microenvironment that would then allow the M-VLPs to go along towards the nucleus for efficient 
unpacking of the viral capsid followed by provirus formation and genomic integration during cell division. 
 
Experimental Procedures: 
Cell Lines and Assays Human embryonic kidney cells, HEK293, were purchased from the American Type 
Culture Collection (Manassas, VA). The MLV producer cell line, GP293Luc, expressing the MLV viral gag-
pro-pol genes and a viral packaging sequence encoding neomycin resistance and luciferase reporter genes was 
purchased from Clontech (Mountain View, CA). Both cell lines were grown in DMEM supplemented with 
10% FBS and cultured at 37 oC in 5% CO2. Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-
buffered saline (PBS) was produced in-house at the Cell Culture Media Facility, School of Chemical 
Sciences, University of Illinois. Fetal Bovine Serum (FBS) was bought from Gemini Bio-Products and used 
as purchased. Luciferase assay and Cell-Titer BlueTM assay kits were bought from Promega and used as per 
the manufacturer's instructions. BCA assay was bought from Thermo Scientific and used as per the 
manufacturer's instructions. 
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) seeded in a 
10 cm dish. The cells were cultured for four days before the M-VLP containing supernatant was collected 
and filtered through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs 
in the supernatant was measured using a q-RT-PCR protocol2. RNA Standards were obtained from the 
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Clontech qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was 
extracted using the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further 
use. Standards and viral RNA samples were prepared for reverse transcription using Taqman reverse 
transcription reagents (Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR 
tubes using the reagent concentrations suggested by the kit plus 250 nM sequence-specific primers. 
Thermal cycling was carried out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of 
the cDNA standards and samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a 
Taqman 7900 Real-Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied 
Biosystems). The final reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time 
PCR reagent:forward primer:reverse primer:cDNA volume). The final concentration of the sample RNA 
was calculated using the calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA 
copies which enabled us to calculate the total number of M-VLPs in a given volume of supernatant. Two 
RNA extracts were collected for each M-VLP sample and quantified using 3 dilutions of each cDNA 
sample. M-VLP supernatant was either used immediately or stored at 4 oC for short term storage (< 4 
weeks) or stored at -80 oC for long term storage. 
Synthesis of φ/M-VLPs Different strategies were tested for this study to optimize the formation of hybrid 
vectors in terms of their size and transfection efficiency.  
Protocol 1 (Dry Film Method): The three lipids dissolved in chloroform were mixed in the desired composition 
in a test-tube and dried under vacuum overnight to form a thin film. The lipid film was rehydrated using a 
5% glucose solution and sonicated briefly to allow the lipids to dissolve completely. The rehydrated 
solution was vortexed every 30 minutes for 30 s for a total duration of 3 h. If not used immediately, the 
lipid solution was stored at 4 °C (< 1 month). The lipid samples were diluted in 5% glucose solution as per 
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the required φ/M-VLP stoichiometry followed by the addition of required volume of M-VLP supernatant 
and incubated for 2 h at 4 °C prior to further analysis or transfection. 
Protocol 2 (Sonication): M-VLP supernatant was ultracentrifuged at 60,000g for 2 h at 4 °C and the pellet was 
resuspended in the same volume of 5% glucose solution. The three lipids dissolved in chloroform were 
mixed in the desired composition in a test-tube and dried under vacuum overnight to form a thin film. 
Required volumes of M-VLPs in 5% glucose solution as per desired φ/M-VLP stoichiometry were added to 
the lipid film followed by additional make-up 5% glucose solution to maintain equal volumes for different 
stoichiometries. These samples were bath sonicated for 2 h at room temperature followed by incubation for 
2 h at 4 °C prior to further analysis or transfections. 
Protocol 3 (Magnetic Stirrer Vortexing): M-VLP supernatant was ultracentrifuged at 60,000g for 2 h at 4 °C and 
the pellet was resuspended in the same volume of 5% glucose solution. The three lipids dissolved in 
chloroform were mixed in the desired composition in a test-tube and dried under vacuum overnight to 
form a thin film. Required volumes of M-VLPs in 5% glucose solution as per desired φ/M-VLP 
stoichiometry were added to the lipid film followed by additional make-up 5% glucose solution to maintain 
equal volumes for different viral stoichiometries. These samples were vortexed using magnetic stirrers over 
a magnetic plate for 2 h at room temperature followed by incubation for 2 h at 4 °C prior to further analysis 
or transfections. 
Protocol 4 (Single-Pass Extrusion): M-VLP supernatant was ultracentrifuged at 60,000g for 2 h at 4 °C and the 
pellet was resuspended in the same volume of 5% glucose solution. The three lipids dissolved in chloroform 
were mixed in the desired composition in a test-tube and dried under vacuum overnight to form a thin film. 
The lipid film was rehydrated using the M-VLPs in 5% glucose and sonicated briefly to allow the lipids to 
dissolve completely. The rehydrated solution was vortexed every 30 minutes for 30 seconds for a total 
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duration of 3 h. The final solution was extruded through an Avanti® Mini-Extruder for 11 passes through a 
100 nm polycarbonate (PC) membrane and incubated for 2 h at 4 °C prior to further analysis or 
transfections. 
Protocol 5 (Multiple-Pass Extrusion): Same as Protocol 4 except that the final solution was extruded through an 
Avanti® Mini-Extruder for five passes each through an 800 nm PC membrane followed by a 400 nm PC 
membrane and a 200 nm PC membrane. 
Protocol 6 (Multiple-Pass Syringe Filtration): Same as Protocol 5 except that the final solution was filtered 
through a Corning Syringe filter (800 nm pore diameter followed by a 450 nm pore diameter and a 200 nm 
pore diameter). 
Protocol 7 (Multiple-Pass Extrusion without M-VLPs): The three lipids dissolved in chloroform were mixed in the 
desired composition in a test-tube and dried under vacuum overnight to form a thin film. The lipid film was 
rehydrated using a 5% glucose solution and sonicated briefly to allow the lipids to dissolve completely. The 
rehydrated solution was vortexed every 30 minutes for 30 seconds for a total duration of 3 h. If not used 
immediately, the lipid solution was stored at 4 °C (< 1 month). The lipid solution was extruded through an 
Avanti® Mini-Extruder for 11 passes through a 100 nm PC membrane. The lipid samples were diluted in 
5% glucose solution as per the required φ/M-VLP stoichiometry followed by the addition of required 
volume of M-VLP supernatant and incubated for 2 h at 4 °C prior to further analysis or transfection. 
Protocol 8 (Sonication + Magnetic Stirrer Vortexing): This protocol was a combination of Protocol 2 and 3 
except that the lipid solution in 5% glucose was sonicated and vortexed using a magnetic stirrer prior to the 
addition of any M-VLPs. 
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Protocol 9 (Lipid Pre-incubation): This protocol was uniquely designed for this project. The three lipids 
dissolved in chloroform were mixed in the desired composition in a test-tube and dried under vacuum 
overnight to form a thin film. The lipid film was rehydrated using a 5% glucose solution and sonicated 
briefly to allow the lipids to dissolve completely. The rehydrated solution was vortexed every 30 minutes 
for 30 s for a total duration of 3 h. The prepared liposomes were added to fresh DMEM (with serum (+) 
and without serum (-)) in varying proportions as required. The GP293Luc cells were seeded (2 x 106) in a 
10 cm dish and cultured for two days before the media was replaced with the media containing the 
liposomes. The media (if using serum-free media) was replaced with DMEM containing serum. M-VLP 
containing supernatant was either collected (b) or collected and filtered through a 0.45 µm surfactant-free 
cellulose acetate syringe filter (a) and stored at 4 °C prior to analysis or transfections.  
Protocol 10 (Ether Vaporization): The three lipids dissolved in chloroform were mixed in the desired 
composition in a test-tube and dried under vacuum overnight to form a thin film. The lipid film was 
resuspended in diethyl ether (with sonication if required). M-VLP supernatant was added rapidly to the 
ether solution and the ether was evaporated by establishing a vacuum line for solution for 4 h. The samples 
were stored at 4 °C prior to further analysis or transfections.  
Protocol 11 (Alcohol Injection): The three lipids dissolved in chloroform were mixed in the desired 
composition in a test-tube and dried under vacuum overnight to form a thin film. The lipid film was 
resuspended in diethyl alcohol (with sonication if required). The alcohol solution was injected rapidly to the 
required volume of M-VLP supernatant and the alcohol was evaporated by establishing a vacuum line for 
solution for 4 h. The samples were stored at 4 °C prior to further analysis or transfections.  
Transfection by φ/M-VLPs φ/M-VLPs were prepared as per the different protocols testing as part of this 
study. HEK293 cells were seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12 well plates. 
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Growth media containing serum was replaced with serum-free DMEM prior to drop-wise addition of 
vectors. DMEM was replaced with normal growth media 4 h post-transfection. 
Luciferase expression assay Luciferase expression was quantified 48 h post-transfection using the Promega 
luciferase assay system following the manufacturer's protocol. Luciferase activity was measured in relative 
light units (RLU) using a Lumat LB 9507 luminometer (Berthold, GmbH, Germany). Lysate protein 
concentration was then determined by BCA assay to standardize expression values.  
Cellular Uptake 20 ml of M-VLP supernatant was centrifuged at 60,000g for 2 h at 4 oC and the pellet was 
resuspended in 50 mM HEPES with 145 mM NaCl. 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyan-
ine, 4-chlorobenzenesulfonate salt (DiD) (Invitrogen, 1 mM in DMSO, Ex = 644 nm, Em = 665 nm) was 
added to the resuspended M-VLPs to give a final concentration of 2 µM DiD. The mixture was incubated 
for 1 h at room temperature. Labeled M-VLPs were separated from the free dye through a PD-10 gel 
filtration desalting column (GE Healthcare). HEK293 cells were seeded in 12-well plates at 4 x 105 cells per 
well 18-24 h prior to transfection. Hybrid vectors composed of liposomes and DiD-labeled M-VLPs were 
synthesized as described above and transfected onto HEK293 cells. The target cells were washed with PBS 
containing 0.001% SDS 2 h post transfection to remove surface-bound, uninternalized vectors followed by 
a regular PBS wash. Cells were then trypsinized followed by neutralization with 50 µl of FBS, collected, 
and analyzed by flow cytometry using a Becton Dickinson (Franklin Lakes, NJ) LSR II Flow Cytometer with 
a 633 nm laser. 
Negative Stain Transmission Electron Microscopy (TEM) M-VLPs and φ/M-VLPs were fixed by adding 
1 ml of Karnovsky’s fixative to 3 ml of sample. The sample was then centrifuged at 60,000g for 2 h at 4 oC. 
The pellet was resuspended in a small volume of 5% glucose and diluted with the fixative. A 40 µl drop of 
the sample was placed on a parafilm sheet with a copper grid placed face down on the sample drop and 
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incubated for 30 minutes. Excess sample was wicked off the grid using filter paper. The grid was then 
placed grid-face down on a drop of 7% uranyl acetate stain for 1 min. Excess stain was again wicked off 
using filter paper and the grid was dried for 15 min before viewing in a Hitachi H600 Transmission Electron 
Microscope. 
Size Measurements φ/M-VLPs were prepared as described above and diluted 10-fold in 5% glucose. The 
sizes of the resulting complexes and the constituents were measured using dynamic light scattering with a 
Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments). Light scattering was measured over 
10 10-second intervals for each sample. 
Surface Charge Measurements M-VLP supernatant was centrifuged at 60,000g for 2 h at 4 oC and the 
pellet was resuspended in the same volume of 5% glucose. φ/M-VLPs were prepared as described above 
and diluted 5-fold in 5% glucose. The electrophoretic mobility of the resulting complexes and the 
constituents was measured using the ZetaPALS module attached to the Brookhaven 90Plus Particle Size 
Analyzer (Brookhaven Instruments) over 10 runs with 30 measurements per run. Zeta Potential was 
estimated using the Smoluchowski Equation. 
Cytotoxicity studies The toxicity of liposomes was determined using the Cell Titer-BlueTM Cell Viability 
Assay. HEK293 cells were seeded in a 96-well plate at 5 x 104 cells/well 18-24 h prior to addition of lipids. 
Liposomes formed in 5% glucose solutions via Protocol 1 were added to the cells in concentrations ranging 
from 0 (control) - 200 (maximum) µg/ml in serum-free medium and left for 4 h before the medium was 
replaced. Fifteen µl of CellTiter-BlueTM reagent was added to each well 24 h after the addition of polymers. 
The cells were incubated for further 4 h at 37 oC before adding 100 µl per well of stop reagent following 
which fluorescence (λ = 570 nm, 650 nm) was measured in a SpectraMax 340PC 96-well plate reader 
Statistical Analysis All statistical analyses mentioned in this study was done using the Student’s t-test. 
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CHAPTER 4 
DESIGN OF FOLATE-TARGETED HYBRID LIPID/RETROVIRAL VECTORS 
Introduction 
 Retroviruses are oncogenic in many species including mice (MLV – Murine Leukemia Virus), 
chickens (RSV - Rous Sarcoma Virus), cattle (BLV – Bovine Leukemia Virus) and humans (HTLV-1 – 
Human T-lymphotropic virus Type I). The development of recombinant retroviral vectors and producer 
cell lines has allowed the reprogramming of retroviruses for effective gene therapy against a variety of 
diseases1. Translational research of gene therapies against cancer and tumors has also seen vast 
improvements over the last 20 years. Tumor-induced angiogenesis and late-stage tumor growth was 
effectively inhibited via the injection of retroviral producer cells that could provide on-site retroviruses 
directed towards tissue inhibition of matrix metalloproteinase-3 (TIMP-3)2. In another study, metastasis 
was inhibited with overall reduction of tumor burden by the use of retroviral producer cells encoding a 
vector for cytokines (IL-2 and IL-4)3. Also, retrovirally mediated transfer of HSV-TK gene induced tumor 
regression in malignant brain tumors exposed to antiviral drug ganciclovir4. A novel retroviral vector-based 
therapeutic approach known as Virus-Directed Enzyme/Prodrug Treatment (VDEPT) has also been 
developed that allows for the selective killing of hepatocellular carcinoma cells once transfected with the 
retrovirus encoding for varicella-zoster virus thymidine kinase (VZV-TK) through drug exposure to 6-
methoxypurinearabinonucleoside (araM)5. However, the majority of the studies required co-injection of the 
retroviral producer cell lines2–4 and were also effective only against smaller tumor masses2,4. The 
introduction of retroviral producer cell lines into the body is not a viable option for all cancer types.  
A better solution would be the systemic delivery of retroviral vectors with the ability to specifically 
target cancer cells that would allow for optimal treatment of the cancer with minimal side-effects. Such an 
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approach has been investigated wherein a retrovirus-mediated p53 gene transfer allowed for successful 
regression or at least stabilization of the lung tumors6. However, in this study, retroviral injections were 
provided at the site of the tumor itself. It is possible that without a specific re-targeting of the retrovirus for 
tumor cells, a systemic approach would have failed in this study. In this chapter, we explore the idea of 
using synthetic lipid envelopes containing a folate-targeted lipid for effective retroviral-based cancer gene 
therapy. 
 It is known that the folate receptor (FR) - glycosyl-phosphatidylinositol anchored glycoprotein 
(GP38) is significantly over-expressed in certain malignant cell lines (>20 times) compared to normal cell 
lines and tissues7–9. For example, KB cells (originally thought to be a nasopharyngeal carcinoma cell line but 
now confirmed to be established via HeLa cell contamination) have 279,000 ± 12,000 receptors/cell as 
measured using a radiolabeling assay10. HeLa cells also exhibit over-expression of FR but four-fold lower as 
compared to KB cells11. This makes KB and HeLa cells very attractive model cell lines to study targeting of 
selective cancer therapeutics and imaging agents such as doxorubicin12–15, polymer-based non-viral 
vectors16–19, lipid-based non-viral vectors/drug delivery agents8,13,15,20–23, baculovirus vectors24, plant-based 
virus vectors11,12 and adenoviruses25.  
Previous studies have also attempted to engineer retroviruses to specifically utilize FR either 
through covalent carbodiimide coupling of folic acid with the amine groups of MLV envelope protein25 or 
through engineering of antibodies complimentary to FR through construction of a novel MLV envelope 
gene cassette26. However, both studies reported the incompatibility of the folate receptor pathway towards 
successful transfection of retroviruses despite significant uptake through the FR. Since our studies use M-
VLPs, initial trafficking through the cell would be determined primarily by the synthetic envelope 
surrounding the M-VLPs that contains the folate-targeted lipids followed by downstream trafficking affected 
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via the M-VLPs themselves. Therefore, we anticipate the potential for improved and specifically targeted 
transfections via our novel methodology of non-covalently attaching lipids to M-VLPs. 
 In Chapter 3, we described the design of lipid-based hybrid retroviral vectors (φ/M-VLPs). In this 
chapter, we extend the design towards the development of targeted lipid-based hybrid retroviral vectors 
through the inclusion of a fourth lipid into the lipid mixture of DOTAP, DOPE and cholesterol - 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (DSPE-PEG2000-
folate, Avanti Polar Lipids, Alabaster, AL) (from now on referred to as φfol/M-VLPs or φxyz-f/M-VLPs 
where x, y, z represents the ratio of DOTAP, DOPE and cholesterol and f = weight fraction of DSPE-
PEG2000-folate based on the overall weight of the other lipids. For e.g., φ587-0.01/M-VLPs stands for 
DOTAP:DOPE:cholesterol = 5:8:7 (w:w) and DSPE-PEG2000-folate as 1% of the total weight of the 
other lipids in solution). DSPE-PEG2000-folate contains a folate moiety covalently attached to the distal 
end of a PEG linker (molecular weight = 2000 g/mol) which in turn is also covalently bonded to the 
phosphoethanolamine head group. This allows the folate molecule to extend flexibly away from the 
liposomal surface to bind FR on the cell surface without steric hindrance from the other lipid head-groups8. 
In order to form φfol/M-VLPs, required amounts of lipid were dried under vacuum to form a thin film and 
hydrated with 5% glucose followed by liposomal extrusion through a 100 nm PC membrane. The hybrid 
vectors were formed using M-VLPs and 5% glucose in the required proportion along with the extruded 
lipids. The vectors were then tested for optimal transfection efficiency and cellular uptake in KB cells along 
with physicochemical characterization through Dynamic Light Scattering and Transmission Electron 
Microscopy. 
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Results and Discussion 
Optimization of KB Seeding Density  
As mentioned before, the overexpression of FR in KB cells makes them a model cell line for 
delivery of cancer therapeutics through the receptor-targeted pathway. While transfections mediated via 
non-specific electrostatic interactions between the hybrid vector lipid envelope and the KB cell membrane 
is expected, the use of φfol/M-VLPs could allow for uptake via the FR pathway via a retargeted retroviral 
vector. In order to investigate gene delivery to KB cells, we optimized the cell seeding density for 
maximizing the transfection efficiency. MLVs cannot infect non-dividing cells since they can enter the 
nuclear region only during mitosis when the nuclear envelope breaks down. A high confluency of cells 
during transfection would be sub-optimal considering that they would be less prone to mitosis thereby not 
allowing transfections despite the uptake of the vectors. In our earlier experiments, we used HEK293 cells 
for investigating the performance of our hybrid vectors and had optimized the HEK293 cell seeding density 
as 4 x 105 cells/well of a 12-well tissue culture plate. KB cells were seeded at seeding density of 0.5-3 x 105 
cells/well of a 12-well tissue culture plate 46 h prior to transfections with φ587/M-VLPs. As seen in Figure 
38, the optimal seeding density for efficient transfection of φ587/M-VLPs was 1.5-2 x 10
5 cells/well. All 
further experiments were conducted using KB cells seeded at 2 x 105 cells/well 46 h prior to transfections. 
For in vitro transfections, target cells are typically seeded one day prior to transfections. However, in order 
to maximize the expression of FR, cells were seeded two days prior to transfections in the absence of folate-
free complete media. It is known that most tumor cells when grown in folate-rich complete media down-
regulate the expression of FR. However, growth in folate-free complete media results in over-expression of 
FR which is a reversible process19,27.  
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Figure 38: Transfection Efficiency (TEs) of φ587/M-VLPs in KB cells at lipid loadings of 2.5, 5 and 10 μg/10
9 M-
VLPs. Y-axis – RLU/mg total protein = Relative Light Units per mg of total protein in cellular lysate. X-axis – Lipid 
loadings/109 M-VLPs and transfections were performed with 2 x 109 M-VLPs/well of a 12-well tissue culture plate 
with vector formation using M-VLP density of 12.0 x 109 particles/ml. Error bars indicate standard deviation (n=3). 
The most optimal seeding density for KB cells was 1.5-2 x 105 cells/well as per the transfection efficiency of φ587/M-
VLPs. 
 
Optimization of Lipid Composition of φxyz-f/M-VLPs 
In Chapter 3, we concluded that φ587/M-VLPs was one of the most optimal lipid composition in 
terms of gene delivery efficiency in HEK293 cells. We wanted to confirm that φ587/M-VLPs were also 
optimal for transfections in KB cells. We transfected KB cells with φ587/M-VLPs, φ505/M-VLPs and 
φ550/M-VLPs in order to verify that the presence of two neutral helper lipids would provide better TE than 
using only one helper lipid as was observed in HEK293 cells. As per Figure 39, all three lipid compositions 
enabled high TEs in KB cells with φ587/M-VLPs being the most optimal composition at higher lipid/M-VLP 
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Figure 39: Transfection Efficiency (TEs) of φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs in KB cells at lipid 
loadings of 2.5-25 μg/109 M-VLPs. Y-axis – RLU/mg total protein = Relative Light Units per mg of total protein in 
cellular lysate. X-axis – Lipid loadings/109 M-VLPs and transfections were performed with 2 x 109 M-VLPs/well of a 
12- well tissue culture plate with vector formation using M-VLP density of 5.1 x 109 particles/ml. Error bars indicate 
standard deviation (n=3). 
 
stoichiometry. In order to design φfol/M-VLPs, we chose the base lipid composition of φ587/M-VLPs along 
with the inclusion of up to 10% DSPE-PEG2000-folate of the total lipid content.  
 The inclusion of a PEG linker in the vector formulation can lead to a decrease in TE due to steric 
hindrance19,27. Hence, it was necessary to optimize the weight fraction of DSPE-PEG2000-folate that could 
be included in φ587/M-VLPs without major reduction in TEs. In Chapter 3, Protocol 7 (Extrusion) was 
found to be the most effective method to reduce the sizes of the hybrid vectors. Hence, φ587-f/M-VLPs 
vectors were also prepared via Protocol 7. Figure 40 shows that the φ587-0.02/M-VLPs was the most optimal 
composition that included DSPE-PEG2000-folate for transfection efficiency in KB cells. Further increase in  
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Figure 40: Transfection Efficiency (TEs) of φ587-f/M-VLPs with f = 0-0.20 in KB cells at lipid loadings of 5-25 
μg/109 M-VLPs. Y-axis – RLU/mg total protein = Relative Light Units per mg of total protein in cellular lysate. X-
axis – Lipid loadings/109 M-VLPs and transfections were performed with 2 x 109 M-VLPs/well of a 12-well tissue 
culture plate with vector formation using M-VLP density of 5.1 x 109 particles/ml. Error bars indicate standard 
deviation (n=3). The inclusion of DSPE-PEG2000-folate at proportions > 0.02 led to significantly reduced 
transfections. 
 
the DSPE-PEG2000-folate proportions led to significant reduction in TEs. It was decided that inclusion of 
DSPE-PEG2000-folate would be limited to f = 0.02. 
 
Competitive Inhibition-based Transfection and Uptake Studies  
Transfections with φfol/M-VLPs would be useful in systemic cancer gene delivery only if successful 
transfections were mediated via cellular uptake through the FR. Since the φfol/M-VLP vectors contain 
DOTAP, which is cationic, transfections would also be expected to proceed through non-specific 
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interactions with the cell membrane. However, if the FR uptake pathway did mediate the cellular uptake, 
the presence of free folate in the media during transfections should decrease the uptake of φfol/M-VLPs due 
to competitive binding of the free folate with FR. Hence, further transfections and uptake experiments 
were performed in the absence and presence of free folate (200 μM). This concentration was previously 
shown to be sufficient to inhibit FR-specific uptake of folate-conjugated polyplexes8. This would confirm 
whether transfections were processed through the FR pathway or not. However, the transfections in the 
presence of 200 μM free folate were at least 1.5-fold higher than the corresponding transfections in the 
absence of free folate (Figure 41). The results were surprising given that free folate should have blocked the 
FR thereby disallowing any uptake via the FR pathway. The higher transfections in the presence of free 
folate could possibly occur for a number of reasons - either the presence of free folate increased the non-
specific electrostatic interactions of the liposomal layer with the cell membrane through further reduction 
in the cationic charge density of DOTAP or the free folate non-covalently attached to the liposomal surface 
or PEG linker chain which led to increased uptake via the FR pathway. It is also likely that the presence of 
excess free folate led to better cellular health and growth leading to higher uptake or faster cell division that 
resulted in higher TE. 
In order to verify whether the uptake of the vectors was through the FR pathway, we decided to 
use M-VLPsDiD that were fluorescently labeled with the lipophilic dye DiD to perform uptake studies via 
flow cytometry in the absence and presence of free folate. In order to further compare the effect of the 
presence of free folate in the transfection media, we decided to increase the free folate concentration to 1 
mM. It is known that the folate on a liposomal surface has a higher affinity for FR as compared to free 
folate. This is due to the clustering of FR as big clusters on the cell membrane increasing the possibility of 
multivalent interactions of FR with the DSPE-PEG2000-folate molecules that themselves are free to  
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Figure 41: Transfection Efficiency (TEs) of φ587-f/M-VLPs with f = 0, 0.01 and 0.02 in KB cells at lipid loadings of 
10-30 μg/109 M-VLPs. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg of total protein in 
cellular lysate normalized to the corresponding transfections in the absence of free folate. X-axis – Lipid loadings/109 
M-VLPs and transfections were performed with 2 x 109 M-VLPs/well of a 12-well tissue culture plate with vector 
formation using M-VLP density of 11.3 x 109 particles/ml. Error bars indicate standard deviation (n=3). 
Transfections were also performed in the presence of free folate (200 μM) that would lead to competitive inhibition 
of FR with the free folate disallowing any coupling of φfol/M-VLPs with FR. 
 
redistribute on the liposomal surface of the vector through lateral diffusion in the membrane. Increasing the 
concentration of free folate from 200 μM to > 1 mM led to > 90% inhibition of FR via the free folate 
molecules in other studies8,10,14. Uptake of φ587-f/M-VLPs was unaffected in the presence of free folate 
except at higher lipid/M-VLPs stoichiometry (20 μg/109 M-VLPs) as well as higher DSPE-PEG2000-folate 
content (f = 0.02) (Figure 42). Thus, it is again possible that the presence of free folate affects the liposomal 
surface either by reduction in cationic charge density increasing the non-specific uptake of liposomes or 
non-covalent attachment to the PEG-linkers leading to increased uptake via the FR pathway.  It has been  
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Figure 42: Uptake of φ587-f/M-VLPs in KB cells at 10-20 μg/10
9 M-VLPsDiD and f = 0, 0.01 and 0.02. M-VLPs were 
labeled with fluorescent lipophilic dye DiD prior to complexing with lipids of different compositions. Any increase in 
mean fluorescence denotes increased presence of M-VLPs within the cells.  Y-axis – Normalized Uptake – [Mean 
fluorescence of cells transfected with (φxyz-f/M-VLPsDiD)/Mean fluorescence of (φxyz-f/M-VLPsDiD) in the absence free 
folate]. X-axis – Lipid loading (μg/109 M-VLPsDiD). Uptake of φ587-f/M-VLPsDiD was minimally affected due to the 
presence of free folate except at higher lipid loadings as well as at f = 0.02. Transfections were performed with 2 x 
109 M-VLPs/well of a 12-well tissue culture plate with vector formation using M-VLP density of 10 x 109 
particles/ml. 
 
reported that f = 0.0002 – 0.005 leads to optimal cell binding while higher proportion of DSPE-PEG2000-
folate could lead to crowding effects reducing folate-FR interaction21. However, upon lowering f < 0.005, 
there was no difference in TE in the presence or absence of free folate (data not shown). We also explored 
the idea of using lipid formulations with no DOTAP content i.e. φ055-fol/M-VLPs along with inclusion of 
DSPE-PEG2000-folate up to f = 0.02. But, these hybrid vectors failed to transfect KB cells. Since DOTAP 
is primarily needed for association of the synthetic lipid envelope with the M-VLPs, it is possible that the 
formation of φfol/M-VLPs was compromised due to the absence of DOTAP.  
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Physicochemical Characterization of φxyz-f/M-VLPs 
Finally, we decided to study the morphology of φfol/M-VLPs through size measurements via DLS 
and visual observation via TEM. Table 18 shows the sizes of φ587-f/M-VLPs and φ505-f/M-VLPs at different 
lipid/M-VLPs stoichiometry. The sizes of these vectors were similar to φ587/M-VLPs and φ505/M-VLPs as 
reported in Chapter 3 but only at lower lipid/M-VLPs stoichiometry (5 and 10 μg/109 M-VLPs). At higher 
lipid/M-VLPs stoichiometry (15 and 20 μg/109 M-VLPs) the vectors were much larger than expected. 
Additionally, we know from Chapter 3 that the presence of DOPE resulted in larger vector sizes especially 
at higher lipid/M-VLPs stoichiometry. However, φ505-f/M-VLPs were much larger than φ505/M-VLPs at 
higher lipid/M-VLPs stoichiometry. The vectors visualized via TEM showed both larger lipid envelopes 
formed around multiple M-VLPs as well as singular hybrid vectors (Figure 43).  
It is well known that the FR pathway, also known as potocytosis, is caveolae-dependent8,28,29. There 
are mixed reports regarding the uptake of large particles via the FR pathway. While it is claimed that >200 
nm DSPE-PEG2000-folate liposomes cannot be internalized through this pathway 8, other studies have 
concluded that 500 nm particles can be endocytosed via a caveolae-dependent pathway30. Furthermore, it is 
known that the uptake mechanisms and intracellular navigation are not only size dependent but also cargo 
dependent31–33. Also, empty caveolae are about 50-80 nm in size while the maximum extent of swelling of 
caveolae vesicles has not been confirmed34,35. Hence, further size reduction of φfol/M-VLPs through other 
methods, such as post-insertion of folate-containing lipids onto preformed liposomes or the use of other 
lipids that are compatible with obtaining smaller unilamellar liposomes, would be a better strategy in order 
to confirm the uptake of targeted hybrid vectors via potocytosis. Certainly ≈1000 nm sizes of hybrid vectors 
are too large for receptor-mediated uptake. Hence, it is unlikely that these vectors were processed via the  
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Table 18: Sizes (in nm) measured via Dynamic Light Scattering of φ587-f/M-VLPs and φ505-f/M-VLPs with f = 0.01 
and 0.02 formed via Protocol 7 at 4 different lipid loadings. Errors are standard deviations (n=2; 10 readings for 
every sample). The size of M-VLPs without addition of any lipid was 93 ± 4 nm.  
  Lipid Loading (μg/109 M-VLPs) 
Type Only Lipid 5 10 15 20 
φ587-0.01/M-VLPs 148 ± 15 409 ± 11 490 ± 14 745 ± 45 849 ± 78 
φ587-0.02/M-VLPs 230 ± 29 427 ± 20 554 ± 32 579 ± 39 1113 ± 94 
φ505-0.01/M-VLPs  279 ± 21 470 ± 40 1003 ± 107 2722 ± 205 
φ505-0.02/M-VLPs  243 ± 7 319 ± 7 672 ± 26 2690 ± 558 
 
  
Figure 43: Negative Stain Transmission Electron Microscopy of φ587-0.02/M-VLPs at 10 μg/10
9 M-VLPs. Lipid 
envelopes of DOTAP, DOPE, cholesterol and DSPE-PEG2000-folate (in white block arrows) can be seen 
surrounding M-VLPs (in black block arrows). Both large aggregates as well as smaller unitary hybrid vectors were 
observed. 
 
FR pathway and that the uptake was mediated via the non-specific electrostatic interactions of cationic 
DOTAP in the lipid envelope. 
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Conclusions 
 In this chapter, we explored the idea of extending the design of φ/M-VLPs to obtain folate-
targeted hybrid vectors (φfol/M-VLPs). We added an additional lipid DSPE-PEG2000-folate that contains a 
folate-ligand attached to the distal end of a PEG spacer molecule allowing the folate ligand to probe the 
target cell surface for FR without steric hindrance from the liposomal envelope of φfol/M-VLPs. KB cells 
have an excess of FR compared to other malignant as well as healthy cell lines and were used as a model cell 
line for studying the feasibility of using the FR pathway for receptor-mediated gene delivery of φfol/M-
VLPs. The seeding density for optimal retroviral transfections of KB cells was optimized at 1.5-2 x 105 
cells/well for a 12-well tissue culture plate with a 2 day seeding period in folate-depleted media for 
ensuring overexpression of FR on the cell surface. φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs all were 
able to successfully transfect KB cells with φ587/M-VLPs being an optimal composition especially at higher 
lipid/M-VLPs stoichiometry (>15 μg/109 M-VLPs). The inclusion of DSPE-PEG2000-folate in φ587-f/M-
VLPs was optimized at f = 0.02. Higher proportions of DSPE-PEG2000-folate led to almost complete 
elimination of transfections in KB cells. Competitive inhibition experiments were performed with 
transfections and uptake in the presence and absence of free folate in the media. It was expected that the 
presence of free folate would have inhibited the transfections due to blocking of FR. However, transfections 
improved in the presence of free folate probably either due to non-covalent association of folate with the 
φfol/M-VLPs or due to further reduction of the cationic charge density of DOTAP. The sizes of φfol/M-
VLPs were also larger than φ/M-VLPs as measured via DLS and visualized through TEM. Both aggregates 
and unitary hybrid vectors were observed with distinct lipid envelopes around M-VLPs. Since the FR 
pathway has been known to work for smaller vector sizes, it is possible that the larger morphology of 
φfol/M-VLPs inhibited the transfections via this pathway. Further size reduction through a different 
fabrication protocol will be required to ensure successful transfections via the FR pathway. On a concluding 
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note, we were able to demonstrate the possibilities of using φ/M-VLPs for effective cancer gene therapy. 
However, receptor-mediated gene delivery of these vectors needs further optimization in terms of size and 
morphology. 
 
Experimental Procedures: 
Cell Lines and Assays Nasopharyngeal epidermal carcinoma cells or HeLa contaminant cells, KB were 
purchased from the American Type Culture Collection (Manassas, VA). The MLV producer cell line, 
GP293Luc, expressing the MLV viral gag-pro-pol genes and a viral packaging sequence encoding neomycin 
resistance and luciferase reporter genes was purchased from Clontech (Mountain View, CA). GP293Luc 
cells were grown in DMEM supplemented with 10% FBS (complete media) and cultured at 37 oC in 5% 
CO2. KB cells were grown in folate-free DMEM supplemented with 10% FBS (folate-free complete media) 
and cultured at 37 oC in 5% CO2. Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-buffered 
saline (PBS) was produced in-house at the Cell Culture Media Facility, School of Chemical Sciences, 
University of Illinois. Fetal Bovine Serum (FBS) was bought from Gemini Bio-Products and used as 
purchased. Luciferase assay kit was bought from Promega and used as per the manufacturer's instructions. 
BCA assay was bought from Thermo Scientific and used as per the manufacturer's instructions. 
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) seeded in a 
10 cm dish. The cells were cultured for four days before the M-VLP containing supernatant was collected 
and filtered through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs 
in the supernatant was measured using a q-RT-PCR protocol36. RNA Standards were obtained from the 
Clontech qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was 
extracted using the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further 
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use. Standards and viral RNA samples were prepared for reverse transcription using Taqman reverse 
transcription reagents (Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR 
tubes using the reagent concentrations suggested by the kit plus 250 nM sequence-specific primers. 
Thermal cycling was carried out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of 
the cDNA standards and samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a 
Taqman 7900 Real-Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied 
Biosystems). The final reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time 
PCR reagent:forward primer:reverse primer:cDNA volume). The final concentration of the sample RNA 
was calculated using the calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA 
copies which enabled us to calculate the total number of M-VLPs in a given volume of supernatant. Two 
RNA extracts were collected for each M-VLP sample and quantified using 3 dilutions of each cDNA 
sample. M-VLP supernatant was either used immediately or stored at 4 oC for short term storage (< 4 
weeks) or stored at -80 oC for long term storage. 
Synthesis of φ/M-VLPs The lipids (DOTAP, DOPE, cholesterol dissolved in chloroform and DSPE-
PEG2000-folate dissolved in chloroform:methanol=9:1) were mixed in the desired composition in a test-
tube and dried under vacuum overnight to form a thin film. The lipid film was rehydrated using a 5% 
glucose solution and sonicated briefly to allow the lipids to dissolve completely. The rehydrated solution 
was vortexed every 30 minutes for 30 s for a total duration of 3 h and extruded through an Avanti® Mini-
Extruder for 11 passes through a 100 nm PC membrane. If not used immediately, the lipid solution was 
stored at 4 °C (< 1 month for unextruded samples and < 4 days for extruded samples). The lipid samples 
were diluted in 5% glucose solution as per the required φfol/M-VLP stoichiometry followed by the addition 
of required volume of M-VLP supernatant and incubated for 2 h at 4 °C prior to further analysis or 
transfections.  
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Transfection by φfol/M-VLPs KB cells were seeded in 12-well plates at 2 x 10
5 cells per well 46 h prior to 
transfection. On the day of transfections, φfol/M-VLPs were synthesized as described above. The folate free 
complete media was replaced with serum-free media containing excess free folate and no free folate 1 h 
prior to transfections and placed in 4 °C. The media was again replaced with folate-free serum-free media 
followed by addition of vectors and maintained at 4 °C for 3 h. The transfection media was replaced with 
normal growth media 3 h post-transfection and then maintained at 37 °C until lysis. For φ/M-VLPs, 
transfections were done as mentioned in Chapter 3.  
Luciferase expression assay Luciferase expression was quantified 48 h post-transfection using the Promega 
luciferase assay system following the manufacturer's protocol. Luciferase activity was measured in relative 
light units (RLU) using a Lumat LB 9507 luminometer (Berthold, GmbH, Germany). Lysate protein 
concentration was then determined by BCA assay to standardize expression values.  
Cellular Uptake 20 ml of M-VLP supernatant was centrifuged at 60,000g for 2 h at 4 oC and the pellet was 
resuspended in 50 mM HEPES with 145 mM NaCl. 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyan-
ine, 4-chlorobenzenesulfonate salt (DiD) (Invitrogen, 1 mM in DMSO, Ex = 644 nm, Em = 665 nm) was 
added to the resuspended M-VLPs to give a final concentration of 2 µM DiD. The mixture was incubated 
for 1 h at room temperature. Labeled M-VLPs (M-VLPsDiD) were separated from the free dye through a 
PD-10 gel filtration desalting column (GE Healthcare). KB cells were seeded in 12-well plates at 2 x 105 
cells per well 46 h prior to transfection. On the day of transfections, φfol/M-VLPsDiD were synthesized as 
described above. The folate free complete media was replaced with serum-free media with excess free 
folate and no free folate 1 h prior to transfection and placed in 4 °C. The media was again replaced with 
folate-free serum-free media followed by addition of vectors and maintained at 4 °C for 1 h and then at 37 
°C for 1 h. The target cells were washed with PBS containing 0.001% SDS 2 h post transfection to remove 
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surface-bound, uninternalized vectors followed by a regular PBS wash. Cells were then trypsinized 
followed by neutralization with 50 µl of FBS, collected, and analyzed by flow cytometry using a Becton 
Dickinson (Franklin Lakes, NJ) LSR II Flow Cytometer with a 633 nm laser. 
Negative Stain Transmission Electron Microscopy (TEM) φfol/M-VLPs were fixed by adding 1 ml of 
Karnovsky’s fixative to 3 ml of sample. The sample was then centrifuged at 60,000g for 2 h at 4 oC. The 
pellet was resuspended in a small volume of 5% glucose and diluted with the fixative. A 40 µl drop of the 
sample was placed on a parafilm sheet with a copper grid placed face down on the sample drop and 
incubated for 30 minutes. Excess sample was wicked off the grid using filter paper. The grid was then 
placed grid-face down on a drop of 7% uranyl acetate stain for 1 min. Excess stain was again wicked off 
using filter paper and the grid was dried for 15 min before viewing in a Hitachi H600 Transmission Electron 
Microscope. 
Size Measurements φfol/M-VLPs were prepared as described above and diluted 10-fold in 5% glucose. 
The sizes of the resulting complexes and the constituents were measured using dynamic light scattering with 
a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments). Light scattering was measured over 
10 10-second intervals for each sample. 
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CHAPTER 5 
FORMULATION CHARACTERIZATION OF HYBRID RETROVIRAL VECTORS 
 
Introduction 
In Chapter 3, we optimized the design of χ/M-VLPs for efficient transfections and vector size. We 
concluded that despite higher uptake of PEI/M-VLPs, χ/M-VLPs were more efficient in transfections. The 
use of low pH chitosan stock solution (pH 3) led to a > 100-fold improvement in transfections via an 
optimized morphology. Additionally, the sizes of the hybrid vectors could be modulated via change in pH, 
pKa of acidic solvent and chitosan stock concentration. In Chapter 4, we optimized the design of φ/M-VLPs 
in terms of the synthetic lipid composition and vector size. We concluded that an extrusion protocol led to 
smaller sizes of hybrid vectors. In this chapter, we investigated the performance of χ/M-VLPs and φ/M-
VLPs for certain clinically and commercially relevant parameters such as the presence of serum proteins 
during transfection, long term stable transgene expression (three weeks) as well as storage stability (two 
weeks). MLV-A (MLVs with amphotropic envelope protein) are efficient in transfection and provide stable 
expression of the target gene long term. However, MLV-A exhibit poor stability on storage even at 4 °C 
and rapidly lose their infectivity potential. We reported earlier that M-VLPs are able to provide significant 
transfection efficiency even after ultracentrifugation and storage at 4 °C for greater than two weeks. In our 
latest study, we will extend the storage stability testing to hybrid vectors rather than just M-VLPs. The 
presence of serum proteins could also potentially inhibit the transfection efficiency of MLV-A. Chitosan is 
known to provide better serum resistance as compared to other non-viral gene delivery vectors1. We 
expect better or at least similar serum resistance as compared to MLV-A for χ/M-VLPs. Finally, hybrid 
vectors should be able to provide stable transgene expression regardless of the nature of the synthetic agent. 
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However, we earlier reported that PEI was unable to mediate such an effect due to its high toxicity. Given 
that both chitosan and the lipids were much less toxic than PEI, we expect the expression of the luciferase 
gene to be maintained for at least three weeks. 
 
Results and Discussion     
Use of DOTAP, DOPE and cholesterol as synthetic envelopes for efficient RNAi and MLV-A generation 
The use of DOTAP, DOPE and cholesterol as non-viral vectors is well documented2–5. In chapter 
3, we optimized the composition of these three lipids for the formation of effective hybrid lipid-based 
retroviral vectors. In order to reaffirm the efficacy of these three lipids for effective non-viral gene delivery 
using one of the optimized compositions from chapter 3, we tested these lipids for transfection of the 
plasmid pMDM.4070A (φ587/pMDM), which encodes for the amphotropic envelope protein in GP293Luc 
cells. The cell supernatant containing MLV-A was then collected two days post-transfection and used to 
transfect HEK293 cells. The efficiency of MLV-A transduction obtained from φ587/pMDM transfection was 
compared to that of MLV-A obtained via the use of a standard liposomal transfection reagent – 
Lipofectamine2000 (LF2000) (LF2000/pMDM) with plasmid:LF2000 = 1:5 (w:w) (Figure 44). The TE of 
MLV-A obtained via φ587/pMDM was equivalent to those obtained via LF2000/pMDM but at a higher 
plasmid:lipid ratio = 1:15. A three-fold increase in the MLV-A viral dose led to higher transfections with 
most optimal being two-fold higher compared to using LF2000/pMDM. While the result is not surprising 
given that all three lipids are known to be effective gene delivery vectors, it is definitely cheaper (< 
$10/mg) than using LF2000 as a synthetic vector (≈$400/mg) to obtain MLVs with any desired envelope 
protein.  
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Figure 44: Transfection Efficiency (TE) of MLV-A obtained via transfection of GP293Luc with pMDM.4070A 
encoding for the amphotropic envelope protein via lipoplexes composed of DOTAP:DOPE:Cholesterol = 5:8:7. Y – 
axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein in cellular lysate normalized to 
the corresponding values obtained through lipoplexes of LF2000 with pMDM.4070A at plasmid:lipid = 1:5 (w:w). X 
– axis – plasmid:lipids stoichiometry from 1:1 to 1:20 (w:w). Error bars represent standard deviation (n = 3).  
 
The use of these three lipids was also investigated for potential gene silencing via siRNA to HeLa 
cells stably expressing the luciferase reporter gene – HeLa-Luc (Figure 45). φ587/siGL3 provided lower 
silencing than the control compositions of φ100/siGL3, φ110/siGL3 and φ101/siGL3. However, upon 
modifying the composition to φ(11)27/siGL3, knockdown efficiencies improved. This confirmed that siRNA 
delivery might also require an optimization of lipid composition. Since the delivery of siRNA is limited to 
the cytoplasm, it is possible that the trafficking mechanisms are different than those of M-VLPs. It is known 
that the composition of the synthetic vector is one of the principal determinant of the intracellular 
trafficking mechanisms6. We shall investigate this in further detail later in this chapter.  
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Figure 45: Knockdown efficiency in HeLa-Luc cells of lipoplexes composed of siGL3 with varied compositions of 
DOTAP, DOPE and Cholesterol at lipids:plasmid = 10:1 (w:w). Y – axis – Knockdown efficiency = Reduction in 
luciferase expression using siGL3 compared to reduction in luciferase expression using a non-specific siRNA 
construct (siLam). X – axis – Variation in composition of DOTAP, DOPE and Cholesterol. Transfections were done 
with 5 nM siRNA/well. Error bars represent standard deviation (n = 3). 
 
Effect of serum proteins on Transfection Efficiency 
 The presence of serum in transfection media is known to inhibit transfections by most gene delivery 
vectors, particularly for charged species which can easily interact with the serum proteins7–10. It is critical 
for gene delivery vectors to be able to resist these non-specific interactions with serum in order to be 
efficacious for systemic gene delivery. Serum constitutes 50% (v:v) of blood3. Hence, any undesired 
interactions of these vectors with serum would increase their clearance from the body before providing the 
desired therapeutic effect. We wanted to test the TE of our hybrid vectors in comparison with MLV-A in 
the presence of serum (up to 50% v:v) in transfection media. χ/M-VLPs at three different stoichiometries  
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Figure 46: Transfection Efficiency (TE) of χ/M-VLPs at 4, 7 and 10 μg/109 M-VLPs and MLV-A in the presence of 
0-50% Fetal Bovine Serum. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein 
in cellular lysate normalized to the same expression at 0% serum for every tested vector. X-axis – Serum (%) in 
transfection media. TE decreased at serum content > 20%.  
 
of 4, 7 and 10 μg/109 M-VLPs were able to maintain their efficiency at 20% serum after which the 
efficiency decreased to 10-20% at 50% serum (Figure 46). MLV-A exhibited a similar trend with TE 
decreasing to 40% at 50% serum. A larger proportion of chitosan around the M-VLPs led to excellent 
transfections especially at lower serum content. At higher serum content, TE decreased regardless of the 
stoichiometry of χ/M-VLPs. TE of φ/M-VLPs, however, decreased rapidly at 10% serum (Figure 47) 
irrespective of the composition of the lipids. It is known that the inclusion of cholesterol in cationic lipid 
formulation leads to better resistance to lipid-based gene delivery vectors7. However, no significant change 
was measured in serum resistance between φ587/M-VLPs and φ505/M-VLPs.  
 
130 
 
 
Figure 47: Transfection Efficiency (TE) of φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs at 10 μg/10
9 M-VLPs and 
MLV-A in the presence of 0-50% Fetal Bovine Serum. Y-axis – Normalized RLU/mg total protein = Relative Light 
Units per mg total protein in cellular lysate normalized to the same expression at 0% serum for every tested vector. 
X-axis – Serum (%) in transfection media. TE decreased rapidly for φ/M-VLPs at serum content ≥ 10%.  
 
In our experiments, the vectors were present in the transfection media for 4 h prior to being 
replaced by complete media (with 10% serum). It is likely that a longer incubation time in the high serum 
content would have allowed the vectors to have an increased interaction with the target cells. Additionally, 
systemic delivery of the cells involves serum that is in continuous flow with the blood-stream. In this 
experiment, the stationary serum media would possibly have a higher interaction with the vectors than the 
continuously flowing serum. Also, M-VLPs and MLV-A have a very low negative surface charge whereas 
φ/M-VLPs have a high positive surface charge (> 10 mV, chapter 3). Hence, it is likely that the lipid 
surface charge was inhibited to a greater extent by the serum proteins. 
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The addition of PEG to viral vectors as well as non-viral vectors has led to lower inhibition of 
serum proteins and immune responses3,11,12. In order to test this hypothesis on our hybrid vectors, we used 
DSPE-PEG2000-methoxy (up to 2% weight fraction of total lipid content, Avanti Polar Lipid, Alabaster, 
AL) as part of the lipid formulation of the hybrid vectors. From chapter 4, we know that any higher PEG  
content reduced TE significantly. However, TE of the PEGylated lipid complexes with M-VLPs was 
completely eliminated at 50% serum content (data not shown).  
 
Effect of Long-Term Storage on Vector Size and TE 
 MLVs are known to be unstable upon storage for > 4 days even at low temperatures (4 °C)13–17. 
The t1/2 of infectivity for MLV-As is ≈5 h at 37 °C
13. Previous studies have shown that the envelope protein 
responsible for efficient transductions is also one of the reasons for poor storage stability13,14,18–20. It has been 
shown, however, that M-VLPs exhibit good long-term storage capabilities16,17. M-VLPs stored at 4 °C (14 
days) used to produce hybrid vectors followed by transfection of HEK293 cells on the same day maintained 
their transfection efficiency whereas storage of MLV-A (> 4 days at 4 °C) had very poor TE. In this study, 
we extended the storage studies to hybrid vectors for 11 days (Figure 48) and store the preformed χ/M-
VLPs rather than just M-VLPs. Both TE as well as the size of the hybrid vectors was measured over the 
testing period. The size of MLV-A was not expected to change over the 12-day period considering the 
absence of loosely-bound synthetic components. The change in size of χ/M-VLPs, however, was dependent 
on the stoichiometry of the vectors. χ/M-VLPs at 2 and 4 μg/109 M-VLPs increased in size over the 11-day 
period. χ/M-VLPs at 7 μg/109 M-VLPs decreased in size and χ/M-VLPs at 10 μg/109 M-VLPs remained 
stable in size. The vectors at low stoichiometry probably aggregated with time with the free chitosan in the 
sample. The reduction in size of χ/M-VLPs at 7 μg/109 M-VLPs to less than the native virus was surprising  
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Figure 48: Storage Stability of χ/M-VLPs at 2, 4,7 and 10 μg/109 M-VLPs in comparison to MLV-A in terms of 
(top) size and (bottom) Transfection Efficiency (TE) over 12 days. (top) Y-axis – Normalized Size in nm of all vectors 
normalized to size on Day 0. X-axis – Time in Days. (bottom) Y-axis – Normalized RLU/mg total protein = Relative 
Light Units per mg total protein in cellular lysate normalized to the same expression on Day 0 for every tested 
vector. X-axis – Time in Days. 
 
but it is likely that this sample degraded over time due to unknown effects. It is noteworthy that χ/M-VLPs 
at 10 μg/109 M-VLPs were small in size (≈300 nm) and also remained stable in size over the 11-day period. 
  The TE of these vectors decreased with time and was stoichiometry dependent. The TE decreased 
to 37%, 10%, 8% and <1% for χ/M-VLPs at 2, 4, 7, and 10 μg/109 M-VLPs while TE of MLV-A 
decreased to 1% over the same 11-day period. The reduction in TE can be directly attributable to the 
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change in size of χ/M-VLPs at 2, 4 and 7 μg/109 M-VLPs. The increase in size at lower stoichiometries 
most likely decreased the uptake of these vectors whereas degradation of the vectors at 7 μg/109 M-VLPs 
led to poor transfections. It is surprising, however, that the χ/M-VLPs at 10 μg/109 M-VLPs led to poor 
TE after 12 days despite the robust size stability. It was observed over the 12 days that χ/M-VLPs were 
likely to precipitate at the bottom of the tubes used to synthesize the vectors that led to inaccurate 
pipetting. The data for TE at days 4 and 8 are not plotted because of the extreme variability in the 
measurements due to the inaccurate pipetting. It is likely that this might have also led to almost no addition 
of vectors to the target cells due to the high precipitation of the M-VLPs at the high stoichiometry (10 
μg/109 M-VLPs). While TE of χ/M-VLPs decreased over the 12-day period, M-VLPs alone showed 
remarkable long term (≈ three months) storage stability at 4 °C in TE for the entire duration of this project 
if hybrid vectors were used for transfections on the same day when complexed with the synthetic envelope 
(data not shown)16,17.  
 φ/M-VLPs displayed better storage stability than χ/M-VLPs during the 12 days of testing (Figure 
49). φ505/M-VLPs were smaller in size as compared to φ587/M-VLPs and φ550/M-VLPs especially at 10 
μg/109 M-VLPs due to the presence of HII phase preferring DOPE (as explained in Chapter 3). The size of 
φ505/M-VLPs decreased at 10 μg/10
9 M-VLPs but remained stable at 5 μg/109 M-VLPs. After 12 days, the 
TE of φ505/M-VLPs at 5 μg/10
9 M-VLPs increased three-fold, but at 10 μg/109 M-VLPs decreased three-
fold. The reduction in TE at the higher stoichiometry could be attributed to the size reduction via 
unpacking of the synthetic lipid envelope from the M-VLPs. The size of φ550/M-VLPs varied significantly 
over the 12-day period wherein sizes increased as well as decreased. However, the TE decreased to <20% 
after 12 days. It is highly likely that the presence of DOPE might have led to change in morphology of the 
vectors over the 12 days wherein the phase structure of the synthetic envelope was modified (Lα to HII).  
134 
 
 
Figure 49: Storage Stability of φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs at 10 μg/10
9 M-VLPs in comparison 
to MLV-A in terms of (top) size and (bottom) Transfection Efficiency (TE) over 12 days. (top) Y-axis – Normalized Size 
in nm of all vectors normalized to size on Day 0. X-axis – Time in Days. (bottom) Y-axis – Normalized RLU/mg total 
protein = Relative Light Units per mg total protein in cellular lysate normalized to the same expression on Day 0 for 
every tested vector. X-axis – Time in Days. 
 
The size of φ587/M-VLPs remained fairly stable over the 12-day period but TE decreased to <30% of TE on 
day 0. The decrease in TE despite the favorable size stability might be again due to the presence of DOPE 
which could have favored the HII phase modifying the phase structure of the synthetic envelope. As 
explained in chapter 3, HII phase is preferable in the design of the synthetic envelope once inside the cell. 
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However, HII phase in the synthetic envelope prior to cell entry is sub-optimal. Hence, despite fairly robust 
storage stability in size of φ587/M-VLPs and φ550/M-VLPs, TE decreased uniformly over the same period. 
Also, unlike χ/M-VLPs, precipitation was not a serious issue with φ/M-VLPs which was evident from low 
errors between replicates during transfections. 
 
Long Term Stable Transfections 
 MLVs are capable of stable transfections with the transgene integrated into the target cell genome. 
It is expected that once the M-VLPs enter a cell either using biological envelope proteins such as the 
amphotropic envelope protein or VSV-G envelope protein or synthetic envelopes such as PEI and PLL, 
stable transgene expression should be achieved. Past studies have shown that even though both PEI and PLL 
were capable of forming efficient hybrid vectors, PEI was toxic over the long term and transgene expression 
was lost within seven days. PLL, however, was capable of stable transfections due to its lower toxicity14,15. 
We explored the possibility of using chitosan and lipid-based synthetic envelopes for stable transgene 
expression (Figures 50 and 51). Both χ/M-VLPs (pH 3) and φ/M-VLPs were able to successfully provide 
stable expression over three weeks. In chapter 3, we showed that φ505/M-VLPs can be toxic at very high 
concentrations. However, since the transfections reported here were performed in the proper therapeutic 
concentration window with cells exposed to < 10 μg/ml of φ505, transfections were efficient and stable 
(Figure 51). 
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Figure 50: Stable Transgene Expression of χ/M-VLPs (pH 3, 5 μg/109 M-VLPs) and MLV-A over three weeks. Y – 
axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein in cellular lysate normalized to 
the same expression on Day 1 for MLV-A and Day 2 for χ/M-VLPs. X – axis – Time in days. Error bars indicate 
standard deviation (n=3). Both MLV-A and χ/M-VLPs were able to provide stable expression over the tested time 
period. 
 
Conclusion 
In the previous chapters, we elucidated the design of χ/M-VLPs and φ/M-VLPs for optimal TE and 
vector morphology. We showed that the pH, pKa of acid solvent and chitosan stock concentration can be 
used to modulate the size and TE of χ/M-VLPs. Similarly, composition and concentration of liposomal 
solutions along with the appropriate lipid size reduction protocols can be used to form highly optimal φ/M-
VLPs. In this chapter, we explained the differences between using φ/M-VLPs and χ/M-VLPs for efficient 
transfections in terms of their storage stability and serum stability. 
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Figure 51: Stable Transgene Expression of φ587/M-VLPs, φ505/M-VLPs, φ550/M-VLPs at 5 μg/10
9 M-VLPs and 
MLV-A over three weeks. Y – axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein 
in cellular lysate normalized to the same expression on Day 1. X – axis – Time in days. Error bars indicate standard 
deviation (n=3). Both MLV-A and φ/M-VLPs were able to provide stable expression over the tested time period. 
 
χ/M-VLPs exhibited better serum resistance compared to φ/M-VLPs. χ/M-VLPs were also 
subject to precipitation issues over long-term storage unlike φ/M-VLPs. Both φ/M-VLPs and χ/M-VLPs 
exhibited better stability as compared to MLV-A. The stability, however, was a function of the vector 
stoichiometry as well as the lipid composition. Both χ/M-VLPs and φ/M-VLPs were able to successfully 
mediate long-term stable transgene expression. 
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Experimental Methods 
Cell Lines and Assays Human embryonic kidney cells, HEK293 and cervical cancer cells, HeLa were 
purchased from the American Type Culture Collection (Manassas, VA). The MLV producer cell line, 
GP293Luc, expressing the MLV viral gag-pro-pol genes and a viral packaging sequence encoding neomycin 
resistance and luciferase reporter genes was purchased from Clontech (Mountain View, CA). All cell lines 
were grown in DMEM supplemented with 10% FBS (complete media) and cultured at 37 oC in 5% CO2. 
Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-buffered saline (PBS) was produced in-house 
at the Cell Culture Media Facility, School of Chemical Sciences, University of Illinois. Fetal Bovine Serum 
(FBS) was bought from Gemini Bio-Products and used as purchased. Luciferase assay and Cell-Titer BlueTM 
assay kits were bought from Promega and used as per the manufacturer's instructions. BCA assay was 
bought from Thermo Scientific and used as per the manufacturer's instructions. 
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) seeded in a 
10 cm dish. The cells were cultured for four days before the M-VLP containing supernatant was collected 
and filtered through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs 
in the supernatant was measured using a q-RT-PCR protocol16. RNA Standards were obtained from the 
Clontech qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was 
extracted using the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further 
use. Standards and viral RNA samples were prepared for reverse transcription using Taqman reverse 
transcription reagents (Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR 
tubes using the reagent concentrations suggested by the kit plus 250 nM sequence-specific primers. 
Thermal cycling was carried out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of 
the cDNA standards and samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a 
Taqman 7900 Real-Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied 
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Biosystems). The final reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time 
PCR reagent:forward primer:reverse primer:cDNA volume). The final concentration of the sample RNA 
was calculated using the calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA 
copies which enabled us to calculate the total number of M-VLPs in a given volume of supernatant. Two 
RNA extracts were collected for each M-VLP sample and quantified using 3 dilutions of each cDNA 
sample. M-VLP supernatant was either used immediately or stored at 4 oC for short term storage (< 4 
weeks) or stored at -80 oC for long term storage. 
MLV-A Production GP293Luc cells, seeded (2 x 106) in a 10 cm dish, were grown for 48 h prior to 
transfection with the envelope plasmid pMDM.4070A. Complete media was replaced with serum-free 
media just before transfections. Plasmid:Lipid vectors were synthesized in the required stoichiometric ratios 
and incubated at room temperature for 10 min prior to drop-wise addition to GP293Luc cells. The media 
was replaced again with complete media 6 h post-transfection. The cells were cultured for a further 48 h 
before the MLV-A containing supernatant was collected and filtered through a 0.45 µm surfactant-free 
cellulose acetate syringe filter. 
Synthesis of φ/M-VLPs The three lipids dissolved in chloroform were mixed in the desired composition in 
a test-tube and dried under vacuum overnight to form a thin film. The lipid film was rehydrated using a 5% 
glucose solution and sonicated briefly to allow the lipids to dissolve completely. The rehydrated solution 
was vortexed every 30 minutes for 30 seconds for a total duration of 3 h. If not used immediately, the lipid 
solution was stored at 4 °C (< 1 month). The lipid solution was extruded through an Avanti® Mini-
Extruder for 11 passes through a 100 nm PC membrane. The lipid samples were then added to the required 
volume of M-VLP supernatant and diluted in 5% glucose solution as per the φ/M-VLP stoichiometry and 
incubated for 2 h at 4 °C prior to further analysis or transfection. 
140 
 
Synthesis of χ/M-VLPs PEI (Molecular Weight = 750 kDa, Sigma Aldrich, 1 mg/ml in ultrapure water), 
PLL (Molecular Weight = 150-300 kDa, Sigma Aldrich, 1 mg/ml in ultrapure water) or Chitosan 
(Molecular Weight = 190-310 kDa, Sigma Aldrich, 1 mg/ml dissolved overnight at 55 oC in 0.6 % acid and 
filtered through a 0.22 µm surfactant-free cellulose acetate syringe filter, pH 3 and 4) was added drop-wise 
to required volume of M-VLP supernatant while vortexing to achieve the desired polymer:M-VLP ratio. 
The hybrid vectors were then incubated at 4 oC for 4 h. 
Transfections HEK293 cells were seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12 well 
plates. Growth media containing serum was replaced with serum-free DMEM prior to drop-wise addition 
of vectors and replaced again with normal growth media 4 h post-transfection. For serum studies, the 
transfection media contained 0-50% serum. For transfections with MLV-A, HEK293 cells were seeded 18-
24 h prior to transfection at 8 x 104 cells/well in 6-well plates. MLV-A containing supernatant was diluted 
in complete media (1:1 or 1:3, v:v) along with addition of 1 μl Sequabrene for every 1 ml of the diluted 
mixture to produce viral media. HEK293 cells were transfected with 1 ml/well viral media. Luciferase 
expression was measured at 24 h post transfection as mentioned below.  
Luciferase expression assay Luciferase expression was quantified 48 h post-transfection for all studies 
except for the passive/active studies as mentioned later using the Promega luciferase assay system following 
the manufacturer's protocol. Luciferase activity was measured in relative light units (RLU) using a Lumat 
LB 9507 luminometer (Berthold, GmbH, Germany). Lysate protein concentration was then determined by 
BCA assay to standardize expression values. 
Stable Transgene Expression Assay Hybrid vectors were synthesizes as described above. HEK293 cells 
were seeded 18-24 h prior to transfection at 8 x 105 cells/well in 6-well plates. Growth media containing 
serum was replaced with serum-free DMEM prior to drop-wise addition of vectors and replaced again with 
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normal growth media 4 h post-transfection. After 48 h, the cells in three wells were lysed and quantified 
for luciferase expression as mentioned above. The cells in the other three wells were split into another 6-
well plate at a 1:8 split ratio. This process was repeated every 3-4 days depending on the confluency of the 
cells for up to at least three weeks. 
Production of HEK293Luc and HeLa-Luc cells HEK293 and HeLa cells were transfected with MLV-A as 
stated above and propagated for two weeks. The cells were grown in G418 selection media for selective 
growth of cells permanently expressing luciferase for a further two weeks. 
siRNA Delivery HeLa-Luc cells (HeLa cells permanently expressing luciferase) were seeded at 1.5 x 105 
cells/well in a 12-well plate 18-24 h prior to transfection. Liposomes in the predetermined ratios were 
synthesized as stated before. siGL3 and siLam were conjugated with the liposomes at 1:10 (w:w) ratio and 
diluted in PIPES buffer followed by incubation at room temperature for 15 min to synthesize siRNA 
lipoplexes. Growth media was replaced with serum-free media prior to addition of 50 μl of siRNA 
lipoplexes (5 nM). The serum-free media was replaced again with complete media 4 h post transfection. 
Luciferase expression was measured 24 h post-transfection as stated above.   
Size Measurements Hybrid vectors were prepared as described above and diluted 10-fold in 5% glucose. 
The sizes of the resulting complexes and the constituents were measured using dynamic light scattering with 
a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments). Light scattering was measured over 
10 10-second intervals for each sample. 
Statistical Analysis All statistical analyses mentioned in this study was done using the Student’s t-test.  
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CHAPTER 6 
INTRACELLULAR TRAFFICKING OF HYBRID RETROVIRAL VECTORS 
 
Introduction 
In our earlier chapters, we discussed the design of polymer-based hybrid vectors (χ/M-VLPs) and 
lipid-based hybrid vectors (φ/M-VLPs). The type of synthetic envelope used for the formation of hybrid 
vectors affected various physicochemical properties of the vectors along with the transfection efficiency. It 
is expected that the intracellular trafficking of these hybrid vectors could also be significantly modulated by 
the synthetic envelope. In this chapter, we elucidate on the various cytosolic mechanisms that work to bring 
about efficient transfections of the hybrid vectors in HEK293 cells.  
Gene delivery vectors primarily have two ways to deliver their cargo – endocytic pathways or non-
endocytic pathways1. Amongst non-endocytic mechanisms, fusion and penetration are two ways of entering 
the cells without the use of physical or chemical aids such as in microinjection, electroporation or 
permeabilization. Penetration mechanisms require the presence of penetrating peptides which our current 
design of hybrid vectors lacks. Endocytic pathways have long been studied as primary mechanisms of cell 
entry for viral as well as non-viral vectors1–6. Endocytosis includes three major sub-types – 
Macropinocytosis (MP), Clathrin-mediated endocytosis (CME) and Caveolae-mediated endocytosis 
(CavME). MP refers to the formation of large irregularly shaped endocytic vesicles that is preceded by 
significant membrane ruffling1,6,7. CME is so called due to the formation of polygonal clusters of clathrin 
and other adapter proteins enveloping the endocytic vesicle1,6,8,9. CavME, on the other hand, contain 
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hydrophilic microdomains rich in cholesterol and glycosphingolipids due to their association with 
cholesterol-binding proteins known as caveolins1,6,10,11.  
Chitosan based non-viral gene delivery vectors have been implicated to be transported via 
endocytic pathways12. The proton-sponge hypothesis has been proposed to play a significant role in the 
trafficking of chitosan-based vectors primarily due to the presence of excess glucosamines in the chitosan 
structure12. It has been reported that chitosan-alginate/DNA nanoparticles primarily use CME as a primary 
trafficking pathway leading to optimal transfections in HEK293 and COS7 cells. In contrast, CHO cells 
used CavME to internalize the vectors that failed to transfect13. In a contrasting report, however, 
chitosan/DNA complexes as well as chitosan/DNA/glutamic acid complexes primarily use MP and CavME 
for efficient transfections in HT1080 cells14. Furthermore, it was reported that the molecular weight (Mw) 
and degree of deacetylation (DDA) was not a primary parameter for the modulation of intracellular 
trafficking kinetics in HEK293 cells15. 
The use of pH sensitive lipid molecules like DOPE in liposomal formulations enables the use of 
endocytic mechanisms that rely heavily on pH-dependent pathways for endosomal destabilization and 
release of cargo into the cytosol16,17. Cholesterol, if included in the liposomal composition, would be 
expected to modulate trafficking mechanisms through CavME as it is also involved in the association with 
caveolin proteins. It is also known that the composition of liposomes consisting of multiple components 
significantly affects the different endocytic mechanisms involved in cellular uptake as well as trafficking 
pathways within the cell. In fact, it has been proposed that lipids with P = 1, favor fluid domains on the 
plasma membrane whereas lipids with P > 1 would favor raft-domains on the plasma membrane for 
efficient cellular uptake18. Also, cationic DOTAP/oligonucleotide lipoplexes primarily endocytose through 
uncoated vesicles19. 
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We investigated the direct effect of the composition of the synthetic envelopes on the various 
trafficking mechanisms of hybrid retroviral vectors. It is understood that the trafficking pathways would 
further allow better design of the hybrid vectors in terms of inclusion of additional synthetic components. 
We initiated this study by measuring the kinetics of the uptake mechanisms for successful transfections at 4 
°C and 37 °C and at various time-points up to 48 h. Energy dependent cellular uptake mechanisms such as 
endocytosis are dormant at 4 °C whereas mechanisms relying on the fusogenic properties of vectors with 
the cell membrane would be unaffected at lower temperatures1. We investigated the trafficking mechanisms 
of our hybrid vectors χ/M-VLPs and φ/M-VLPs through transfections and cellular uptake studies in the 
presence of various drug inhibitors that would affect certain pathways within the cell. Finally, we also 
visualized the trafficking of the vectors within the cell via fluorescent labeling of M-VLPs and the synthetic 
envelopes through confocal microscopy at three time points – 4, 8 and 20 h.   
 
Results and Discussion     
Effect of Time and Temperature on Cellular Uptake and TE of χ/M-VLPs and φ/M-VLPs 
The optimal design of χ/M-VLPs and φ/M-VLPs led to high transfection efficiency, low toxicity, reduced 
vector sizes and stable transgene expression. We wanted to understand the differences between MLV-A, 
χ/M-VLPs and φ/M-VLPs in terms of their intracellular trafficking mechanisms in HEK293 cells. One is 
the active process of endocytosis whereby the vectors use the cell machinery to gain entry through vesicles 
and be directed towards the appropriate intracellular location while the other is a non-specific mechanism 
wherein the vectors enter the cell through the passive process of fusion with the plasma membrane. 
Endocytosis being an energy dependent process is inhibited at lower temperatures whereas low 
temperature has minimal effect on the fusion mechanism1. The successful gene delivery via MLV-A required  
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endocytosis of the vectors with TE in HEK293 cells incubated at 4 °C reaching 17% of TE in cells incubated 
at 37 °C (Figure 52). We transfected χ/M-VLPs at four different stoichiometries of 2, 4, 7 and 10 μg/109 
M-VLPs onto HEK293 cells incubated with serum-free media at 4 °C and 37 °C. The cell media was 
replaced with serum-free media 4 h post-transfection and further incubation was done at 37 °C for all 
samples. We assayed the cells at regular intervals up to 48 h for luciferase expression (Figure 53). χ/M-
VLPs at all stoichiometry displayed significantly lower TE in HEK293 cells incubated at 4 °C. TE at 48 h for 
HEK293 cells incubated at 4 °C was 16%, 27%, 18% and 16% of TE at 48 h for HEK293 cells incubated at 
37 °C. In order to investigate if the low TE was due to low cellular uptake at 4 °C, we repeated the 
experiment with fluorescently labeled M-VLPsDiD and measured mean fluorescence via flow cytometry at 2, 
4 and 8 h post-transfection (Figure 54). The cellular uptake of χ/M-VLPsDiD was higher in HEK293 cells 
incubated at 37 °C than at 4 °C. The change in incubation temperature from 4 °C to 37 °C 4 h post 
transfection improved the cellular uptake. This implied that the vectors that remained in contact with the 
plasma membrane were unable to enter the cells via fusion but were actively endocytosed at the higher 
temperature when the media was changed along with the increase in incubation temperature. Thus, it can 
be concluded that χ/M-VLPs use an active endocytic process for cellular entry. Furthermore, as per Figure 
53, χ/M-VLPs at 4 and 7 μg/109 M-VLPs exhibited the greatest increase in TE between 24 h and 32 h 
whereas χ/M-VLPs at 2 and 10 μg/109 M-VLPs had the steepest increase in TE between 32 h and 48 h. 
This implies that the trafficking process for χ/M-VLPs at 4 and 7 μg/109 M-VLPs was faster than χ/M-
VLPs at 2 and 10 μg/109 M-VLPs. We shall further discuss the trafficking kinetics later in this chapter. 
Lipid-based non-viral vectors are known to mediate cell entry through a fusogenic mechanism that 
may or may not require endocytic vesicles. While fusion with the plasma membrane can allow the direct 
entry of the vector into the cytoplasm, fusion with endocytic vesicles may happen post-entry or might even  
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Figure 52: Transfection Efficiency (TE) of MLV-A at 4 °C and 37 °C. Y-axis – Normalized RLU/mg total protein = 
Relative Light Units per mg total protein in cellular lysate normalized to the corresponding values 48 h post-
transfection at 37 °C. X-axis – Time (h) post-transfection. TE at 4 °C was lower compared to 37 °C. 
 
induce an endocytic event for initiating successful transfections1. As discussed earlier, χ/M-VLPs were 
internalized through the active mechanisms of endocytosis. To compare the cellular uptake of χ/M-VLPs 
with φ/M- VLPs, HEK293 cells were transfected at 4 °C or 37 °C with φ587/M-VLPs, φ505/M-VLPs and 
φ550/M-VLPs at 10 μg/10
9 M-VLPs. The transfection media was replaced with complete media 4 h post-
transfection and further incubation was done at 37 °C for all samples. Luciferase expression was measured 
at regular intervals up to 24 h (Figure 55). TE of φ/M-VLPs in HEK293 cells incubated at 4 °C was 
significantly lower than at 37 °C. Furthermore, φ/M-VLPs performed worse than χ/M-VLPs at 4 °C with 
TE being 9%, 6% and 4% of the control for φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs, respectively. 
We also measured cellular uptake of φ/M-VLPsDiD at regular intervals up to 8 h in HEK293 cells 
incubated at 4 °C or 37 °C for 4 h followed by 4 h at 37 °C (Figure 56). Cellular uptake of φ/M-VLPs at 4  
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Figure 53: Transfection Efficiency (TE) of χ/M-VLPs at (a) 2 μg/109 M-VLPs, (b) 4 μg/109 M-VLPs, (c) 7 μg/109 
M-VLPs and 10 μg/109 M-VLPs at 4 °C and 37 °C. Y-axis – Normalized RLU/mg total protein = Relative Light 
Units per mg total protein in cellular lysate normalized to the corresponding values 48 h post-transfection at 37 °C. 
X-axis – Time (h) post-transfection. TE at 4 °C was lower at every stoichiometry compared to 37 °C. 
 
°C was similar to 37 °C especially for φ587/M-VLPs with no difference between uptake at 4 °C and 37 °C. 
Uptake further increased for φ587/M-VLPs in HEK293 cells at 4 °C after replacement of media and change 
in incubation temperature to 37 °C. Cellular uptake of φ505/M-VLPs and φ550/M-VLPs was also 
significantly higher than χ/M-VLPs in HEK293 cells at 4 °C (≈40% and ≈50% respectively) in the first 4 h. 
Uptake improved marginally after replacement of media and increase in the incubation temperature. A 
noteworthy difference between χ/M-VLPs and φ/M-VLPs was the constant or marginal decrease of  
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Figure 54: Cellular Uptake of χ/M-VLPs at (a) 2 μg/109 M-VLPs, (b) 4 μg/109 M-VLPs, (c) 7 μg/109 M-VLPs and 
10 μg/109 M-VLPs at 4 °C and 37 °C. Y-axis – Normalized Uptake = Uptake of χ/M-VLPs normalized to the 
corresponding values 8 h post-transfection at 37 °C. X-axis – Time (h) post-transfection. Uptake at 4 °C was lower 
at every stoichiometry compared to 37 °C.  
 
fluorescence in HEK293 cells incubated at 37 °C when transfected with φ/M-VLPs. This indicated that the 
gradual removal of natural lipid bilayer of the M-VLP was already being initiated within 8 h post-
transfection in φ/M-VLPs. Upon removal of the lipid bilayer, it is likely that the dye was removed from the 
lipid bilayer. The dye being lipophilic is fluorescent only upon being in a lipophilic environment leading to 
loss of fluorescent signal. Hence, the initial uptake mechanisms are slower in χ/M-VLPs compared to φ/M- 
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Figure 55: Transfection Efficiency (TE) of (a) φ587/M-VLPs, (b) φ505/M-VLPs and (c) φ550/M-VLPs at 10 μg/10
9 
M-VLPs at 4 °C and 37 °C. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein 
in cellular lysate normalized to the corresponding values 24 h post-transfection at 37 °C. X-axis – Time (h) post-
transfection. TE of φ/M-VLPs at 4 °C was lower than TE of χ/M-VLPs 
 
VLPs. A direct comparison between TE of χ/M-VLPs and φ/M-VLPs (Figures 53 and 55) also suggested 
that the initial trafficking of φ/M-VLPs led to quicker release of M-VLPs compared to χ/M-VLPs. TE of 
φ/M-VLPs 18 h post transfection was 64%, 96% and 79% of TE at 24 h at 37 °C for φ587/M-VLPs, 
φ505/M-VLPs and φ550/M-VLPs, respectively, while TE of χ/M-VLPs 18 h post-transfection was 15%, 8%, 
5% and 5% of TE at 24 h for 2, 4, 7 and 10 μg/109 M-VLPs.  
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Figure 56: Cellular Uptake of (a) φ587/M-VLPs, (b) φ505/M-VLPs and (c) φ550/M-VLPs at 10 μg/10
9 M-VLPs at 4 
°C and 37 °C. Y-axis – Normalized Uptake = Uptake of φ/M-VLPs normalized to the corresponding values 8 h post-
transfection at 37 °C. X-axis – Time (h) post-transfection. Uptake of φ/M-VLPs at 4 °C was higher compared to 
uptake of χ/M-VLPs. 
 
From Figure 55, we know that TE in cells transfected with φ/M-VLPs incubated at 4 °C was much 
lower than TE in cells incubated at 37 °C. This indicates that the initial uptake via fusion is sub-optimal in 
terms of the later trafficking pathway. The initial uptake via endocytosis is significantly better in terms of 
successful gene delivery. Alternatively, it is highly likely that post-internalization events relied on endocytic 
mechanisms for successful gene delivery which was absent in cells incubated at 4 °C. Further change in the 
incubation temperature to 37 °C should have led to better transfections. However, given the faster 
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trafficking kinetics, the slow removal of the synthetic lipid envelope had probably already been initiated 
within 4 h. This delay of 4 h was not enough for the synthetic lipid envelope to direct the M-VLP towards 
an optimal endocytic mechanism. Hence, it can be suggested that φ/M-VLPs requires endocytosis to be 
active despite significant fusogenic uptake for efficient transfections. This is possible if fusion invites 
endocytic vesicles to the plasma membrane or the lipids fuse with the endocytic vesicles post-entry. In fact, 
it is known that DOTAP:DOPE and DC-Chol:DOPE liposomes initiate fusion with the cell post-
endocytosis in unidentified organelles20. 
 
Effect of Pharmacological Inhibitors on Cellular Uptake and TE of MLV-A, χ/M-VLPs and φ/M-VLPs 
The use of pharmacological inhibitors are well known for their application in studying intracellular 
trafficking mechanisms of drug and gene delivery vectors1. These inhibitors are also typically toxic beyond 
certain concentrations and could also potentially inhibit the transgene expression via non-specific 
mechanisms21. For accurate implementation of the inhibition, the drug concentration was optimized for 
both toxicity as well as normalized luciferase expression in HEK293Luc cells. Toxicity was determined 
through the Cell-Titer™ Blue Assay and compatibility with luciferase expression was determined via the 
luciferase assay 48 h after of addition of drugs. The optimal concentration was decided based on the highest 
drug concentration that resulted in > 90% cell viability and luciferase expression. Table 19 summarizes the 
mechanism of the action of the drugs on intracellular trafficking mechanisms as well as the concentration for 
their optimal use to study their inhibition 
Inhibition by drugs on specific pathways or proteins would result in modified trafficking 
mechanisms and/or shut down of the pathway leading to reduced transfections. The collective result of the 
various inhibitions would allow the mapping of the trafficking network for efficient transfections by the  
154 
 
Table 19: Mechanism of action and optimal concentration of drug inhibitors used in this study. 
Drug Effect Optimal Concentration 
Amiloride (AMD) Inhibition of Na+/H+ exchange22,23 (MP) 50 μg/ml (Figure 57) 
Amantadine (AMN) Stabilization of clathrin-coated vesicles24 (CME) 100 μg/ml (Figure 58) 
Chlorpromazine (CPZ) Disrupts assembly and disassembly of clathrin 
from coated pits25 (CME) 
20 μM (Figure 59) 
Genistein (GST) Inhibits tyrosine phosphorylation preventing 
caveolae formation26 (CavME) 
20 μg/ml (Figure 60) 
Bafilomycin A1 (BFN) Prevents re-acidification of synaptic vesicles 
inhibiting release of endosomal cargo27,28 
5 nM (Figure 61) 
Cytochalasin D (CCN) Inhibits actin microfilaments that can also inhibit 
caveolae formation29,30 (CavMe, Fusion)  
10 μM (Figure 62) 
Azidothymidine (AZT) Inhibits reverse transcription31 20 μM (Figure 63) 
MP – Macropinocytosis  
CME – Clathrin-mediated endocytosis  
CavME  - Caveolae-mediated endocytosis 
 
hybrid vectors. Transfections with MLV-A were also tested in the presence of drug inhibitors to serve as 
effective controls for elucidating the changes that occur in the trafficking mechanism due to the presence of 
a synthetic envelope in place of the amphotropic envelope protein. Luciferase expression decreased 
significantly for MLV-A in the presence of both CCN (to 37%, p < 0.02) and GSN (to 59%, p < 0.05) 
(Figure 64) but was unaffected by the other drugs in the study. This implies that MLV-A are internalized via 
CavME lead to successful transfection. It would have been valuable to obtain data on uptake of MLV-A but 
the present scheme of labeling of retrovirus via DiD on the lipid bilayer would have been useless in this 
study since the lipid bilayer gets removed during internalization of the virus. The dye would then be a part 
of the plasma membrane that would get washed off during our protocol to prepare samples. While the role 
of actin in the MLV-A trafficking is uncertain, it is known that the inhibition by CCN of actin can also lead 
to reduced formation of caveolae without disrupting the clathrin vesicles, which might have resulted in 
reduced transfections29. Indeed, it is known in literature that MLV-A trafficking is caveolae dependent 
utilizing the Pit2 receptor for efficient uptake32. 
155 
 
 
Figure 57: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of AMD. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μg/ml). Normalization 
was done with respect to untreated cells. The optimal concentration of AMD was concluded to be 50 μg/ml. 
 
 
Figure 58: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of AMN. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μg/ml). Normalization 
was done with respect to untreated cells. The optimal concentration of AMN was concluded to be 100 μg/ml. 
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Figure 59: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of CPZ. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μM). Normalization was 
done with respect to untreated cells. The optimal concentration of CPZ was concluded to be 20 μM. 
 
 
Figure 60: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of GST. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μg/ml). Normalization 
was done with respect to untreated cells. The optimal concentration of GST was concluded to be 20 μg/ml. 
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Figure 61: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of BFN. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (nM). Normalization was 
done with respect to untreated cells. The optimal concentration of BFN was concluded to be 5 nM. 
 
 
Figure 62: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of CCN. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μM). Normalization was 
done with respect to untreated cells. The optimal concentration of CCN was concluded to be 10 μM. 
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Figure 63: Cytotoxicity on HEK293 cells and Luciferase Expression of HEK293Luc cells after exposure to different 
concentrations of AZT. Y-axis – Normalized Values of Absorbance Values for Toxicity and Luciferase Expression in 
terms of Relative Light Units per mg total protein cellular lysate. X-axis – Concentration (μM). Normalization was 
done with respect to untreated cells. The optimal concentration of AZT was concluded to be 20 μM. 
  
For χpH3/M-VLPs, TE decreased in the presence of CPZ (to 57%, p < 0.05), GST (to 9%, p < 
0.002), BFN (to 29%, p < 0.02) and CCN (to < 1%, p < 0.002) (Figure 64) while uptake decreased in the 
presence of AMD (to 73%, p < 0.05) and GST (to 47%, p < 0.05) (Figure 65). Hence, uptake of χpH3/M-
VLPs was significantly affected if CavME or MP was inhibited and TE was severely inhibited if CavME was 
inhibited along with disruption of actin microfilaments. There was also a minor reduction in TE when 
endosomal acidification as well as early-stage CME was inhibited through CPZ. This implies that the late-
stage endosomal trafficking is significant for χpH3/M-VLPs which can be reached via caveosomes in CavME, 
early endosomes in CME and macropinosomes in MP. Early stage trafficking, however, is significant via 
CME and CavME for successful gene delivery. Since we concluded that fusogenicity of χpH3/M-VLPs is not 
important for uptake (Figure 54), the significant reduction in TE due to actin disruption can be attributed to  
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Figure 64: Transfection Efficiency (TE) of MLV-A and χ/M-VLPs (pH 3 and pH 4, 5 μg/109 M-VLPs) in the 
presence of drug inhibitors. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein 
in cellular lysate normalized to the same expression for untreated cells. X-axis = Drugs at optimal concentrations. # 
- p < 0.05, ## - p < 0.02, ### - p <0.002 and * - p <0.0001. 
 
the disruption of CavME by CCN. Hence, it can be concluded that the χpH3/M-VLPs uses CavME and CME 
(to a minor extent) for successful gene delivery. 
TE for χpH4/M-VLPs decreased in the presence of AMD (to 48%, p < 0.002), CPZ (to 4%, p < 
0.0001), GST (to 14%, p < 0.002) and CCN (to 0%, p < 0.0001) (Figure 64) while uptake increased in 
the presence of AMN (to 238%, p < 0.02) and CCN (to 141%, p < 0.05) (Figure 65). Uptake of χpH4/M-
VLPs was promoted when CME was inhibited due to stabilization of clathrin-coated vesicles (CCV) and 
when actin microfilaments were disrupted. However, transfections were severely hampered due to 
inhibition of CME when CCV formation was inhibited. Hence, not only was vesicular transport important 
for χpH4/M-VLPs, early stage trafficking was mediated via CME and CavME with MP playing a minor role.  
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Figure 65: Cellular Uptake of χ/M-VLPs (pH 3 and pH 4, 5 μg/109 M-VLPs) in the presence of drug inhibitors. Y-
axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein in cellular lysate normalized to 
the same expression for untreated cells. X-axis = Drugs at optimal concentrations. # - p < 0.05, ## - p < 0.02, 
### - p <0.002 and * - p <0.0001. 
 
It is likely that the vector morphology of χpH4/M-VLPs was unable to efficiently release themselves from the 
endosomes at the appropriate stage of trafficking at lower than optimal stoichiometry. We know from 
chapter 2 that the optimal stoichiometry of χpH4/M-VLPs was higher than that for χpH3/M-VLPs. Hence, a 
caveolar pathway involving late-stage caveosomes where pH is higher than late-stage endosomes is more 
significant for χpH4/M-VLPs. It is also likely that there is a lot more interplay between CavME, CME and 
MP during the late-stage trafficking of χpH4/M-VLPs and at higher stoichiometry of χpH4/M-VLPs, the 
trafficking changes to an optimal pathway as mediated via χpH3/M-VLPs. Therefore, pH not only plays a 
significant role in vector morphology in terms of size, it plays an important role in mediating trafficking via 
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the optimal route for efficient transfection. It has been reported earlier that chitosan vectors can proceed via 
either of these three trafficking pathways but are cell-line dependent for deciding the optimal pathway13,14. 
For φ505/M-VLPs, TE decreased in the presence of AMN (to 43%, p < 0.02), CPZ (to 18%, p < 
0.002), GST (to 4%, p < 0.0001) and CCN (to 5%, p < 0.0001) (Figure 66) while cellular uptake 
decreased in the presence of CPZ (to 73%, p < 0.05) and GST (to 40%, p < 0.0001) (Figure 67). We 
know from Figure 56 that uptake of φ/M-VLPs can be mediated via fusogenicity. However, TE achieved 
through an early-stage fusogenic pathway only was significantly low (Figure 55). Since uptake via fusion is 
passive and non-specific, it is expected that a significant proportion of φ/M-VLPs would enter cells via this 
sub-optimal pathway. Additionally, any effect mediated via CCN could be significantly attributed to 
disrupting of actin microfilaments initially. The high fusogenicity also implies that as long as the synthetic 
lipid envelope is still in contact with the M-VLPs, φ/M-VLPs can mediate fusion even with the endocytotic 
vesicles within the cell thereby using the active machinery of the cell to reach the nucleus. This might also 
explain why the TE was low in cells at 4 °C since the low temperature allowed the vectors to enter but 
since no endocytic machinery was active, the vectors were essentially misplaced within the cell. The mild 
increase in the uptake after 4 h due to increase in the temperature might explain the low TE still measured 
in those cells. Both uptake and TE were significantly affected in the presence of GST. It can be concluded 
that CavME is a significant pathway for φ505/M-VLPs while CME and MP play a minor role. 
For φ550/M-VLPs, TE increased in the presence of AMD (to 131%, p < 0.02) and decreased in the 
presence of CPZ (to 20%, p < 0.0001), GST (to 6%, p < 0.0001), BFN (to 57%, p < 0.02) and CCN (to 
22%, p < 0.0001) (Figure 66) while cellular uptake increased in the presence of GST (to 135%, p < 0.05) 
(Figure 67). TE for φ550/M-VLPs was affected when either CME or the late-stage endosomal pathway was 
inhibited and promoted when MP was inhibited. It can be concluded that CME is a significant pathway for  
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Figure 66: Transfection Efficiency (TE) of MLV-A and φ587/M-VLPs, φ505/M-VLPs and φ550/M-VLPs (10 μg/10
9 
M-VLPs) in the presence of drug inhibitors. Y-axis – Normalized RLU/mg total protein = Relative Light Units per 
mg total protein in cellular lysate normalized to the same expression for untreated cells. X-axis = Drugs at optimal 
concentrations. # - p < 0.05, ## - p < 0.02, ### - p <0.002 and * - p <0.0001. 
 
φ550/M-VLPs while CavME played a small role in the late-stage trafficking through interplay between the 
late-stage endosomes and caveosomes. It is important to know that the mechanism of release from 
endosomal compartments for DOPE-based vectors is the conversion to HII phase from Lα. Endosomal 
acidification can lead to disruption of these vectors leading to release into the cytosol through this phase 
change. However, inhibition of the acidification via BFN will not lead to this phase change thereby reducing 
the TE. 
For φ587/M-VLPs, TE decreased in the presence of AMD (to 47%, p <0.02), CPZ (to 35%, p < 
0.02), GST (to 4%, p < 0.0001) and CCN (to 9%, p < 0.0001) (Figure 66) while cellular uptake was not 
significantly affected by any of the inhibitors (Figure 67). Since all three lipids were present in the synthetic  
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Figure 67: Cellular Uptake of φ587/M-VLPsDiD, φ505/M-VLPsDiD and φ550/M-VLPsDiD (10 μg/10
9 M-VLPs) in the 
presence of drug inhibitors. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein 
in cellular lysate normalized to the same expression for untreated cells. X-axis = Drugs at optimal concentrations. # 
- p < 0.05, ## - p < 0.02, ### - p <0.002 and * - p <0.0001. 
 
envelope, it is possible that both the neutral helper lipids helped to promote their own specific pathway 
(DOPE for CME and cholesterol for CavME). Cellular uptake was not significantly affected in the presence 
of any drugs since other pathways were always a viable option for φ587/M-VLPs. This is supported by the 
data on TE wherein there was a decrease due to inhibition of every pathway. Since, the effect of GST was 
more significant than CPZ wherein CCV formation is inhibited, it is possible that CavME plays a slightly 
bigger role in the late-stage trafficking of φ587/M-VLPs. Thus, it can be concluded that cholesterol plays a 
larger role as the neutral helper lipid than DOPE. Overall, it can be inferred that the lipid composition 
plays a significant role in the trafficking of φ/M-VLPs. The choice of φ587/M-VLPs over φ325/M-VLPs as 
the optimal lipid composition was a good choice overall given that is highly likely that the majority presence 
of cholesterol would have driven the transfections through CavME with minimal diversion through CME. 
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The dependence of DOPE on intracellular trafficking of φ/M-VLPs would have remained in doubt in the 
optimal composition synthetic lipid envelope. 
CavME is a significant trafficking pathway for MLV-A. As late-stage CavME was implicated in all 
the hybrid vectors for successful gene delivery, it is highly likely that trafficking closer to the nucleus was 
affected by the M-VLP. Since early stage-trafficking involved all the other pathways, it appears that the 
synthetic envelope plays a significant role in the trafficking kinetics just after cellular uptake. In chapter 3, 
we reported that the optimal composition of synthetic lipid envelopes needs low DOTAP; low DOPE and 
high cholesterol for maximal TE. Through our trafficking studies, we found that DOPE-heavy liposomes 
prefer CME while the native pathway for MLV-A is CavME. Thus, even though optimal transfections were 
achieved via the presence of DOPE, φ/M-VLPs favored the higher presence of that lipid component which 
was more amenable to the viral native trafficking mechanism, i.e., cholesterol. In contrast, CME was 
implicated for the better performing χpH3/M-VLPs in comparison to the χpH4/M-VLPs that relied more on 
CavME and MP. 
 
Measurement of trafficking kinetics via inhibition of reverse transcription of MLV-A, χ/M-VLPs and φ/M-VLPs 
AZT is a potent inhibitor of reverse transcriptase and was one of the first anti-retroviral drugs sold 
for the control of HIV31. The addition of AZT during the transfection period will block the transfection of 
MLV-A as well as the hybrid vectors at the last trafficking step prior to nuclear entry, i.e. prevent the 
formation of the provirus. If added at regular intervals during the transfection period, AZT would block all 
further reverse transcription thus effectively disallowing any further increase in transgene expression while 
the vectors that were able to reach the nucleus prior to the addition of AZT would still go on to integrate 
the luciferase gene. In this manner, AZT would serve as an effective measure of trafficking kinetics of 
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vectors until nuclear entry. Figure 68 plots the luciferase expression in HEK293 cells as a function of the 
time at which AZT was added to the cells.  
MLV-A transfection was the fastest amongst all the vectors. Luciferase expression did not increase 
even when AZT was added 24 h and 32 h post-transfection. This implies that the entire MLV-A viral load 
was able to reach the nucleus by 16 h. In contrast, the hybrid vectors were slower since the addition of AZT 
at 32 h led to a significant increase in the luciferase expression from the TE at 24 h for all hybrid vectors. 
Particularly, χ/M-VLPs were much slower than φ/M-VLPs with χ/M-VLPs having reached < 20% TE at 
the 24 h time point whereas φ/M-VLPs had reached 45-60% TE. This trend also reaffirms our earlier result 
(Figures 53 and 55) where we concluded that the initial trafficking kinetics of χ/M-VLPs was slower than 
that of φ/M-VLPs. Additionally, the composition of the lipid synthetic envelope did not have a significant 
impact on the trafficking kinetics from 0 – 32 h. For χ/M-VLPs, using a higher pH synthetic envelope (pH 
4) not only had a significant effect on the trafficking mechanism but also was significantly slower compared 
to the low pH synthetic envelope (pH 3). MLV-A is the fastest amongst all our vectors because the hybrid 
vectors have an additional barrier in delivery in terms of stripping of the synthetic envelope. 
 
Visualization of trafficking of χ/M-VLPs and φ/M-VLPs through confocal microscopy 
In order to confirm the kinetics of hybrid vector transfections as discussed above, we used confocal 
microscopy to visualize fluorescently labeled vectors at three time-points – 4 h, 8 h and 20 h post-
transfection. M-VLPs were labeled with the lipophilic dye DiD to form M-VLPsDiD. Chitosan at pH 3 was 
labeled with Rhodamine-B Isothiocyanate using a previously reported protocol33,34 and used to form χRhod-
B/M-VLPsDiD. For visualizing the lipid-based synthetic envelopes – DOPE labeled with Rhodamine-B 
(DOPE-Rhod-B) and NBD-6 cholesterol was added to the lipid formulation. The composition of φ587/M- 
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Figure 68: Transfection Efficiency (TE) of MLV-A, φ587/M-VLPs, φ505/M-VLPs, φ550/M-VLPs (10 μg/10
9 M-
VLPs) and χ/M-VLPs (pH 3 and pH 4, 5 μg/109 M-VLPs) in the presence of AZT added 0, 4, 18, 24 and 32 h post-
transfection. Y-axis – Normalized RLU/mg total protein = Relative Light Units per mg total protein in cellular 
lysate normalized to the same expression for cells treated with AZT 32 h post-transfection for every tested vector. X-
axis = Time in h. 
 
VLPsDiD was supplemented with DOPE-Rhod-B up to 3% of total DOPE content and with NBD-6-chol up 
to 3% of total cholesterol content to form φ587(l)/M-VLPsDiD. Similarly, φ505(l)/M-VLPs and φ550(l)/M-VLPs 
were also synthesized.  
 The trafficking kinetics of χ/M-VLPs was found to be slower than φ/M-VLPs (Figures 53, 55 and 
68). χRhod-B/M-VLPsDiD were visualized via confocal microscopy and is shown in Figures 69, 70 and 71 
respectively. The colocalization of chitosan (red) and M-VLPs (white) is maintained even at 20 h post-
transfection implying that χ/M-VLPs take a long time for the removal of the chitosan synthetic envelope. 
The longer time is most likely a function of the trafficking kinetics of χ/M-VLPs. In contrast, while 
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significant colocalization was observed for φ587(l)/M-VLPsDiD, φ505(l)/M-VLPsDiD and φ550(l)/M-VLPsDiD at 4 h, 
a rapid decay in the fluorescence signal of DOPE-Rhod-B and NBD-6-chol was observed along with 
significant loss of colocalization between M-VLPsDiD and the fluorescent lipids (Figures 72-80). This 
confirms our earlier conclusion that φ/M-VLPs have a faster trafficking process through the cell. It also 
confirms that the stripping of the synthetic lipid envelope from M-VLPs is quicker than the synthetic 
chitosan envelope. We know from our earlier studies that the trafficking mechanisms of φ/M-VLPs are 
dependent on the lipid composition with the significant exception being that all three lipid compositions 
were able to mediate cell fusion through the plasma membrane. Given the quick removal of the synthetic 
lipid envelope, it is definitely a surprise that the lipids are able to exert a significant influence on the 
trafficking process of M-VLPs despite being a component of the hybrid vector for a shorter duration than 
χ/M-VLPs. Hence, the optimal trafficking pathway seems to be chosen at a relatively early stage of the 
transfection. The fusion of the φ/M-VLPs with endocytic vesicles is also possible once inside the cells, 
which could also be a significant reason for their quicker kinetics. On the other hand, χ/M-VLPs have more 
time for the optimization of the trafficking path which can be modulated with the vector morphology. 
While the colocalization of M-VLPs with cholesterol was minimal at all time-points, we concluded earlier 
that cholesterol might have a more significant role to play in trafficking of φ587/M-VLPs despite the 
presence of DOPE. It can be inferred that the optimal pathway is a lot more dependent on the early-stage 
trafficking compared to late-stage trafficking. 
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Figure 69: Confocal Microscopy of χ/M-VLPs (5 μg/109 M-VLPs) at 4 h post-transfection. (top left) – brightfield; 
(top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – chitosan (red); (bottom right) – M-VLPs 
colocalized with chitosan (magenta). Scale bar = 10 μm. 
 
 
 
 
 
 
    
 
Figure 70: Confocal Microscopy of χ/M-VLPs (5 μg/109 M-VLPs) at 8 h post-transfection. (top left) – brightfield; 
(top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – chitosan (red); (bottom right) – M-VLPs 
colocalized with chitosan (magenta). Scale bar = 10 μm. 
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Figure 71: Confocal Microscopy of χ/M-VLPs (5 μg/109 M-VLPs) at 20 h post-transfection. (top left) – brightfield; 
(top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – chitosan (red); (bottom right) – M-VLPs 
colocalized with chitosan (magenta). Scale bar = 10 μm. 
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Figure 72: Confocal Microscopy of φ505/M-VLPs (10 μg/10
9 M-VLPs) at 4 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – cholesterol (green); (bottom 
right) – M-VLPs colocalized with cholesterol (cyan blue). Scale bar = 10 μm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 73: Confocal Microscopy of φ505/M-VLPs (10 μg/10
9 M-VLPs) at 8 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – cholesterol (green); (bottom 
right) – M-VLPs colocalized with cholesterol (cyan blue). Scale bar = 10 μm.   
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Figure 74: Confocal Microscopy of φ505/M-VLPs (10 μg/10
9 M-VLPs) at 20 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – cholesterol (green); (bottom 
right) – M-VLPs colocalized with cholesterol (cyan blue). Scale bar = 10 μm.   
 
 
 
 
 
 
 
 
 
 
 
Figure 75: Confocal Microscopy of φ550/M-VLPs (10 μg/10
9 M-VLPs) at 4 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – DOPE (red); (bottom right) – M-
VLPs colocalized with DOPE (magenta). Scale bar = 10 μm.     
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Figure 76: Confocal Microscopy of φ550/M-VLPs (10 μg/10
9 M-VLPs) at 8 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – DOPE (red); (bottom right) – M-
VLPs colocalized with DOPE (magenta). Scale bar = 10 μm.     
 
 
 
 
 
   
 
 
 
 
 
 
Figure 77: Confocal Microscopy of φ550/M-VLPs (10 μg/10
9 M-VLPs) at 20 h post-transfection. (top left) – 
brightfield; (top center) – nucleus (yellow); (top right) – M-VLPs (blue); (bottom left) – DOPE (red); (bottom right) – M-
VLPs colocalized with DOPE (magenta). Scale bar = 10 μm.   
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Figure 78: Confocal Microscopy of φ587/M-VLPs (10 μg/10
9 M-VLPs) at 4 h post-transfection. (top left) – 
brightfield; (top center) – nuclear region (yellow); (top right) – M-VLPs (blue); (middle left) – DOPE (red); (middle 
center) – cholesterol (green); (middle right) – M-VLPs colocalized with DOPE (magenta) (bottom left) – M-VLPs 
colocalized with cholesterol (cyan blue); (bottom right) – DOPE colocalized with cholesterol (yellow). Scale bar = 10 
μm. 
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Figure 79: Confocal Microscopy of φ587/M-VLPs (10 μg/10
9 M-VLPs) at 8 h post-transfection. (top left) – 
brightfield; (top center) – nuclear region (yellow); (top right) – M-VLPs (blue); (middle left) – DOPE (red); (middle 
center) – cholesterol (green); (middle right) – M-VLPs colocalized with DOPE (magenta) (bottom left) – M-VLPs 
colocalized with cholesterol (cyan blue); (bottom right) – DOPE colocalized with cholesterol (yellow). Scale bar = 10 
μm. 
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Figure 80: Confocal Microscopy of φ587/M-VLPs (10 μg/10
9 M-VLPs) at 20 h post-transfection. (top left) – 
brightfield; (top right) – cholesterol (green); (middle left) – DOPE (red); (middle right) – M-VLPs (white); (bottom) – 
nuclear region (blue). 
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Conclusion 
In this chapter, we concluded our investigation on the design of χ/M-VLPs and φ/M-VLPs in 
terms of the differences in trafficking mechanisms and kinetics compared to the enveloped virus MLV-A. 
Trafficking of χ/M-VLPs was slower than φ/M-VLPs as confirmed from AZT inhibited transfections as 
well as visualization via confocal microscopy. χ/M-VLPs relied heavily on the active processes of 
endocytosis whereas φ/M-VLPs had significant uptake through fusion with the plasma membrane. 
However, the fusion-dependent process was sub-optimal for efficient transfections and it is highly likely that 
the fusion with the plasma membrane either induced an endocytic process at the higher temperatures or 
fusion with the plasma membrane was accompanied with fusion with endocytic vesicles. Both hybrid 
vectors were able to use CME, CavME or MP for favorable trafficking mechanisms. χ/M-VLPs when 
synthesized using chitosan at pH 3 were able to effectively use the endosomal release mechanism typically 
part of late-stage CME for high transfection efficiency. The lipid composition of φ/M-VLPs significantly 
affected the optimal uptake and trafficking pathways for effective gene delivery. Cholesterol preferred 
CavME while DOPE preferred CME for optimal transfections.  
 
Experimental Methods 
Cell Lines and Assays Human embryonic kidney cells, HEK293 and cervical cancer cells, HeLa were 
purchased from the American Type Culture Collection (Manassas, VA). The MLV producer cell line, 
GP293Luc, expressing the MLV viral gag-pro-pol genes and a viral packaging sequence encoding neomycin 
resistance and luciferase reporter genes was purchased from Clontech (Mountain View, CA). All cell lines 
were grown in DMEM supplemented with 10% FBS (complete media) and cultured at 37 oC in 5% CO2. 
Dulbecco's Modified Eagle's Medium (DMEM) and Phosphate-buffered saline (PBS) was produced in-house 
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at the Cell Culture Media Facility, School of Chemical Sciences, University of Illinois. Fetal Bovine Serum 
(FBS) was bought from Gemini Bio-Products and used as purchased. Luciferase assay and Cell-Titer BlueTM 
assay kits were bought from Promega and used as per the manufacturer's instructions. BCA assay was 
bought from Thermo Scientific and used as per the manufacturer's instructions. 
M-VLP Production and Quantification M-VLPs were produced in GP293Luc cells (2 x 106) seeded in a 
10 cm dish. The cells were cultured for four days before the M-VLP containing supernatant was collected 
and filtered through a 0.45 µm surfactant-free cellulose acetate syringe filter. The concentration of M-VLPs 
in the supernatant was measured using a q-RT-PCR protocol35. RNA Standards were obtained from the 
Clontech qPCR Retroviral Quantification Kit and stored at -80 oC before further use. Viral RNA was 
extracted using the QIAGEN Viral RNA Extraction kit and stored in a 60 µl eluate at -80 oC before further 
use. Standards and viral RNA samples were prepared for reverse transcription using Taqman reverse 
transcription reagents (Applied Biosystems, Carlsbad, CA). Twenty μl samples were mixed in 200 μl PCR 
tubes using the reagent concentrations suggested by the kit plus 250 nM sequence-specific primers. 
Thermal cycling was carried out on a Peltier Thermocycler (PTC)-100 (MJ Research). Real-time PCR of 
the cDNA standards and samples was carried out in triplicate in 10 µl/well samples on a 384-well plate in a 
Taqman 7900 Real-Time PCR Machine (Applied Biosystems) and analyzed using SDS software (Applied 
Biosystems). The final reaction mixture ratio of the components was 5:1:1:3 (2X SYBRGreen real-time 
PCR reagent:forward primer:reverse primer:cDNA volume). The final concentration of the sample RNA 
was calculated using the calibration curve obtained via the cDNA standards. Each viral particle has 2 RNA 
copies which enabled us to calculate the total number of M-VLPs in a given volume of supernatant. Two 
RNA extracts were collected for each M-VLP sample and quantified using 3 dilutions of each cDNA 
sample. M-VLP supernatant was either used immediately or stored at 4 oC for short term storage (< 4 
weeks) or stored at -80 oC for long term storage. 
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MLV-A Production GP293Luc cells, seeded (2 x 106) in a 10 cm dish, were grown for 48 h prior to 
transfection with the envelope plasmid pMDM.4070A. Complete media was replaced with serum-free 
media just before transfections. Plasmid:Lipid vectors were synthesized in the required stoichiometric ratios 
and incubated at room temperature for 10 min prior to drop-wise addition to GP293Luc cells. The media 
was replaced again with complete media 6 h post-transfection. The cells were cultured for a further 48 h 
before the MLV-A containing supernatant was collected and filtered through a 0.45 µm surfactant-free 
cellulose acetate syringe filter. 
Synthesis of φ/M-VLPs The three lipids dissolved in chloroform were mixed in the desired composition in 
a test-tube and dried under vacuum overnight to form a thin film. The lipid film was rehydrated using a 5% 
glucose solution and sonicated briefly to allow the lipids to dissolve completely. The rehydrated solution 
was vortexed every 30 minutes for 30 seconds for a total duration of 3 h. If not used immediately, the lipid 
solution was stored at 4 °C (< 1 month). The lipid solution was extruded through an Avanti® Mini-
Extruder for 11 passes through a 100 nm PC membrane. The lipid samples were then added to the required 
volume of M-VLP supernatant and diluted in 5% glucose solution as per the φ/M-VLP stoichiometry and 
incubated for 2 h at 4 °C prior to further analysis or transfection. 
Synthesis of χ/M-VLPs PEI (Molecular Weight = 750 kDa, Sigma Aldrich, 1 mg/ml in ultrapure water), 
PLL (Molecular Weight = 150-300 kDa, Sigma Aldrich, 1 mg/ml in ultrapure water) or Chitosan 
(Molecular Weight = 190-310 kDa, Sigma Aldrich, 1 mg/ml dissolved overnight at 55 oC in 0.6 % acid and 
filtered through a 0.22 µm surfactant-free cellulose acetate syringe filter, pH 3 and 4) was added drop-wise 
to required volume of M-VLP supernatant while vortexing to achieve the desired polymer:M-VLP ratio. 
The hybrid vectors were then incubated at 4 oC for 4 h. 
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Transfections HEK293 cells were seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12 well 
plates. Growth media containing serum was replaced with serum-free DMEM prior to drop-wise addition 
of vectors and replaced again with normal growth media 4 h post-transfection. For serum studies, the 
transfection media contained 0-50% serum. For transfections with MLV-A, HEK293 cells were seeded 18-
24 h prior to transfection at 8 x 104 cells/well in 6-well plates. MLV-A containing supernatant was diluted 
in complete media (1:1 or 1:3, v:v) along with addition of 1 μl Sequabrene for every 1 ml of the diluted 
mixture to produce viral media. HEK293 cells were transfected with 1 ml/well viral media. Luciferase 
expression was measured at 24 h post transfection as mentioned below.  
Luciferase expression assay Luciferase expression was quantified 48 h post-transfection for all studies 
except for the passive/active studies as mentioned later using the Promega luciferase assay system following 
the manufacturer's protocol. Luciferase activity was measured in relative light units (RLU) using a Lumat 
LB 9507 luminometer (Berthold, GmbH, Germany). Lysate protein concentration was then determined by 
BCA assay to standardize expression values. 
Synthesis of M-VLPsDiD 20 ml of M-VLP supernatant was centrifuged at 60,000g for 2 h at 4 
oC and the 
pellet was resuspended in 50 mM HEPES with 145 mM NaCl at a density of 1 x 1010 M-VLPs/ml. 1,1'-
dioctadecyl-3,3,3',3'-tetramethylindodicarbocyan-ine, 4-chlorobenzenesulfonate salt (DiD) (Invitrogen, 1 
mM in DMSO, Ex = 644 nm, Em = 665 nm) was added to the resuspended M-VLPs to give a final 
concentration of 2 µM DiD. The mixture was incubated for 1 h at room temperature. Labeled M-VLPs 
were separated from the free dye through a PD-10 gel filtration desalting column (GE Healthcare).  
Stable Transgene Expression Assay Hybrid vectors were synthesizes as described above. HEK293 cells 
were seeded 18-24 h prior to transfection at 8 x 105 cells/well in 6-well plates. Growth media containing 
serum was replaced with serum-free DMEM prior to drop-wise addition of vectors and replaced again with 
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normal growth media 4 h post-transfection. After 48 h, the cells in three wells were lysed and quantified 
for luciferase expression as mentioned above. The cells in the other three wells were split into another 6-
well plate at a 1:8 split ratio. This process was repeated every 3-4 days depending on the confluency of the 
cells for up to at least three weeks. 
Production of HEK293Luc and HeLa-Luc cells HEK293 and HeLa cells were transfected with MLV-A as 
stated above and propagated for two weeks. The cells were grown in G418 selection media for selective 
growth of cells permanently expressing luciferase for a further two weeks. 
Passive/Active Transfection Studies Hybrid vectors were synthesized as stated above. HEK293 cells 
were seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12 well plates. Growth media containing 
serum was replaced with serum-free DMEM 1 h prior to drop-wise addition of vectors. The plates were 
maintained at 4 °C or 37 °C for 4 h following which media was replaced again with complete media. 
Luciferase expression was measured at 4, 8, 18, 24, 32, 48 h post transfection as mentioned above. 
Passive/Active Uptake Studies Hybrid vectors with M-VLPsDiD were synthesized as described above. 
HEK293 cells were seeded in 12-well plates at 4 x 105 cells per well 18-24 h prior to transfection. Growth 
media containing serum was replaced with serum-free DMEM 1 h prior to drop-wise addition of vectors. 
The plates were maintained at 4 °C or 37 °C for 4 h following which media was replaced again with 
complete media. The target cells were washed with PBS containing 0.001% SDS at 2, 4 and 8 h post 
transfection to remove surface-bound, uninternalized vectors followed by a regular PBS wash. Cells were 
then trypsinized followed by neutralization with 50 µl of FBS, collected, and analyzed by flow cytometry 
using a Becton Dickinson (Franklin Lakes, NJ) LSR II Flow Cytometer with a 633 nm laser. 
Drug Cytotoxicity and Compatibility Studies The toxicity of drugs was determined using the Cell Titer-
BlueTM Cell Viability Assay. HEK293 cells were seeded in a 96-well plate at 5 x 104 cells/well 18-24 h prior 
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to addition of drugs. Different concentrations of drugs were added to the cells in serum-free medium and 
left for 5 h before the medium was replaced with complete media. Fifteen µl of CellTiter-BlueTM reagent 
was added to each well 24 h after the addition of drugs. The cells were incubated for further 4 h at 37 oC 
before adding 100 µl per well of stop reagent following which fluorescence (λ = 570 nm, 650 nm) was 
measured in a SpectraMax 340PC 96-well plate reader. For compatibility studies, HEK293 cells 
permanently expressing luciferase (HEK293Luc) were seeded at 4 x 105 cells/well in a 12-well tissue 
culture plate 18-24 h prior to addition of drugs. Different concentrations of drugs (up to the highest 
concentration with minimal toxicity) were added to the cells in serum-free medium and left for 5 h before 
the medium was replaced. Luciferase expression was measured 48 h post addition of drugs as mentioned 
above. 
Drug Inhibitors-based Trafficking Studies (Transfections) Hybrid vectors were synthesized as stated 
above. HEK293 cells were seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12-well plates. 
Growth media containing serum was replaced with serum-free DMEM along with addition of 
predetermined concentrations of drugs. After 1 h of incubation with drugs, hybrid vectors were added 
drop-wise. The transfection media was replaced again with complete media 4 h post-transfection. 
Luciferase expression was measured 48 h post transfection as mentioned above. 
Drug Inhibitors-based Trafficking Studies (Uptake) Hybrid vectors with M-VLPsDiD were synthesized 
as described above. HEK293 cells were seeded in 12-well plates at 4 x 105 cells per well 18-24 h prior to 
transfection. Growth media containing serum was replaced with serum-free DMEM along with addition of 
predetermined concentrations of drugs. After 1 h of incubation with drugs, hybrid vectors were added 
drop-wise. The target cells were washed with PBS containing 0.001% SDS 2 h post transfection to remove 
surface-bound, uninternalized vectors followed by a regular PBS wash. Cells were then trypsinized 
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followed by neutralization with 50 µl of FBS, collected, and analyzed by flow cytometry using a Becton 
Dickinson (Franklin Lakes, NJ) LSR II Flow Cytometer with a 633 nm laser. 
siRNA Delivery HeLa-Luc cells (HeLa cells permanently expressing luciferase) were seeded at 1.5 x 105 
cells/well in a 12-well plate 18-24 h prior to transfection. Liposomes in the predetermined ratios were 
synthesized as stated before. siGL3 and siLam were conjugated with the liposomes at 1:10 (w:w) ratio and 
diluted in PIPES buffer followed by incubation at room temperature for 15 min to synthesize siRNA 
lipoplexes. Growth media was replaced with serum-free media prior to addition of 50 μl of siRNA 
lipoplexes (5 nM). The serum-free media was replaced again with complete media 4 h post transfection. 
Luciferase expression was measured 24 h post-transfection as stated above.   
Synthesis of χRITC/M-VLPsDiD Labeling of chitosan with Rhodamine-B Isothiocyanate (RITC) was 
performed as described before33,34. In brief, 10 ml of chitosan (Molecular Weight = 190-310 kDa, Sigma 
Aldrich) was prepared at 10 mg/ml dissolved overnight at 55 oC in 0.6 % acid and filtered through a 0.22 
µm surfactant-free cellulose acetate syringe filter, pH 3 and 4). An equal volume of methanol as the 
chitosan solution was then added under stirring. After 3 h, the solution was degassed and kept under N2 
atmosphere. Rhodamine-B isothiocyanate was dissolved in methanol at a concentration of 4 mM and 2.64 
mL was injected into the chitosan solution under stirring. The reaction mixture was protected from light 
and left to proceed for 17 hours. The unreacted rhodamine B-isothiocyanate was removed by precipitation 
of chitosan with drop-wise addition of 0.2 M NaOH to the mixture until the pH is above 10. After 5 washes 
with deionized water and centrifugations (3500 rpm, 5 min), the chitosan precipitate was recovered for 
freeze-drying. The Chitosan-RITC pellet was resuspended in 0.6 % acid at pH 3 and pH 4. Chitosan-RITC 
was added drop-wise to required volume of M-VLPsDiD while vortexing as per the desired stoichiometry. 
The hybrid vectors were then incubated at 4 oC for 4 h. 
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Synthesis of φl/M-VLPsDiD DOTAP, DOPE, DOPE-Rhodmaine-B, cholesterol and NBD-6 cholesterol 
dissolved in chloroform were mixed in the desired composition in a test-tube and dried under vacuum 
overnight to form a thin film. The lipid film was rehydrated using a 5% glucose solution and sonicated 
briefly to allow the lipids to dissolve completely. The rehydrated solution was vortexed every 30 minutes 
for 30 seconds for a total duration of 3 h. If not used immediately, the lipid solution was stored at 4 °C (< 1 
month). The lipid solution was extruded through an Avanti® Mini-Extruder for 11 passes through a 100 nm 
PC membrane. The lipid samples were then added to the required volume of M-VLP supernatant and 
diluted in 5% glucose solution as per the φ/M-VLP stoichiometry and incubated for 2 h at 4 °C prior to 
further analysis or transfection. 
Confocal Microscopy HEK293 cells were seeded at 4 x 105 cells per well of a 6-well plate on a cover slip 
46 h prior to transfections. The cells were then transfected with φl/M-VLPsDiD and χRITC/M-VLPsDiD 
synthesized as described before. Slides of the transfected cells were prepared at 4, 8 and 20 h post-
transfection as follows. The cells were washed twice with 1 ml PBS, fixed with 1 ml 3.7% formaldehyde 
solution and incubated at room temperature in the dark for 20 mins. The cells were washed again with 1 ml 
PBS. A drop of mounting solution (ProLong® Gold Antifade Reagent with DAPI, Life Technologies, 
Carlsbad, CA) was placed on a glass slide. The cover slip was wedged out with a forceps and placed face-
down onto the glass slide directly over the drop of mounting solution. The four edges of the cover slip were 
then sealed with clear nail polish and kept at 4 °C. The glass slides were then visualized with a Zeiss LSM 
700 Confocal Microscope. 
Reverse Transcription Inhibition Hybrid vectors were synthesized as stated above. HEK293 cells were 
seeded 18-24 h prior to transfection at 4 x 105 cells/well in 12-well plates. Growth media containing serum 
was replaced with serum-free DMEM followed by drop-wise addition of hybrid vectors. The transfection 
media was replaced again with complete media 4 h post-transfection. Azidothymidine (AZT) was added to 
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the transfected cells at 0, 4, 16, 24 and 32 h post-transfection at predetermined concentrations. Luciferase 
expression was measured 48 h post transfection as mentioned above. 
Size Measurements Hybrid vectors were prepared as described above and diluted 10-fold in 5% glucose. 
The sizes of the resulting complexes and the constituents were measured using dynamic light scattering with 
a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments). Light scattering was measured over 
10 10-second intervals for each sample. 
Statistical Analysis All statistical analyses mentioned in this study was done using the Student’s t-test. A 
result was deemed not significant (ns) if p > 0.05. (# - p < 0.05; ## - p < 0.02; ### - p < 0.002; * - p 
< 0.0002). 
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
 Retroviruses were the earliest class of viruses that were used for clinical trials of human gene 
therapy. While these viral vectors are highly efficient and provide stable transfection of the target gene, 
they suffer from many issues such as expensive pharmaceutical production, low stability over storage even 
at 4 °C, unfeasible modification of tropism for specific targeting for different cell lines and high 
immunogenicity. These disadvantages are particularly associated with the presence of the envelope protein 
on the lipid bilayer of the retrovirus. The envelope protein, however, is solely responsible for mediating 
transfections with target cells without which the retroviral particle is ineffective. In this dissertation, we 
explored the possibility of using synthetic envelopes derived from polymers and lipids to mediate effective 
retroviral transfections by effectively performing the functions of the native biological envelope protein. 
This replacement of the envelope protein would also provide certain advantages of synthetic agents with 
respect to clinical implementation of human gene therapy while still maintaining the superior transfection 
capabilities of the retrovirus thereby leading to the design of a superior hybrid gene delivery vector. 
As per our results reported in this document, chitosan-based hybrid retroviral vectors (χ/M-VLPs) 
were more efficient at transfecting HEK293 cells in vitro compared to PEI/M-VLPs and PLL/M-VLPs 
despite the lower uptake of the vectors. Chitosan was also highly biocompatible as compared to PEI and 
PLL exhibiting much lower toxicity in HEK293 cells. The reduction in pH of the chitosan stock solution to 
pH 3 led to > 100-fold improvements in transfections. This result is especially significant considering that 
transfections by MLV-A viruses under similar conditions were of the same order of magnitude as χ/M-
VLPs. These vectors also required lower pH compared to the pKa of the acidic solvent for high transfection 
efficiencies. The sizes of the vectors were also significantly reduced by reducing the stock concentration of 
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the chitosan from 1 mg/ml to 0.5 mg/ml along with the use of low pH. χ/M-VLPs formed using M-VLPs 
resuspended in 5% glucose solution as well as in serum-free media with reduced serum content, were 
inefficient in transfections. χ/M-VLPs exhibited better serum resistance compared to lipid-based hybrid 
retroviral vectors (φ/M-VLPs) and similar resistance as compared to Amphotropic Murine Leukemia Virus 
(MLV-A). χ/M-VLPs also exhibited better stability as compared to MLV-A in terms of size and transfection 
efficiency with the stability being a function of the vector stoichiometry. However, χ/M-VLPs suffered 
from precipitation issues over long-term storage. χ/M-VLPs were also able to successfully mediate long-
term stable transgene expression. The future directions for the design of χ/M-VLPs should be directed 
towards improving vector morphology through optimal association of M-VLPs in clinically useful buffers 
such as PBS or HEPES-based buffers along with suitable solution parameters for chitosan. Once, optimal 
vector morphology and size has been achieved, chitosan conjugated with folic acid or mannose can be 
potentially used for targeted systemic gene therapy following appropriate characterization of the 
biodistribution and efficacy of these hybrid complexes in vivo.  
 φ/M-VLPs were formed using DOTAP, DOPE and cholesterol in various compositions for 
formation of the synthetic liposomes. We concluded that φ325/M-VLPs was the most optimal lipid 
composition in terms of transfection efficiency. Extrusion of lipids prior to associating with M-VLPs led to 
improved sizes and better transfections. On comparison of the sizes, surface charge and transfection 
efficiencies of these hybrid vectors, it was probable that the lipids which promoted the formation of the HII 
phase at the appropriate lipid/M-VLP ratios as well as the right time during transfection provided for the 
most optimal transfections. We suggested that the most optimal lipid formulation as well as lipid 
stoichiometry were such that the hybrid vector structure was on the verge of arranging in the HII phase 
which occurred during transfection in the appropriate vesicles within the cellular microenvironment that 
would then allow the M-VLPs to go along towards the nucleus for efficient unpacking of the viral capsid 
190 
 
followed by provirus formation and genomic integration during cell division. φ/M-VLPs exhibited better 
stability on storage in terms of the transfection efficiency and vector sizes compared to MLV-A as well as 
χ/M-VLPs and had minimal precipitation issues compared to χ/M-VLPs. φ/M-VLPs also enabled long-
term stable transgene expression similar to MLV-A. However, φ/M-VLPs lost > 90% of their transfection 
capabilities in the presence of serum. The possibility of using targeted φ/M-VLPs was tested by using 
folate-targeted lipids. However, we reported that the size and morphology of these vectors is still sub-
optimal for efficient uptake via the folate-receptor pathway. These lipids in their current form seem 
unsuitable for systemic gene delivery given their high propensity for inhibition by serum proteins. 
However, excellent ex-vivo transfection efficiency can be potentially achieved using φ/M-VLPs.  
 The cellular uptake and intracellular trafficking of these vectors significantly differed based on the 
type of envelope used for the M-VLP. MLV-A and χ/M-VLPs relied significantly on endocytic mechanisms 
for efficient uptake whereas φ/M-VLPs were also able to fuse with the plasma membrane along with 
endocytic uptake. However, successful transfections required active endocytic mechanism irrespective of 
the nature of the envelope. MLV-A preferred CavME for efficient transfections, as is known in literature. 
The trafficking of χ/M-VLPs was dependent on the pH of the chitosan stock solution used to synthesize the 
vectors. χ/M-VLPs formed using lower pH was able to successfully navigate via CME, a pathway alien to 
the MLV-A, whereas if a higher pH was used, trafficking was mediated via CavME and MP. Similarly, the 
lipid composition of the synthetic envelope of φ/M-VLPs was a primary determinant of the trafficking 
mechanism for optimal transfections. DOPE-heavy liposomes preferred CME whereas cholesterol-heavy 
lipid compositions used CavME. Lipid compositions that had all three lipids were able to successfully use 
either trafficking pathways for optimal transfections. φ/M-VLPs exhibited faster trafficking kinetics as 
compared to χ/M-VLPs on the path towards the nucleus. The synthetic lipid envelope allowed faster 
release of M-VLPs compared to the chitosan synthetic envelope leading to faster transfections.  
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Overall, we have shown in this study that stable retroviral gene transduction can not only be 
achieved successfully via smaller-sized hybrid vectors, but their properties in terms of extracellular stability 
and early-stage intracellular trafficking can be modified via the appropriate choice of synthetic envelope. 
We wholly expect that the design of these hybrid vectors can be extended towards other non-infectious 
viruses such as HIV-VLPs, thus, allowing transfections of non-dividing cells. Future studies should be 
targeted towards design of therapeutic hybrid vectors that have a clinically useful target gene or an RNAi 
construct such as for cancer or cardiovascular gene therapy. Finally, the ultimate goal should be the 
construction of an artificial virus enabling other viral functions through synthetic constructs and peptides.
 
